Regulation of the 16S rRNA aminoglycoside resistance methyltransferases: a functional and mutational analysis of the armA 5’ UTR by Hoefer, Andreas
UNIVERSIDAD COMPLUTENSE DE MADRID 
FACULTAD DE VETERINARIA 
DEPARTAMENTO DE SANIDAD ANIMAL 
© Andreas Hoefer, 2017 
 
 
 
 
 
 
  
 
  
TESIS DOCTORAL 
Regulation of the 16S rRNA aminoglycoside resistance 
methyltransferases: a functional and mutational analysis of 
the armA 5’ UTR 
 
Regulación de las metiltransferasas del ARNr 16S de resistencia 
a aminoglucósidos: análisis funcional y mutacional del 5’ UTR de 
armA 
 
MEMORIA PARA OPTAR AL GRADO DE DOCTOR 
PRESENTADA POR 
Andreas Hoefer 
   
 DIRECTOR  
Bruno González Zorn 
Madrid, 2018 
TESIS DOCTORAL Regulation of the 16S rRNA 
aminoglycoside resistance methyltransferases:
 A functional and mutational analysis of the armA 5’ UTR Regulación de las metiltransferasas del ARNr 16S de resistencia a aminoglucósidos: Análisis funcional y mutacional del 5’ UTR de armA 
MEMORIA PRESENTADA PARA OPTAR AL GRADO DE DOCTOR POR Andreas Hoefer 
Bajo la dirección del Profesor Bruno González Zorn 
Madrid, mayo de 2017 
UNIVERSIDAD COMPLUTENSE DE MADRID FACULTAD DE VETERINARIA Departamento de Sanidad Animal 

D. Bruno González Zorn, Profesor Titular del Departamento de Sanidad Animal de la Facultad de Veterinaria de la Universidad Complutense de Madrid (UCM), 
CERTIFICA: Que la Tesis Doctoral titulada 
“Regulation of the 16S rRNA aminoglycoside resistance methyltransferases: A 
functional and mutational analysis of the armA 5’ UTR” 
presentada por Don Andreas Hoefer, Licenciado en Microbiología y Máster en Investigación en Ciencias Biomédicas por la Universidad de Warwick, Reino Unido, ha sido realizada bajo mi dirección en las dependencias del Departamento de Sanidad Animal de la Facultad de Veterinaria, y estimamos que cumple todos los requisitos necesarios para optar al grado de Doctor por la Universidad Complutense de Madrid. 
De acuerdo con la normativa vigente, firmo el presente certificado, autorizando a su defensa y presentación, como director de la mencionada tesis doctoral. 
Madrid, mayo de 2017 
Fdo.: Dr. Bruno González Zorn 

ACKNOWLEDGEMENTS
 
An erster Stelle würde ich mich gerne bei meinen Eltern und meiner Schwester be­danken! Meine Eltern die für mich unendlich viel Geduld hatten um mich für die letzten 12 Jahre zu unterstützen! Ohne euch währe diese Arbeit unmöglich gewesen! An meine Schwester, mit der ich immer über alles reden konnte, die ich immer anrufen konnte als ich mich ablenken wollte, auch ohne dich wäre diese Arbeit unmöglich gewesen. Vielen vielen Dank an euch drei, hoffentlich werde ich jetzt mehr zeit haben, die ich mit euch verbringen kann! Ich würde mich auch gerne am Rest der Familie bedanken; an alle die mich hier besucht haben und alle die immer Zeit hatten als ich zu besuch in Deutschland war – Vielen Dank! 
Next I would like to send a big thank you to all the close friends that have stood by me through the years, without all those special times in the past I wouldn’t be the person I am today. From our earliest experiments designing and building parachutes (that obvi­
ously did nothing) to more recent experimentation with fluid dynamics I treasure each and every memory with all of you – you know exactly who you are. 
To everyone in the UK, that really shaped me as an – I want to say adult, but I’m not quite sure if I’m there yet – it has been my upmost pleasure to have shared these life de­
fining moments with you. Whether we were out camping, spending endless days walk­ing around outside or up late night discussing the most absurd things, I sincerely thank you! A special thanks to those of you that took the time to come visit me here in Spain and, again, to those that were always ready to go when I stopped by. 
Next I would like to thank everyone in Madrid that made this time so special, both in and out of the lab! Bruno, thank you for all the time and effort that you invested in the project and me. Without the late nights, and hard work you put in there wouldn’t have even been a project. A very special thank you (and probably an apology as well) goes 
to Nata! Without you taking better care of us than we deserve, nothing would move forward. Thank you for the patience and tireless support over the years to both of you. 
This environment that we are so lucky to call our ‘working’ environment is more spe­cial than any of us will realize until its in the past. A very special thank you to every 
single one of you in the lab that really made me feel at home from the first minute. A special thank you to Dani and Laura, who helped me with everything at the beginning, and Dani for literally always being there when you need a hand and always with a smile! Dani, you’re a great guy and I really hope that at least one of the applications we wrote together is accepted and you can go do whatever you want! Gabi and Alfonso, for all the nights rollerblading in the garage, throwing things out of my window, the festivals etc. To Belen for teaching me everything I know! A very special thank you to Bosco as well, you’ve been a great student and I very very much appreciate the time and effort you put into our experiments. Carri for all the times we shared inside and out of the lab! A big thank you to Cristina for all the patience, help and good times! Cris and Jose… the 
methylase group… its been a real pleasure. And last but definitely not least, thank you to Manu for deleting all the protocols off the thermo cycler ;) and for carefully proof­reading my thesis. To each and every one of you, you have been more than friends in my time here and I very much look forward to times with you in the future! 
Within the faculty, a very special thank you also goes to Belen and her lab downstairs for her extremely helpful attitude - many of the experiments performed wouldn’t have been possible without you! Also, a big thank you to Gustavo and Javi for letting me vis­ualize 1000s of Western Blots in their lab! 
Wow… so many people to thank. I can’t not mention the TRAIN-ASAP group for all the very excellent times spent around Europe ‘Training’ – I also very much look forward to times shared with you in the future! Thank you to Mathieu, Carlos, Ali and many many more outside of the lab! 
Finally, and most importantly! Thank you Maria! You have been there pretty much throughout my entire thesis! You were calm when I was stressed, you were patient when I was in the lab until the early hours of the morning and you were always there when I needed you! You took a lot of interest in our work even though it is so very different from your work. You spent a lot of great time with me in the lab and with the lab group (that basically all like you more than me – and I don’t blame them). Genu­inely, without you, this process would have been 100 times harder! I cannot thank you enough! And to your family as well! Your mom, dad, Diego, Helena, Manu and Veronica thank you very much for all the wonderful times we had! 
Thank you all so very much! 
  
 
INDICE
TABLE OF CONTENTS 
List of figures
List of tables 
1 
SUMMARY 
RESUMEN2 
VI
 
VIII
 
IX
 
XII
 
XVI
 
XXI
 
1 
3 4 7 8 11 12 13 18 19 19 20 
List of abbreviations 
INTRODUCTION 3 
3.1 The origins and discovery of antibiotics 
3.1.2 Aminoglycosides 3.1.2.1 Nomenclature and structure of aminoglycosides3.1.2.2 The ribosome as a drug target 3.1.2.3 Mode of action 3.1.2.4 Therapeutic properties and clinical applications 3.1.2.5. Aminoglycoside toxicity 3.1.2.6. Antibiotic resistance3.1.2.7. Aminoglycoside resistance Decrease in intracellular drug concentration Aminoglycoside-modifying enzymes 
Target modification 
I
 
    
 
 
  
 
 
 
  
 
 
 
3.2. 16S rRNA methyltransferase mediated aminoglycoside resistance 
3.2.1.Intrinsic aminoglycoside resistance conferring 16S rRNA methyltransferases 
3.2.2.Acquired aminoglycoside resistance conferring 16S rRNA methyltransferases 3.2.2.1. History and nomenclature3.2.2.2. Mode of action
3.2.2.3. Clinical significance and prevalence
3.2.3.The genetic environment of the 16S rRNA methyltransferases 

and its role in their dissemination
 3.2.3.1. armA 3.2.3.2. rmtA 3.2.3.3. rmtB/B2 3.2.3.4. rmtC 3.2.3.5. rmtD/D2 3.2.3.6. rmtE/E2 3.2.3.7. rmtF 3.2.3.8. rmtG 3.2.3.9. rmtH 
3.3. Regulation associated with antibiotic resistance 
3.3.1.Global transcriptional regulation 3.3.1.1. Sigma factors3.3.1.2. Sigma factor recognition of promoter regions initiates transcription
3.3.2. Regulation of intrinsic antibiotic resistance mechanisms3.3.2.1. Regulation of intrinsic resistance genes within the biosynthetic 
gene clusters of the antibiotic
 3.3.2.2. Regulation of intrinsic resistance genes modulated by 
intracellular concentrations of the antibiotic
 3.3.2.3. Regulation of intrinsic resistance genes in correspondence with the growth phase
3.3.3.Regulation of acquired antibiotic resistance mechanisms 3.3.3.1. Transcriptional regulation of acquired antibiotic resistance genes (in class 1 integrons) 3.3.3.2. Post-transcriptional regulation of resistance genes 
3.3.4.The impact of insertion sequences on the expression of resistance genes 
22 
22 
25 25 26 27 
30 
30 31 32 32 33 33 34 34 35 
38 
38 40 41 
44 44 
47 
48 
49 50 51 
54 
II
 
   
 
 
  
 
     
  
  
 
  
  
  
  
  
 
   
  
OBJECTIVES AND JUSTIFICATION 594 
MATERIALS AND METHODS 655 
5.1. In silico sequence management 65 
5.2 Strains utilized 65 
5.3. Genetic constructions 65 5.3.1. lacZα reporter constructions 69 5.3.2. Western Blot constructions 70 5.3.3. Promoter region mutagenesis 70 
5.4. Antimicrobial susceptibility testing 71 
5.5. Bacterial growth conditions 71 
5.6. RNA extractions and reverse transcription 71 
5.7. Rapid amplification of cDNA ends (RACE) 72 
5.8. lacZα screening 74 
5.9. Western Blot 74 
5.10. RT-qPCR 76 
RESULTS - 816 
6.1. In silico analysis of the 16S rRNA methyltransferases 81 
and their 5’ upstream regions 
6.1.1.Coding region conservation of the 16S rRNA methyltransferases 81 6.1.1.1. Conservation of the acquired aminoglycoside resistance conferring 81 methyltransferase CDS 6.1.1.2. Acquired vs. Intrinsic aminoglycoside resistance conferring methyltransferases 82 CDS conservation 6.1.1.3. The conservation between the resistance conferring and house keeping 84 16S rRNA methyltransferases 
6.1.2.The plasticity of the 16S rRNA methyltransferase 5’ upstream regions 86 6.1.2.1. Acquired 16S rRNA methyltransferase 5’ upstream regions conservation 86 6.1.2.2. Acquired vs. Intrinsic resistance conferring methyltransferase 5’ 91 upstream region conservation 
6.1.3.Acquired 16S methyltransferase promoter predictions 92 6.1.3.1. Degree of -35 and -10 box conservation among the acquired 16S methyltransferases 92 
III
 
 
 
   
 
 
 
 
 
  
 
 
 
  
6.2. The characterisation of the armA 5’ UTR 
6.2.1.armA reference sequence conservation
 
6.2.2.In vitro identification of the armA 5’ untranslated region
 
6.2.3.Phenotypic effects upon the truncation of the armA 5’ UTR
 
6.2.4.armA 5’ UTR: lacZα reporter construct
 
6.3. Growth phase dependent expression of armA mediated 
by σ70 factor promoter region 
6.3.1.Evaluation of the predicted σ70 promoter region of armA
 
6.3.2.Single nucleotide resolution of promoter elements 

required for the fine-tuned expression of armA 6.3.2.1. Initial mutagenesis of highly conserved nucleotides 6.3.2.2. Comprehensive -35 and -10 ‘GG’ substitution assay - 35 Box substitutions - 10 Box substitutions 
6.3.3.Growth phase dependent expression of armA 6.3.3.1. Translational levels of armA over a 12 hour growth period6.3.3.2. Transcriptional levels of armA over a 12 hour growth period 
DISCUSSION 
7.1.The origin of the 16S rRNA methyltransferases and 
the evolution of their 5’ upstream region 
7.1.1.The coding region conservation of the acquired 

16S rRNA methyltransferases
 
7.1.2.Investigating the origin of the acquired methyltransferases 
7.1.3.The maintenance vs. evolution of the 5’ upstream regions of acquired 
methyltransferases 
7.1.4.The conservation of 5’ upstream region with regards to select intrinsic
 resistance conferring methyltransferases 
7.1.5.Coding region promoter elements identified
94 
94 
96 
98 
101 
106 
106 
107 
107 110 111 113 
116 116 119 
123 7 
125 
125 
127 
129 
132 
136 
IV
 
 
  
 
 
 
  
  
 
 
 
7.2. The armA 5’ untranslated region 
7.2.1.Defining the extremes of the armA transcript
 
7.2.2.Identification of regulatory domains with the 5’ UTR
	
7.2.3.Environmental factors that influence armA expression
 
7.3. Identification of -35 and -10 box nucleotides necessary for 
the transcriptional induction of armA 
7.3.1.Promoter region conservation with RpoD recognized promoters
7.3.2.Site-directed mutagenesis of most conserved -35 and -10 elements
7.3.3.Dissection of the promoter elements required for the expression of armA 
7.3.4.Growth phase dependent expression of armA 
7.4 Future work
CONCLUSIONS 
BIBLIOGRAPHY 
8 
9 
135 
136 
136 
138 
141 
141 
142 
143 
144 
147 
151 
157 
V
 
  
 
 
 
 
  
LIST OF FIGURES 
Figure 1: Photography of Alexander Fleming penicillium plate 1
 
Figure 2: War-time penicillin advertisement 2
 
Figure 3: Aminoglycoside structures 5
 
Figure 4: Antibiotic that act on the prokaryotic ribosome 7
 
Figure 5: Aminoglycosides interacting with target residues 9
 
Figure 6: 70S ribosome with A-site 10
 
Figure 7: Mortality rates related to antimicrobial resistance 15
 
Figure 8: Antimicrobial drugs approved 16
 
Figure 9: Aminoglycoside resistance mechanisms 18
 
Figure 10: 70S ribosome with methylation sites of the A-site 24
 
Figure 11: Genetic environment of acquired 16S methyltransferases 36
 
Figure 12: RNA polymerase holoenzyme 39
 
Figure 13: Sigma factors 40
 
Figure 14: Sigma factor RpoD promoter conservation 42
 
Figure 15: Streptomycin biosynthetic pathway 46
 
Figure 16: Aminoglycoside resistance gene riboswitch 52
 
Figure 17: ermC regulatory mRNA structure 53
 
Figure 18: Rapid amplification of cDNA 73
 
Figure 19: Dendrogram of acquired 16S rRNA methyltransferases 81
 
Figure 20: Dendrogram of acquired and intrinsic methyltransferases 83
 
Figure 21: Dendrogram of acquired and housekeeping methyltransferases 84
 
Figure 22: Dendrogram of acquired, intrinsic and housekeeping methyltransferases 85
 
Figure 23: Dendrogram of acquired methyltransferase 5’ upstream regions 88
 
Figure 24: Dendrogram of select acquired methyltransferase 5’ 90
 upstream regions compared to coding regions
 
Figure 25: Dendrogram of acquired and intrinsic methyltransferase 5’ upstream regions 91
 
Figure 26: Promoter region alignments 93
 
Figure 27: armA sequence alignments 95
 
Figure 28: armA sequence map 97
 
Figure 29: Upstream promoter RT-PCR check 98
 
VI
 
          
          
   
Figure 30: Resistance profile of truncations 99
 
Figure 31: Western Blot analysis of truncations 100
 
Figure 32: Diagram of armA:lacZα 101
 
Figure 33: Constitutive expression of lacZα reporter construct 102
 
Figure 34: lacZα reporter construct truncations 102
 
Figure 35: lacZα reporter construct truncations with gentamicin 103
 
Figure 36: Western blot analysis of armA in the presence of gentamicin 104
 
Figure 37: armA:lacZα reporter construct co-transformations 104
 
Figure 38: RpoD recognized promoter region conservation 106
 
Figure 39: Initial promoter region mutagenesis 108
 
Figure 40: Initial promoter region mutagenesis resistance profile 108
 
Figure 41: Western Blot analysis of initial promoter region mutagenesis 109
 
Figure 42: Promoter substitution positions 110
 
Figure 43: -35 box ‘GG’ substitutions 111
 
Figure 44: -35 box ‘AA’ substitutions 112
 
Figure 45: -10 box ‘GG’ substitutions 114
 
Figure 46: -10 box ‘AA’ substitutions 115
 
Figure 47: Western Blot analysis of armA expression during growth period 117
 
Figure 48: Initial promoter region mutagenesis growth curves 118
 
Figure 49: RT-qPCR analysis of armA transcription levels 119
 
VII
 
   
LIST OF TABLES 
Table 1: Intrinsic resistance methyltransferases 22
 
upstream regions
 
upstream region compared to the coding region
 
Table 2: Primers used 66
 
Table 3: Primers used for -35 box substitutions 68
 
Table 4: Primers used for -10 box substitutions 68
 
Table 5: RT-qPCR conditions 77
 
Table 6: Nucleotide conservation of acquired methyltransferase 5’ 87
 
Table 7: Nucleotide conservation of acquired methyltransferase 5’ 89
 
VIII
 
                      
         
                                  
LIST OF ABBREVIATIONS 
2-DOS 2-Deoxystreptamine 
AAC Aminoglycoside acetyltransferase 
AMR Antimicrobial Resistance 
ANT Aminoglycoside 
Arm Aminoglycosde resistance methyltransferase 
BHI Brain Heart Infusion 
CDS Coding sequence 
CFU Colony forming units 
CLSI Clinical and Laboratory Standards Institute 
ECDC European Center for Disease Control 
EDP Energy dependent process 
ESBL Extended spectrum β-lactamases 
EUCAST European Committee on Antimicrobial Resistance Testing 
IDSA Infectious Diseases Society for America 
Inc Incompatibility group 
IS Insertion sequence 
ISCR Insertion sequence common region 
Kam Kanamycin-apramycin methyltransferase
Kgm Kanamycin-gentamicin methyltransferase
KPC Klebsiella pneumoniae carbapenemase 
LB Lysogeny broth 
MDR Multi-drug resistance 
MH Mueller-Hinton 
MIC Minimal inhibitory concentration 
mRNA Messenger ribonucleic acid 
NDM New Delhi Metallo-beta-lactamase 
NMR Nuclear magnetic resonance
nt(s) Nucleotide(s) 
ORF Open reading frame 
PAM Pan-aminoglycoside resistance methyltransferase 
IX
 
  
  
  
    
                  
PCR Polymerase chain reaction 
RACE Rapid amplification of cDNA ends 
RMTases           Ribosomal methyltransferases 
ROS Reactive oxygen species 
RpoD RNA polymerase sigma factor 
rRNA Ribosomal ribonucleic acid 
Rsm Ribosomal small subunit methyltransferase 
RT-PCR Reverse transcription polymerase chain reaction 
RT-qPCR Qualitative reverse transcription polymerase chain reaction 
SAM S-adenosylmethionine 
spp. Species 
Tn Transposon 
tRNA Transfer ribonucleic acid 
UTR Untranslater region 
WHO World Health Organization 
XDR Extensively drug-resistant 
X
 

SUMMARY 2 
Antimicrobial resistance remains one of the most serious threats to modern medicine. As such, the selection and administration of antibiotics must be carefully considered, especially since the discovery of novel antimicrobial agents has reduced substantially. Agents that have previously been dismissed for unfavorable secondary activity are 
becoming increasingly valuable as the resistance prevalence towards the first choice antibiotic increases drastically. The aminoglycosides are a family of antibiotics that belong to this category. Shortly after their introduction to the market, problems with toxicity became apparent and they were no longer considered a drug of choice for physicians. However, increasingly worrisome resistance trends have forced physicians to reevaluate the application of aminoglycosides for life-threatening infections caused by Gram-negative pathogens. 
Among other resistance mechanisms, the 16S ribosomal RNA methyltransferases have emerged in Gram-negative pathogenic bacteria as an acquired resistance mechanism conferring high-level resistance to all clinically relevant aminoglycosides, even ones that have not yet been released to the market. Since their discovery in 2003, 
a total of 13 acquired methyltransferases have been identified including three variants. The rate at which these resistance determinants are spreading, combined with the 
broad resistance profile they confer to most clinically significant aminoglycosides, is jeopardizing the aminoglycosides as a viable last resort antibiotic. 
Initially, the objectives of the here presented doctoral thesis were to perform a comprehensive in silico analysis of the various families of 16S rRNA methyltransferases, including acquired resistance conferring-, intrinsic resistance conferring- and housekeeping- methyltransferases.  The aim of this was to identify a putative origin of the acquired resistance conferring methyltransferases, to potentially discovering their ancestral regulatory mechanism. This study revealed that the acquired 16S 
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methyltransferases most likely convergently evolved from a number of differentRNA methyltransferases. Furthermore, this study also demonstrated a high degree ofplasticity in the 5’ upstream regions between the various acquired resistance conferringmethyltransferases, although the region immediately upstream of the coding region wasrelatively conserved throughout isolate of the same genes. This plasticity is most likely aresult of the highly versatile mobile genetic elements in which these acquired resistancedeterminants are found.
Subsequent promoter predictions performed within a 400 nucleotide region upstreamof the CDS of the acquired methyltransferases demonstrated a general conservationof a ‘TTGACG’ -35 box and a ‘TTACACT’ -10 box. Using armA, the most prevalent 16Saminoglycoside resistance methyltransferase as a model system, we then set out tocharacterize the region responsible for the expression of armA. Sequence alignmentsdemonstrated a very high degree of conservation in the region 221 nucleotides upstreamof the resistance gene in all available reference sequences, which harbors the putative
promoter elements mentioned. Subsequent rapid amplification of cDNA ends (RACE)
identified a 5’ UTR of precisely 139 nucleotides. A truncational analysis of this upstreamregion demonstrated the presence of a domain absolutely necessary for the expressionof armA immediately upstream of the confirmed 139 nucleotide 5’ UTR, as confirmed via
the resistance profile and Western Blot analysis by means of a triple FlagTag.
The fusion of the extended armA 5’ upstream region to a lacZα reporter constructdemonstrated that under the regulation of the armA upstream region the reportergene was constitutively expressed. Subsequent investigations revealed this constitutiveexpression was not affected by the presence or absence of neither aminoglycosides noractive methyltransferases in trans. As the armA encoding methyltransferase does notappear to be regulated by any known post-transcriptional mechanisms, the study thenfocused on the upstream promoter region.
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We then performed a mutational analysis of this promoter region to identify the specificnucleotides required for the accurate expression of the resistance gene. The results ofthis study were in-keeping with the model of a sigma factor RpoD recognized promoterregion. Substitutions of conserved nucleotides resulted in the complete suppression of
armA to levels of the susceptible phenotype. Substitutions of less conserved nucleotides
also resulted in a three to five fold drop in the MIC conferred by armA, which was alsodemonstrated by Western blot analysis. This suggests that the housekeeping sigmafactor RpoD, which preferentially transcribes genes associated with the protein synthesismachinery, induces the transcription of this resistance gene.
Investigations into the expressional profile of armA throughout its growth phasesindicated an augmented expression that correlates with the exponential phase of bacterialgrowth. Both Western Blot and RT-qPCR analysis indicated an expressional peak between2-5 hours of growth as compared to chromosomal reference genes. This further supportsthe capacity of the promoter region to recruit the RpoD sigma factor to modulate armAexpression according to expressional levels of other components of the protein synthesismachinery.
As such, this study constitutes an in depth analysis into the putative origins of the
acquired 16S rRNA methyltransferases as well as a first mutational study of the promoterregion of armA. A single nucleotide resolution of this promoter region identifies thekey nucleotides responsible for the accurate expression of this prevalent resistancemechanism. Finally, this promoter is likely to ensure adequate resistance levels in thehost as it is transcribed using the housekeeping sigma factor RpoD, responsible for the
transcription of protein synthesis related gene clusters. This study constitutes a firstattempt to elucidate the underlying regulatory mechanisms of the acquired16S rRNAresistance methyltransferases. This resistance mechanism, that results in high level
resistance to most clinically significant aminoglycosides, endangers the use of thisvaluable antibiotic family as a last resort treatment for future medicine.
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RESUMEN
 
La resistencia a antibióticos supone una de las principales amenazas para la medicina moderna. Esto, junto con la drástica disminución del descubrimiento de nuevas moléc­ulas antibióticas, hace que la elección y administración de tratamientos antibióticos deba ser controlada escrupulosamente. Fármacos que anteriormente eran rechazados por sus efectos adversos están comenzando a utilizarse de nuevo debido a los elevados niveles de resistencia a los antibióticos de primera elección. Los aminoglucósidos son un grupo de antibióticos que pertenecen a esta categoría. Poco después de su introduc­ción en el mercado fueron desechados como fármacos de elección debido a su elevada toxicidad. Sin embargo, el alarmante incremento de la resistencia a antibióticos ha ob­ligado a los clínicos a reevaluar el uso de los aminoglucósidos para tratar infecciones graves producidas por patógenos Gram negativos. 
Entre otros mecanismos de resistencia, las metiltransferasas del ARNr 16S han emergido en bacterias patógenas Gram negativas como un mecanismo de resistencia 
adquirido, confiriendo elevados niveles de resistencia frente a todos los aminoglucósi­dos clínicamente relevantes, incluso también frente a nuevos aminoglucósidos que to­davía no han salido al mercado. Desde su descubrimiento en el año 2003, se han identi­
ficado un total de 13 metiltransferasas, incluyendo tres variantes. La velocidad a la que estos determinantes de resistencia se están diseminando, junto con el amplio espectro 
de aminoglucósidos frente a los que confieren resistencia, está poniendo en peligro el empleo de este grupo de fármacos como antibióticos de último recurso. 
Inicialmente, los objetivos de esta Tesis Doctoral consistieron en realizar un estudio in silico en profundidad de las diferentes familias de metiltransferasas del ARNr 16S, que incluyen a las metiltransferasas de resistencia, tanto adquiridas como intrínsecas, 
y a las metiltransferasas endógenas. El objetivo de este análisis fue poder identificar el 
origen putativo de las metiltransferasas de resistencia adquiridas, con la finalidad de 
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descubrir el origen de su mecanismo de regulación. Este estudio reveló que las metil­transferasas adquiridas del ARNr 16S probablemente evolucionaron de manera con­vergente a partir de las metilasas intrínsecas del ARN. Además, este análisis también 
mostró el alto grado de plasticidad en la región 5´ no codificante de las metiltrans­
ferasas adquiridas, aunque en distintos aislados de cada uno de los genes codificantes pudimos observar que la región inmediatamente corriente arriba de la secuencia cod­
ificante presentaba un alto grado de conservación. Esta plasticidad es debida, presum­iblemente, a la versatilidad de los elementos genéticos móviles en los que estos deter­minantes de resistencia se localizan. 
Seguidamente, se estudió la presencia de regiones promotoras comprendidas en los 
400 nucleótidos situados corriente arriba de las secuencias codificantes de las metila­sas adquiridas. Este análisis reveló la existencia de un promotor putativo conservado, siendo la caja -35 “TTGACG” y la caja -10 “TTACACT”. Usando como modelo ArmA, la metiltransferasa 16S de resistencia a aminoglucósidos más prevalente, se caracterizó la región responsable de la expresión del gen armA. El alineamiento de las secuencias descritas de armA mostró un alto grado de conservación de los primeros 221 nucleóti­dos corriente arriba del comienzo del gen entre todas las secuencias de referencia disponibles, estando situada en esta secuencia la región promotora putativa descrita 
previamente. Posteriormente, mediante la técnica de rapid amplification of cDNA ends 
(RACE), se identificó una región 5´UTR de exactamente 139 nucleótidos. El análisis me­diante truncamientos de esta región de 221 nucleótidos demostró la presencia de un dominio, situado inmediatamente corriente arriba del 5´UTR, absolutamente necesario para la expresión de armA, que también se confirmó analizando el perfil de resistencia y con la técnica de Western Blot con tripe FlagTag. 
La fusión de la región extendida 5´ de armA al gen reportero lacZα reveló que, bajo la regulación de esta región situada corriente arriba de armA, el gen reportero se expre­saba de manera constitutiva. El análisis en profundidad de esta construcción también 
XVII
 
  
demostró que la expresión constitutiva de lacZα no se veía afectada por la presencia o ausencia de aminoglucósidos en el medio ni por la presencia de metiltransferasas ac­
tivas en trans. Dado que estos resultados sugerían que el gen codificante de ArmA no está regulado por ningún mecanismo post-transcripcional, nuestro estudio se centró en el análisis de la región promotora situada corriente arriba del gen. 
A continuación realizamos un análisis mutacional de esta región promotora para iden­
tificar los nucleótidos específicos requeridos para la correcta expresión del gen de re­sistencia. Los resultados de este estudio se correspondieron con el modelo de la región promotora que es reconocida por el factor sigma RpoD. La sustitución de los nucleóti­dos conservados dio lugar a la supresión completa de la expresión de armA, alcanzando los niveles del fenotipo susceptible. Por otro lado, sustituciones en nucleótidos menos conservados dieron lugar a una reducción de 3 a 5 veces de la Concentración Mínima Inhibitoria conferida por armA, lo cual también se comprobó mediante Western Blot. Esto sugiere que el factor sigma RpoD, que preferentemente inicia la transcripción de genes asociados con la síntesis proteica, también induce la transcripción del gen de resistencia armA. 
El análisis del perfil de expresión de armA a lo largo de una curva de crecimiento bac­teriana indicó un aumento en la expresión durante la fase de crecimiento exponencial. Tanto el Western Blot como la RT-PCR cuantitativa indicaron la presencia de un pico en la expresión de armA entre las 2 y 5 horas de la curva de crecimiento, en comparación con los genes cromosómicos de referencia. Esto, una vez más, sugiere la capacidad de la región promotora para reclutar el factor sigma RpoD y modular así la expresión de 
armA de acuerdo a los niveles de expresión de otros componentes relacionados con la síntesis proteica.  
En conclusión, este estudio lleva a cabo un análisis en profundidad de los orígenes putativos de las metiltransferasas adquiridas del ARNr 16S y un primer análisis mutac-
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ional de la región promotora de armA. El análisis nucleótido a nucleótido de esta región 
promotora ha permitido identificar los nucleótidos claves para la correcta expresión de este mecanismo de resistencia tan prevalente. Por último, los resultados de nues­tro trabajo sugieren que este promotor es el responsable de asegurar unos niveles de resistencia adecuados en el hospedador, gracias a su transcripción por parte del factor sigma RpoD, responsable de la transcripción de clusters génicos relacionados con la síntesis proteica. 
Este estudio constituye la primera aproximación para dilucidar los mecanismos regu­
latorios de las metiltransferasas adquiridas del ARNr 16S, un mecanismo que confiere altos niveles de resistencia frente a todos los aminoglucósidos de relevancia clínica y que, a día de hoy, ya limita la utilidad de esta familia de antibióticos de importancia crítica. 
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3AMINOGLYCOSIDES AND AMINOGLYCOSIDE RESISTANCE 
3.1 The origins and discovery of antibiotics It is a well-established fact that antibiotics revolutionized modern medicine in the 20th century. That being said, the use of mixtures containing antibiotic properties rang­es back over 2000 years, with ancient Greeks and Egyptians using specially selected moulds and plants to treat infections (Forrest, 1982). 
In 1928, Alexander Fleming accidentally discovered the first antibiotic, penicillin, when a plate containing Staphylococcus was mistakenly contaminated by what was 
eventually identified as the fungus Penicillium notatum (Fleming, 1929). 
Figure 1. A photograph of a plate demonstrating the inhibition of Staphylococcus growth around a 
Penicilium colony (Figure from Fleming 1929) 
Although this phenomenon had been described with a number of moulds in the late 19th century, researchers at the time were unable to discover the mechanism under­lying this growth prevention. When Fleming noticed the inhibition zones around the fungus, it lead him to conclude that something was being released by the fungus that 
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results in the lysis of the bacterial cells  (Figure 1) (Fleming, 1929). In as early as 1930, 
the English physician C.G. Paine registered the first cure using crude penicillin (Wain­wright et al., 1986). Over the years, the discovery of penicillin would finally provide humanity with a strong therapeutic option to combat infectious diseases, which was of dire need at the time. Due to its effectiveness and relatively easy access, penicillin and a number of other antibiotics discovered in the following years were used to treat a very large number of infections, especially during World War II (Figure 2) (Bud, 2007). 
Figure 2: Illustration from a war-time advertisement for the products of Shenley Laboratories (Life Magazine)
As penicillin was inactive against Mycobacterium tuberculosis, a very common and ex­tremely dangerous pathogen at the time, in the early 1940’s Selman Waksman started 
the first systematic screening of soil bacteria in the search for agents exhibiting inhib­
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itory activity to this deadly pathogen. In 1944, one of Waksman’s PhD students, Albert Schatz, discovered such an inhibitory activity, mediated by the bacterium Streptomyces 
griseus (Waksman, 1944). What would later commonly be known as streptomycin, was 
the first antibiotic compound to exhibit inhibitory effects towards M. tuberculosis, and would result in Waksman being awarded a Nobel Prize in Medicine in 1952.  However, with the discovery of streptomycin, Albert Schatz did not only discover an antibiotic 
effective against tuberculosis but also the first of a large group of antibiotics known as the aminoglycosides. 
3.1.2 Aminoglycosides In 1949, not long after the discovery of streptomycin, Waksman and another of his students discovered the antibiotic neomycin, isolated from the bacterium Streptomyces 
fradiae (Waksman et al., 1949). Both streptomycin and neomycin found numerous ap­plications in the treatment of infectious diseases. However, the discovery of aminogly­cosides was far from over. The increasing resistance towards streptomycin combined with unfavourable levels of toxicity when treating life-threatening infections added pressure to discover more aminoglycosides. During this early struggle with antibiotic resistance, a large number of aminoglycosides were discovered from soil bacteria of the Streptomyces and Micromonospora genera. Among them were agents such as gen­
tamicin in 1963, which constituted a significant advance in the treatment of aerobic gram-negative bacterial infections (Weinstein et al., 1967). The emerging resistance as well as their relative toxicity are responsible for an array of medicinal biochemis­try approaches attempting to extend their antibacterial spectrum and potency while reducing their troubling toxicity. These efforts have resulted in semi-synthetic agents such as dibekacin and amikacin (derived from kanamycin), or more recently arbeka­cin (derived from dibekacin) among others, which have demonstrated that compounds obtained by this method are not only capable of overcoming certain resistance mech­
anisms but they also display distinct toxicological profiles (Jana et al., 2006). Today, 
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aminoglycosides remain highly potent, broad-spectrum antibiotics that are considered a critically needed last resort antimicrobial by the WHO (WHO, 2007).  Especially, as gram-negative bacterial strains acquire more advanced antimicrobial resistance pro-
files, physicians have had to re-consider the application of aminoglycosides. 
3.1.2.1 Nomenclature and structure of aminoglycosides As previously mentioned, all naturally occurring aminoglycosides were isolated from bacteria of either the Streptomyces (bearing the suffix -micin) genus or Micromono-
spora (bearing the suffix –mycin). 
Aminoglycoside activity is highly dependent on their chemical structure, which re­lies on the presence of one or more aminated sugars joined to a dibasic cyclitol back­bone via pseudoglycosidic linkages (Figure 3)(Vincens et al., 2002).  The nature of this backbone is the foundation of aminoglycoside function, as both the number of attached sugars and their precise location drastically alter the biological activity (Magnet et al., 2005; Benveniste et al., 1973). Furthermore, it has been shown that the presence of at least one amino group in these sugars is required for biological activity, although exceptions such as spectinomycin (an aminocyclitol not linked to amino sugars) and compounds like astromicin that bear the aminocyclitol fortamine, are also included in this family (Jana et al., 2006). 
The naturally occurring aminoglycosides identified to date are therefore categorized based on the nature of their aminocyclitol ring. As such, most literature divides this family of antibiotics into two groups: 2-deoxystreptamine (2-DOS) and non-2-deox­ystreptamine (non-2-DOS) (Figure 3). Based on the subtle differences within the 
backbone of antibiotics in these groups some choose to define the aminoglycosides based on the position of their glycosidic bonds e.g. 4,6 2-deoxystreptamine, 4,5 2-deox­ystreptamine and non-2-DOS agents (Figure 3)(Magnet et al., 2005). 
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Figure 3. Representation of 4,6 2-DOS, 4,5 2-DOS and other aminoglycosides organized by their aminocycli-
tol ring and the positions of their glycosidic bonds (adapted from Doi et al., 2016) 
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Aminoglycosides belonging to the 4,6 2-DOS family are among the most clinically sig­
nificant aminoglycosides including agents such as kanamycin and gentamicin (WHO, 2007). As these compounds were extremely successful, they were frequently used as templates for semi-synthetic drug development (Park et al, 2013). Within this group 
of antibiotics, there are two major subgroups. The first group consists of the aminogly­cosides kanamycin A and its derivatives (dideoxy-kanamicin and amikacin), kanamy­cin B and its derivatives (dibekacin and arbekacin) as well as tobramycin. The second subgroup of the 4,6 2-DOS aminoglycosides consists of gentamicin related compounds, 
which were first described in 1963, including the naturally occurring gentamicin, gen­tamicin B, gentamicin C, sisomicin and geneticin. As with the kanamycin subgroup, the gentamicin related aminoglycosides were potent antimicrobials that were used as tem­plates for derivatives such as netilmicin and isepamicin (Magnet et al., 2005). Due to its low cost and stability, gentamicin is the number one choice aminoglycoside in hospitals with low levels of resistance among Enterobacteriaceae and Pseudomonas aeruginosa. 
Aminoglycosides bearing an aminocyclitol ring substituted at positions 4 and 5 con­stitute the second subgroup of 2-DOS aminoglycosides (Figure 3). This family is made up of a number of naturally occurring agents isolated from the Streptomyces genus, in­cluding (but not limited to) neomycins, paromomycins, and butirosins. Another mem­ber of this group, ribostamycin, isolated from Streptomyces ribosidificus, is thought to be the precursor of the 4,5-2-DOS aminoglycosides (Kudo et al., 2016). 
All other members of the aminoglycoside family that do not bear a 2-DOS aminocy­clitol, belong to the non-2-DOS subgroup (Figure 3). This includes agents such as the original aminoglycoside streptomycin, which possesses a streptidine ring as the central aminocyclitol, and its derivatives (dihydrostreptomycin), fortimicin A and its deriva­tives (dactimicin) and apramycin (Magnet et al., 2005). 
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3.1.2.2 The ribosome as a drug target Before detailing the biochemical properties of aminoglycosides, it is important to high­light the prokaryotic ribosome and its features as an antimicrobial drug target (Figure 4).
Figure 4. Binding sites of antibiotics on the prokaryotic ribosomal subunits. The 30S subunit is shown on 
the left and the 50S subunit on the right. These sites were initially identified via biochemical and genetic 
techniques and later confirmed by means of X-ray crystallography. The ribosomal RNA is shown in yellow 
and grey, the ribosomal proteins (some of which have been removed for clarity) in bronze and blue. 
(Poehlsgaard et al., 2005) 
Since the structure of the prokaryotic ribosome was resolved by X-ray crystallogra­phy (Tischendorf et al., 1975), researchers have worked tirelessly to unravel the precise mechanisms of antibiotics that act on this intricate molecular machine that is so highly conserved throughout all living cells. While being highly conserved, subtle differences 
enable for the development of compounds with a surprising degree of specificity (Bött­ger et al., 2001). 
Prokaryotic and eukaryotic cells last shared a common ancestor a staggering 3.5 bil­
lion years ago, and since then the evolutionary changes have significantly diversified ribosomes while maintaining the same function in their various hosts (Poehlsgaard et 
al., 2005). Ribosomal activity is a very precisely regulated task that relies on a vast ar­
ray of supporting proteins, methylations and other post-transcriptional modifications to function accurately. The prokaryotic ribosome consists of two subunits: the smaller 30S subunit and the larger 50S subunit. The large component of the bacterial ribosome 
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consists of a 120 ribonucleotide 5S, a 2900 ribonucleotide 23S and a total of 31 pro­teins. The smaller component of the prokaryotic ribosome contains a 1540 ribonucle­otide 16S rRNA subunit that is bound to a further 21 proteins (Melnikov et al., 2012). 
Ribosomal fidelity is dependent on a highly orchestrated assembly process, requir­ing the precise regulation of ribosomal proteins and methylations. As such, even small 
modifications in certain functionally conserved regions of the ribosome (e.g. the A-site) can be fatal to the cell. 
To summarize, the strength of the ribosome as an antimicrobial drug target can be 
attributed to both its conservation and its diversification. The high degree of conser­vation means that even subtle changes of this extremely complex machinery can result 
in cell death, while its diversification permits for the design of therapeutic agents that 
target elements of the ribosome that are not present (or sufficiently altered) in eukar­yotic cells. 
3.1.2.3 Mode of action The cellular internalization of highly polar aminoglycosides begins with a self-pro­moted process requiring the drug-induced disruption of Mg2+ bridges between adja­cent lipopolysaccharide molecules of the outer membrane (Vaara, 1992). Thereafter, aminoglycosides pass through the cytoplasmic membrane via an energy dependent process (EDP-I) utilizing the electron transport chain (Bryan et al., 1983). This sensi­tive process is rate limiting and can be inhibited by divalent cations, hyperosmolarity, low pH and anaerobiosis (Xiong et al., 1996). Based on the biochemical properties of 
aminoglycosides, once within the cytosol, they exhibit a high affinity for the A-site with­in the 30S subunit of prokaryotic rRNA (Figure 5). 
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Figure 5. Molecular representation of a 4,6 2-DOS (left) and a 4,5 2-DOS (right) aminoglycoside interacting
with specific residues within their ribosomal target (Dashed lines represent possible hydrogen bonds, N1 and
N7 refer to the position of the methyl group). The aminoglycosides are depicted in green whereas the riboso-
mal residues G1405 and A1408 are depicted in red and blue respectively. (Figure from Wachino et al., 2012) 
The binding to their target in the A-site of the 16S rRNA is the second energy de­pendent process (EDP-II) of aminoglycoside action (Bryan et al., 1983). The interaction between aminoglycosides and the ribosome they act on has been the subject of com­prehensive biochemical research using nuclear magnetic resonance (NMR) and X-ray crystallization. The application of X-ray diffraction methods in 2000 shed considerable light on the exact mechanism that is being disrupted by the presence of aminoglyco­sides in the A-site (Yoshizawa et al., 1998). Studies performed in the presence and ab­sence of aminoglycosides bound to their target site demonstrated that aminoglycosides interrupt a crucial proofreading step required for translocation and further translation. When functioning correctly, there is an initial recognition of the mRNA codon and its charged tRNA counterpart (the anticodon), after which a proofreading step is required prior to translocation (Melançon et al., 1992; Green et al., 1997, Jenner et al., 2010). A hydrogen bond network formed by A1492 and A1493 (of helix 44) with the ribose 
2’-hydroxyl groups of the first two bases of both the codon and anticodon allows for the discrimination of correct codon-anticodon matches (Cate et al., 1999). If and when the cognate mRNA-tRNA complex is recognized, the two adenine residues 1492 and 1493 
flip out of the helix, which results in an increased affinity for the cognate tRNA and thereby stabilizes the complex (Vicens et al., 2002). 
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The aminoglycoside-binding site is located at the 16S tRNA acceptor A-site (aminoa­cyl site), which includes portions of loop 530, helix 34 and helix 44 (involved in codon anticodon matching) as well as a less described secondary site in helix 69 of the 23S portion of the ribosome, involved in ribosomal recycling. The cationic amine groups of 
aminoglycosides bind specifically to the major grove of helix 44, in a negatively charged pocket on the 16S rRNA (Figure 6)(Moazed et al., 1987; Woodcock et al., 1991). 
Figure 6. Representation of the prokaryotic 70S ribosome, with the large 50S subunit (tan) and the small 
30S subunit (light blue) with an enlarged view of the decoding site which forms the aminoglycoside binding 
pocket within helix 44 of the 16S rRNA. Bases A1492-A1493 (orange) flip out upon cognate codon-antico-
don recognition or constitutively in the presence of aminoglycosides. Figure depicts gentamicin (yellow) 
and neomycin (red) bound to the decoding site. (Figure from Feldman et al., 2010) 
These interactions result in a constitutional flip-out within helix 44, which not only decreases the rate of A-site tRNA dissociation but also increases the tRNA binding af­
finity (Fourmy et al., 1996; Recht et al., 1996). Recent literature expands our tradition­al understanding of this process, demonstrating that some aminoglycosides (such as apramycin) but not all, do not displace A1492 and A1493, and that their main activity is a result of blocking translocation (Figure 6)(Feldman et al., 2010; Tsai et al., 2013). As such, the consequence of aminoglycosides binding to the A-site constitutively and indiscriminately stabilizes both cognate and noncognate mRNA-tRNA complexes and translation can continue. Subsequent peptide synthesis will thus be faulty and/or trun­
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cated, due to the loss of translational fidelity; eventually, the build-up of faulty proteins results in cell death. Additionally, the incorporation of these faulty proteins into the cytoplasmic membrane facilitates further aminoglycoside uptake (Busse et al., 1992). 
3.1.2.4 therapeutic properties and clinical applications 
One of the most important features of any therapeutic agents is the specificity of its action. Achieving the adequate bioavailability of a therapeutic agent in the correct location is the key to a successful treatment. Aminoglycoside toxicity levels have been 
well described since the first applications of aminoglycosides (Heilman et al., 1945; Hettig, 1946). However, in the early days of the aminoglycosides, streptomycin was the 
first, and at the time, only antibiotic to show activity against M. tuberculosis and, as such, the advantages of its application overshadowed issues with toxicity, especially in 
life threatening situations. Today aminoglycosides are still a very significant last resort therapeutic agent despite their unfavourable side effects. 
Aminoglycosides are water-soluble and have a relatively low molecular weight of around 500-800 g/mol. They are highly stable at room temperature and a pH between 7.5 and 8.5, giving them a shelf life of several months in solution (Vining, 1990). This 
stability also makes them heat resistant, which amplifies their clinical potential. Mem­bers of this family of antimicrobials, such as gentamicin, have a number of key positive attributes including their broad spectrum, low cost as well as their capacity to be ad­ministered synergistically with other antibiotics. When aminoglycosides are adminis­
tered with β-lactams or other cell wall synthesis inhibiting agents, their activity is in­creased due to augmented cellular uptake, especially in intrinsically resistant microbes unable to internalize the aminoglycosides (Eliopoulos, 1989). 
Aminoglycosides are considered to be broad-spectrum antimicrobial agents that act in a concentration dependent fashion. With the exception of spectinomycin and kasug­
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amycin (inhibitors of translocation), they act in a bactericidal manner (Levitan, 1967; Tsai et al., 2013). Currently, the 4,6 2-DOS aminoglycosides (e.g. gentamicin and ami­
kacin) are the most clinically significant aminoglycosides. They exhibit high levels of activity against a wide range of mostly aerobic gram-negative bacteria such as Pseu-
domonas spp., while they have also been shown to display bactericidal activity on some mycobacteria and staphylococci (Jana et al, 2006). Due to their biochemical properties aminoglycosides are poorly absorbed in the gut and are therefore usually administered via injection or infusion (Kadurugamuwa et al., 1993; Edson et al., 1999). Convention­ally, aminoglycosides have been administered in multiple doses per day, although it has 
been shown that single daily doses achieve a similar antimicrobial efficacy (Freeman 
et al., 1997). As mentioned, their action is concentration based, whereby typically ≤ 25 
μg/ml of clinically applied aminoglycosides are required to inhibit protein synthesis (Takano et al., 1994). Although the clinical application of aminoglycosides has largely been replaced by cephalosporins, their broad spectrum of activity makes them ideal agents for emergency treatments. 
3.1.2.5 Aminoglycoside toxicity Unfortunately, it is known that aminoglycosides also exhibit activity on eukaryotic 
80S ribosomes - although they have at least 10 times more affinity for the prokary­otic ribosome - leading to toxicity and secondary effects during treatment (Recht et 
al., 1999). Specifically, they result in ototoxicity, nephrotoxicity and, in very rare cases, neurotoxicity, all of which can be mitigated based on the choice of drug, duration of treatment and the patients kidney function (Jiang et al., 2007). While the nephrotox­icity of aminoglycosides can be counteracted, the drug induced hearing loss is typical­ly permanent. Side effects such as hearing loss are usually associated with long-term treatments. There are isolated cases in which a single injection has led to hearing loss, 
but a significant proportion of those cases have been linked to a guanosine to aden­osine substitution at position 1555 of the human mitochondrial ribosomes (Forge et 
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al., 2000). The mechanism underlying aminoglycoside toxicity has been the focus of many studies. It has been described that this toxicity originates due to the interrup­tion of mitochondrial ribosomes and the subsequent release of reactive oxygen species (ROS) (Gutell et al., 1994). The ototoxicity of aminoglycosides has been linked to their metal-chelating capacities, as demonstrated using metal complexes with gentamicin and neomycin (Xie et al., 2011). The, in some cases, permanent side effects of amino­glycoside toxicity is a major drawback of this entire family of antibiotics, which must be taken into careful consideration when selecting an appropriate therapeutic agent. Although in many cases clinicians prefer antibiotics with less toxicological side effects, 
rising resistance levels to other antibiotics and their efficacy in emergency situations make aminoglycosides a crucial therapeutic option. 
3.1.2.6 Antibiotic resistance Antibiotic resistance is the ability of a microbe to survive otherwise lethal concentrationsof an antimicrobial agent. Such resistance can be achieved in three ways: (i) a bacteriummay be intrinsically resistant; (ii) resistance can be achieved via genetic mutation; (iii) aresistance determinant can be acquired horizontally from other bacteria (Davies, 1997).
As antibiotics are produced by microbes themselves, resistance genes preventing thesuicidal action of these agents to their producers are equally ancient mechanisms. In­trinsic resistance in producers is generally mediated by one of three main pathways: (i)
inactivation of the antibiotic, (ii) efflux of the antibiotic and (iii) modification of the sus­ceptible molecular target. However, intrinsic resistance is not limited to antibiotic pro­ducers. Depending on the species of bacteria, for example, differences in the compositionof the membrane may naturally prevent the internalization of the compound, renderingthe bacterium resistant (Nikaido, 1994).
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Although resistance can appear spontaneously because of random genetic mutations, factors such as the excessive misuse of antibiotics greatly facilitate the prevalence of resistance (Fair et al., 2014).  Since antibiotics have been in ever-widening therapeutic use, the development of antibiotic resistance has followed. Researchers and clinicians were quick to realize that, every time a novel antibiotic, a derivative of an existing anti­biotic or a broader spectrum variant of an antibiotic is released to the market, clinically 
significant resistance emerges rapidly. For a number of antibiotics, such as penicillin, resistance was discovered almost immediately after the introduction of the agent to the market, as early as 1940 (Abraham et al., 1940), whereas in other cases such as vanco­mycin, resistance took almost 30 years to be reported (1987) (Schwalbe et al., 1987). This has largely been associated with the limited use of vancomycin compared to peni­cillin. Furthermore, the resistance mechanisms to various antibiotics differ substantial­
ly. While β-lactam resistance can be achieved by the action of a single gene product, the 
hydrolytic β-lactamase, the vancomycin resistant Enterococcus (VRE) requires a 5-gene resistance cassette (Bugg et al., 1991). Hospital environments are especially troubling for antibiotic resistance dissemination, as there is an intensive virtually constant expo­sure of bacteria to antibiotics. In such conditions there is a very strong selective pres­sure for microbes to maintain resistance determinants, compensate for their biological burden and disseminate them (Schulz zur Wiesch et al., 2010). 
The troubling rate of increased resistance prevalence is also in large part due to the horizontal transfer of resistance determinants (Courvalin, 1994). Resistance confer­ring genes are often found within genetic elements capable of mobilizing resistance genes between genetic environments and even between bacteria of different families (Barlow, 2009). Such mobile genetic environments greatly facilitate the dissemination of resistance genes as multiple determinants can be quickly acquired and integrated by a receiving strain. Many resistance genes exclusively exist in such highly variable genetic environments (Martinez, 2008). 
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Figure 7 Mortality impact of antimicrobial resistance in relationship to other major diseases between now 
and 2050 (Figure from O’Neill, 2014) 
The rate at which antimicrobial resistance is disseminating is truly alarming for the future of modern medicine. It is estimated that prior to the introduction of antibiot­ics, approximately 30% of all deaths in the United States were as a result of bacterial infections (tuberculosis, pneumoniae and gastrointestinal infections) (Department of Commerce and Business administration, 1906). In 2014, an estimated 700,000 deaths were associated with antimicrobial resistance and in the same review on AMR it was 
16 
published that, by 2050, mortality rates associated with antimicrobial resistance will rise to around 10 million per year (Figure 7)(O’Neill et al., 2014). While this dilemma is spiralling out of control, pharmaceutical policies and new regulatory hurdles are mak­ing the antimicrobial market increasingly unattractive (Figure 8). 
Figure 8. Representation of the antimicrobial drugs approved in the United States (Figure from Spellberg, 
2011) 
In 2004, only 1.6% of drugs in clinical developments by the world’s 15 largest phar­maceutical companies were antibiotics (Shlaes, 2010). This is due to a variety of fac­tors. Primarily, antibiotic treatment is typically administered for a short time-period 
and then no longer necessary, making this market much less profitable than medicines related to chronic conditions. Additionally, in order to prevent the rapid emergence of antimicrobial resistance to new agents, recently approved antibiotics are typical­
ly reserved for complicated infections that have shown to be resistant to older first-choice antibiotics. While this is an effective strategy to conserve the functionality of these drugs, it greatly diminishes the initial investment return for the pharmaceutical companies. However, depending on the type of resistance mechanism (e.g. target mod­
ification), bacteria may even harbor resistance to antimicrobial agents that have not yet been released to the market, which also greatly limits the return (e.g. plazomicin) (Doi 
et al., 2016). 
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To make matters worse, regulatory measures grow increasingly tight for antibiotics (Fair et al., 2014). While the tolerance for side effects grows smaller, pharmaceutical companies are now required to demonstrate superiority of novel agents rather than non-inferiority, as was the case in the past (Spellberg et al., 2008). As a result of the aforementioned complications, currently the cost of developing a single antimicrobial agent has skyrocketed to around $1.7 billion and takes between 12 and 15 years. As such, it is not surprising, but very concerning, that as of 2013 there are only 4 multina­tional pharmaceutical companies that produce antibiotics (Fair et al, 2014). 
While there are government initiatives to introduce novel antibiotics, no such entity has ever discovered and developed an antibiotic and as of now, major contributions from this sector are not expected. In response to the diminishing antimicrobial market, policies have been enacted and incentives have been offered by international organiza­tions such as the World Health Organisation (WHO), the European Center for Disease Control (ECDC), and the Infectious Diseases Society for America (IDSA) to revitalize this market (Fair et al., 2014). Additionally, the US senate and the European Union, among others, are placing increasing emphasis on tackling antimicrobial resistance by offering funds and scholarships to educate the next generation of antimicrobial resist­ance researchers (European Medicines Agency, 2010; WHO, 2014). 
There are four acquired mechanisms by which microbes resist antibiotic activity: (i) 
mutation/modification of the drug target site (ii) enzymatic drug modification or in­activation (iii) decreased permeability of the drug across the membrane  and (iv) in­
creased efflux of the drug out of the cell (Figure 9). 
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Figure 9. Representation of the normal activity of aminoglycosides (blue) and the four mechanisms of re-
sistance: target modification (orange), enzymatic modification (purple), decreased drug permeability (tan) 
and efflux pumps (pink). (Figure from Garneau-Tsodikova et al., 2016) 
3.1.2.7 Aminoglycoside resistance Shortly after the discovery of streptomycin as an antimicrobial agent, Waksman him­self recognized that bacteria grown in the presence of streptomycin quickly became resistant to its effects (Waksman et al., 1945). As previously described, this early strug­gle with antibiotic resistance lead to the discovery of a large number of antibiotics, in­cluding aminoglycosides, from soil bacteria such as Streptomyces and Micromonosporaspecies as well as the formulation of semi-synthetic derivatives (Park et al, 2013). Un­fortunately, no matter how many new antibiotics are discovered, resistance will always 
follow shortly. In the following sections, I will briefly introduce the three major path­ways by which microbes can become aminoglycoside resistant. 
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Decrease in intracellular drug concentration This resistance mechanism is most commonly found in Pseudomonas spp. as well as other non-fermenting gram-negative bacilli and is associated with membrane imper­meabilization (Taber et al.,1996). Although this mechanism only results in intermedi­
ate resistance levels, it is clinically significant as it is a stable phenotype that affects all aminoglycosides. Additionally, it has been shown that prolonged aminoglycoside treat­ments of aerobic gram-negative bacteria, gradually renders previously susceptible mi­crobes more resistant (Karlowsky et al., 1997; Xiong et al., 1997). This is most likely 
a result of gradually acquiring membrane modifications that reduce aminoglycoside uptake into the cell. 
Energy dependent bacterial efflux of aminoglycosides is another significant cause of antibiotic resistance and has been shown to confer resistance to agents such as kana­mycin, neomycin and hygromycin A (Hayashi et al., 1997). Recently it has been demon­
strated that aminoglycosides are substrates for a number of multidrug efflux pumps, 
including members of the five major families of bacterial transporters (Poole, 2005). This is interesting because initially it was assumed that multidrug transporters were 
specific for either hydrophobic or amphiphilic compounds and that, as such, aminogly­cosides would not be affected (Putman et al, 2000). Fortunately, at times, this resist­ance mechanism can be overcome by the synergistic application of aminoglycosides 
with cell wall destabilizing agents such as the β- lactams (Ioannis et al., 2005). 
Aminoglycoside-modifying enzymes Aminoglycoside modifying enzymes constitute the most prevalent and widely distrib­uted form of resistance to this family of antibiotics, as they are typically found within mobile genetic elements such as transposons and plasmids (Tolmasky, 2007). Although 
levels of resistance do not reach those achieved by target modification, there are many 
different enzymes capable of modifying specific aminoglycosides and multiple such en­
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zymes can reach significant levels of resistance to a broad range of aminoglycosides. Deactivating enzymes such as N-acetyltransferases (AAC), O-nucleotidyltransferases (ANT) and O-phosphotransferases (APH) are commonly found in both gram-positive and gram-negative microbes (Ramirez et al., 2010). These enzymes typically catalyse 
the covalent modifications of specific amino or hydroxyl residues. The resulting mod­
ified agent then displays a much lower binding capacity for its ribosomal target site (Shaw et al., 1993). Additionally, these modifications also interrupt the second energy dependent process (EDP-II) of aminoglycoside activity, which prevents the binding of the aminoglycosides to the A-site of the ribosome (Mingeot-Leclercq et al., 1999). Al­though not entirely clear, these enzymes most likely originate from intrinsic enzymes of the bacteria that, under normal conditions, do not result in a resistance phenotype 
to aminoglycosides. However, small modifications or the overexpression of such an en­zyme (especially under the pressure of aminoglycoside treatment) could lead to low levels of resistance (Wright et al., 1997). Even minor alterations in the amino acid se­
quence of these proteins have a profound effect on the substrate specificity (Wu et al., 1997). Therefore, it has also been speculated that a number of the current deactivating enzymes have originated from one or a few common ancestors (Magnet et al., 2005). The variety of molecules in combination with their substrate plasticity are concerning because even if newly derived aminoglycosides can avoid the action of such an enzyme, 
simple modifications under antibiotic pressure may render this new agents ineffective (Jana et al., 2006). 
Target modification There are two types of aminoglycoside resistance mechanisms that are mediated by 
modifications of the ribosomal target site. The first, although uncommon (due to the high degree of conservation within this region), are point mutations in the ribosomal 16S RNA as well as mutations in the rpsL gene, which codes for the ribosomal protein S12 that has been associated with aminoglycoside resistance (Cooksey et al., 1996). 
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Mutations of the 16S rRNA are only clinically relevant for streptomycin resistance of M. 
tuberculosis, as Mycobacteria are the only genus of eubacteria with a single copy of the ribosomal operon, implying that a single mutation can confer resistance (Finken et al., 
1993). The second, and clinically much more significant mechanism of resistance con­
ferring target modification, is the post-transcriptional methylation of the 16S A-site. Such methyltransferases are very common in aminoglycoside producing Streptomyces 
spp. and Micromonospora spp. but are becoming increasingly relevant, as there is an ev­er-growing number of acquired resistance methyltransferases isolated from mobile ge­netic elements, facilitating their dissemination to clinically relevant bacteria (Wachino 
et al., 2012). The details of both the intrinsic and acquired aminoglycoside resistance conferring 16S rRNA methyltransferases will be the subject of the following section. 
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3.2 16S rRNA methyltransferase mediated aminoglycoside resistance The 16S rRNA methyltransferases, whether acquired or intrinsic, confer extremely high levels of resistance to a broad range of aminoglycosides, including the most clini­cally relevant. This section will outline the key characteristics of both groups of meth­yltransferases. 
3.2.1 Intrinsic aminoglycoside resistance conferring 16S rRNA 
methyltransferases Antibiotics are naturally occurring secondary metabolites that have been produced bymicrobes long before man discovered their potential applications in medicine. As such,
antibiotic resistance is an equally ancient phenomenon. The first resistance conferringmechanisms were likely to those protecting antibiotic producers from the toxic effects ofthese agents. While this can be achieved in many ways, as outlined in the previous sec­
tion, target modification is a very effective way of ensuring that the expression of thesesecondary metabolites does not kill the producer (Cundliffe, 1989).
Especially for antibiotics that act on the ribosome, target modification is a very wide­
spread and effective form of self-defence. This is usually achieved by site-specific methyl­ation of ribosomal residues within the target site of the antibiotic in question, and resultsin high levels of resistance to agents sharing that target site. Microorganisms producingagents that act on the risobome such as macrolides, lincosaminides or thiopeptides have
been shown to use ribosomal target modification to protect themselves from antibioticaction (Cundliffe et al., 2010). That being said, not all producers of antibiotics that act onthe ribosome rely on this mechanism of resistance. However, producers of agents suchas neomycin, streptomycin and tetracycline have not been found to carry intrinsic resist­ance conferring rRNA methyltransferases (Table 1)(Cundliffe et al., 2010). 
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Table 1. Intrinsic 16S rRNA methyltransferases harboured by aminoglycoside producers.
	
Actinomycetes are ground dwelling gram-positive microorganisms that are, in large part, made up of Streptomyces spp. and Micromonospora spp., that naturally produce aminoglycosides as secondary metabolites. This is achieved by a post-transcriptional methylation of either the N-7 position of nucleotide G1405 or the N1 position of nucle­otide A1408 (Figure 10) (Beauclerk et al., 1987). 
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Figure 10. Representation of the ribosomal A-site, the target site of aminoglycosides and both intrinsic and ac-
quired aminoglycoside resistance conferring 16S methyltransferases (Figure adapted from Magnet et al., 2005) 
While methyltransferases acting on G1405 have been identified in both Streptomy-
ces spp. and Micromonospora spp., methylations of A1408 have only been described in Streptomyces spp. (Wachino et al, 2012). Methyltransferases acting on both of these residues require S-adenosyl-L-methionine (SAM) as the source of the methyl group to generate 7-methylguanosine or 1-methyladenosine, respectively. These intrinsic resist­ance determinants can be divided into two categories: the Kgm family and the Kam family (Holmes et al., 1991a Husain et al., 2010). Methyltransferases pertaining to the Kgm (kanamycin gentamicin methyltransferase) family, methylate position N7 of res­idue G1405 whereby they confer high levels of resistance (>1000mg/L) to 4,6-2-DOS aminoglycosides such as kanamycin, gentamicin and tobramycin, but remain suscep­tible to other aminoglycosides (Cundliffe, 1989; Holmes et al., 1991a). The specificity 
of this resistance is based on the specific structure of the 4,6-2-DOS aminoglycosides that form a hydrogen bond with G1405. Due to structural differences in the 4,5-2-DOS group of aminoglycosides, they do not require such an interaction and therefore mi­crobes methylating G1405 remain susceptible. 
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The second family of intrinsic resistance methyltransferases is known as the Kam (kanamycin apramycin methyltransferases) family, which methylate position N1 of res­idue A1408 (Holmes et al., 1991b). Like the Kgm family, this family of intrinsic meth­yltransferases confers equally high levels of resistance (>1000mg/L), but to neomycin and apramycin as well as kanamycin but less so to gentamicin. 
Producing microbes must ensure that this methylation takes place prior to the pro­duction of the aminoglycosides. As such, both the Kgm and Kam family of intrinsic methyltransferases are commonly found within gene clusters responsible for the bi­osynthetic production of the respective aminoglycoside (Mak et al., 2014). This is an elegant form of ensuring the producers safety after the production of this potentially lethal secondary metabolite while minimizing the biological burden incurred. 
3.2.2 Acquired aminoglycoside resistance conferring 16S rRNA methyltransferases 3.2.2.1 History and nomenclature In the year 2000, a Klebsiella pneumoniae isolated from a urinary tract infection inFrance displayed unusually high levels of resistance to all 4,6-2-DOS aminoglycosides(Galimand et al., 2003). The genetic fragment bearing the resistance determinant wascloned and sequenced, before comparing it to previously uploaded sequences in Gen­bank. This unknown determinant was later shown to be identical to a sequence upload­ed from a Citrobacter freundii strain bearing a pCTX-M3 (Accession number AF550415)plasmid in Poland (Golebiewski et al., 2007). Interestingly, the sequence of pCTX-M3 wasalready ‘completely’ annotated, however this methyltransferase like gene was missed. In2003 Galimand et al. characterized and named this protein ArmA (aminoglycoside re­sistance methyltransferase A) (Galimand et al., 2003). It is also noteworthy that even the
first isolate bearing armA was discovered alongside the ESBL gene bla
CTX-M-3. It did nottake long to realize that armA was just the tip of the iceberg. Only 4 months after thepublication describing armA, Yokoyama et al. published an article describing another 16S
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rRNA methyltransferase from a 1997 P. aeruginosa isolate, rmtA (ribosomal RNA meth­yltransferase A) (Yokoyama et al., 2003). Like armA, this gene conferred unusually highresistance to 4,6-2-DOS aminoglycosides. 
Since the discovery of ArmA and RmtA until now, more than ten distinct acquired 16S rRNA methyltransferases have been published, in addition to three variants (Doi et al., 2016). The acquired 16S RMTases can be divided into two families, Arm (aminoglyco­side resistance methyltransferase) and Pam (pan-aminoglycoside resistance methyl­transferase). All of the previously described RMTases (ArmA and RmtA-H) belong to the Arm family of methyltransferases and confer resistance to the most clinically rel­evant aminoglycosides. Interestingly, the only known acquired 16S methyltransferase that belongs to the Pam family is NpmA, which methylates position N1 of A1408 result­ing in resistance to structurally diverse aminoglycosides such as kanamycin, neomycin or apramycin (Wachino et al., 2007). 
3.2.2.2 Mode of action The acquired aminoglycoside resistance conferring 16S rRNA methyltransferases func­tion very similarly to the intrinsic resistance RMTases. In fact, based on their GC content(rmtA has a GC content of >55%), it has been speculated that these acquired resistancemethyltransferases originated from ancestral intrinsic resistance RMTases within high GCcontent species (e.g. actinomycetes)(Liou et al., 2006; Doi et al., 2007). Their action alsodepends on SAM as a source of the methyl group. Furthermore, these 16S RMTases alsoact on the N-7 position of residue G1405 or the N1 position of residue A1408 to produce7-methylguanosine or 1-methyladenosine, respectively (Kotra et al., 2000, Gutierrez et
al., 2012). The respective methylation greatly reduces the affinity of aminoglycosides fortheir target-site, without affecting the function of the ribosome, resulting in high levelsof resistance to a number of aminoglycosides. This enzymatic activity has been further
characterized in vitro with purified ArmA, RmtB and RmtC, demonstrating that the SAMdependent methylation occurs once the 30S subunit of the ribosome is fully assembled
27 
INTRODUCTION
 
 
 
 
   
   
 
 
  
  
    
(Wachino et al., 2010). As this methylation does not occur with 16S rRNA alone, it is clear
that the affinity of these enzymes requires the full 3D binding pocket to function. Exper­iments conducted using Matrix-assisted laser desorption/ionization mass spectrometry
(MALDI-MS) have also confirmed that the methylation site of these enzymes is positionN7 of residue G1405 (Gutierrez et al., 2012). Similar experiments have also demonstrat­
ed that the affinity of NpmA for the N1 position of residue A1408 also requires the ma­ture 30S subunit of the ribosome (Wachino et al., 2010). In summary, these precise target
modifications are capable of preventing aminoglycoside binding, without interfering withthe proof reading mechanisms in place to allow for the accurate translation of proteins.The methylation of G1405 does however interfere with the housekeeping methylation ofC1407 by the rsmF methyltansferase (Gutierrez et al., 2012). Despite displacing this high­ly conserved methylation, the deletion of this intrinsic methylation does not incur effects
on the fitness of the bacterium (Gutierrez et al., 2012). Lioy et al, however, demonstratedthat the expression of armA did incur a biological cost on the host. By generating mutants
incapable of interacting with the ribosomal RNA they demonstrated that this fitness costis a result of the methylation rather than the transcription/translation of armA (Lioy et
al., 2014). 
3.2.2.3 Clinical significance and prevalence 
As aminoglycosides are typically not a first line antibiotic, until recently, the clinical im­pact of this resistance mechanism was thought to be relatively limited (Doi et al., 2016).However, the increasing prevalence of this resistance determinant alongside other clin­ically relevant resistance genes is troubling. Furthermore, the nature of this resistancemechanism is very concerning. A single methylation of residue G1405, for example,
causes an unusually high-level resistance to almost all clinically significant (4,6 2-DOS)aminoglycosides (Magnet et al., 2005). As previously outlined in the clinical applicationsof aminoglycosides, their broad-spectrum activity towards Gram-negative microbesmakes them an ideal agent for emergency treatments of multidrug-resistant (MDR) and
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extensively drug-resistant (XDR) microbial infections, which makes this resistance mech­anism even more concerning (WHO, 2007).
Clinically, the most prevalent mechanism of aminoglycoside resistance is mediated 
by enzymatic modification; however, strategies are currently being employed to ensure 
the continued efficacy of the aminoglycosides (Magnet et al., 2005).  Amikacin, for ex­
ample, is typically reserved for pathogens that exhibit resistance to both the first line antibiotic and aminoglycosides. As amikacin is, for the most part, immune to enzymat­
ic modifications, it can be utilized despite the presence of this resistance mechanism (Ramirez et al., 2010). A key difference between 16S rRNA methyltransferases and re­sistance mechanisms like the modifying enzymes is the level of MIC they achieve. Deac­tivating enzymes are also typically less broad spectrum and as such confer resistance to some aminoglycosides, but others can still be used in their place, as is the case for amikacin (Garneau-Tsodikova et al., 2016). 
Since their discovery in the early 2000’s, 16S rRNA methyltransferases have been 
increasingly identified alongside other resistance determinants, such as carbapene­mase genes, which confer resistance to other last resort antibiotics (Doi et al., 2016). The global spread of carbapenem-resistant Enterobacteriaceae has greatly accelerated since the appearance of KPC and NDM-type carbapenemases, demonstrating a 30% increase in carbapenem resistant A. baumannii from 1995-2004 (Fair et al., 2014). Al­though the 16S RMTases are a relatively new resistance mechanism, they appear to be converging with the carbapenemase epidemic, which is greatly facilitating the ap­pearance of extensively drug-resistant and even pandrug-resistant microbes that cause untreatable life-threatening infections (Fair et al., 2014). In pathogens where carbap­enems have already been ruled out due to resistance, the presence of 16S methyltrans­ferases remove key aminoglycosides such as gentamicin, amikacin and tobramycin as a last resort option (Garneau-Tsodikova et al., 2016). For example, plazomicin, which 
is a new aminoglycoside under development specifically for the treatment of carbape­
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nem-resistant Enterobacteriaceae, cannot be applied to treat infections caused by bac­teria that also harbor 16S methyltransferases (Doi et al., 2016). Currently, in Europe, Japan and Argentina, the prevalence of 16S rRNA methyltransferases remains relatively low, around 1% of Enterobacteriaceae have been shown to harbor these methyltrans­ferases (Doi et al., 2016). That being said, several single-center surveillance studies 
have placed 16S RMTase prevalence in Enterobacteriaceae significantly higher, espe­cially in Asia. In Korea prevalence rates have been published to be as high as 11.4% in Enterobacteriaceae (Doi et al., 2016). A more comprehensive study of Chinese isolates between 2006 and 2008 demonstrated that 5.4% and 6.2% of E. coli and K. pneumoniaeclinical isolates harbored either armA or rmtA (Livermore et al., 2011). Studies con­cerning methyltransferace prevalence in Enterobacteriaceae demonstrated that out of 1000 consecutive clinical isolates, collected in an Indian hospital between 2010 and 2011, a total of 14% carried at least one 16S rRNA methyltransferase. However, even higher rates have been reported: in Saudi Arabia, 37% of 330 Enterobacteriaceae iso­lates carried at least one 16S RMTase, in 2011 (Al Sheikh et al., 2014). While the prevalence of the Arm family of acquired resistance conferring 16S meth­yltransferases is consistently augmenting, there has still only been one isolated case of a Pam family N1-A1408 methyltransferase, npmA, in a Japanese E. coli isolated in 2003 (Wachino et al., 2007). This is interesting, as a widespread dissemination of a pan-aminoglycoside resistance methyltransferase could be a serious problem for the future of aminoglycosides. While recent reports of npmA in K. pneumoniae spp. and 
Enterobacter spp. in Saudi Arabia are troubling, the dissemination of npmA is virtually non-existent when compared to the dissemination of the most prominent Arm family 16 methyltransferases (Doi et al., 2016). The 16S rRNA methyltransferases are steadily 
increasing in more and more clinically significant bacteria, including in some of the ES­KAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species), which are highly resistant bacteria responsible for 2/3 of the deaths caused by resistant path­ogens worldwide (Rice., 2008). 
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3.2.3 The genetic environment of the 16S rRNA methyltransferases and its role 
in their dissemination Due to the potential impact of this resistance mechanism and the fast rate of its dissemination, a number of studies have focused on the genetic environment that underlies the dissemination of 16S rRNA methyltransferases (Galimand et al., 2003; Gonzalez-Zorn et al., 2005; Toleman et al., 2006). As is the case with many troubling re­sistance mechanisms, the acquired 16S rRNA methyltransferases are exclusively found within mobile genetic elements (Doi et al., 2016). While most 16S methyltransferases are encoded on plasmids (both conjugative and non-conjugative) alongside a number of other resistance mechanisms, recent literature also describes these acquired meth­yltransferases within the chromosomes of multi-drug resistant pathogens (Rahman et 
al., 2015). As such, the rate of their dissemination is greatly facilitated by both horizon­tal and vertical gene transfer. In the following section I will outline the genetic environ­ments, plasmid incompatibility groups and any resistance determinants found along­side the acquired 16S rRNA methyltransferases. 
3.2.3.1 armA ArmA, the most disseminated 16S methyltransferase has been almost exclusively 
identified on plasmids, although very recent publications now describe armA within the chromosome (Karah et al., 2016). Initially it was discovered alongside the ESBL gene 
blaCTX-M3 on the IncL/M plasmids pCTX-M3 and pIP1204 in C. freundii and K. pneumoni-
ae respectively (Galimand et al., 2005). The armA gene has exclusively been identified 
within the 16.6kb transposon Tn1548. Specifically armA is located downstream of an insertion sequence (ISCR1) and followed by a class 1 integron containing the resistance genes dhfrXII (a dihydrofolate reductase conferring trimethoprim resistance), aadA2(an adenyltransferase conferring streptomycin resistance) as well as sul1 (conferring sulfonamide resistance). Typically, the macrolide resistance conferring genes mel and 
mph2 aswell as trpA (a transposase-like gene) have been identified downstream of 
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armA. While the genetic environment of armA within the class 1 integron have been shown to vary slightly this global genetic context of armA appears to be very well con­served despite being widely disseminated amongst Enterobacteriaceae and Acineto-
bacter baumannii (Doi et al., 2007; Bercot et al., 2008; Granier et al., 2011). 
Within Tn1548 armA was shown to be flanked by two copies of IS6, which have been experimentally shown to readily transpose armA between genetic environments (Gal­imand et al., 2005). This in combination with the vast array of resistance genes armAcan be co-selected with, have greatly facilitated the global dissemination of armA, mak­ing it, alongside rmtB, the most prevalent 16S rRNA methyltransferase. The prevalence of both armA and rmtB has been repeatedly associated with the co-selection of these methyltransferases alongside the global emergence of blaNDM-1 harboring Enterobacte­riaceae (Carattoli et al., 2012). 
3.2.3.2 rmtA To date, rmtA has also only been identified within transferable plasmids or more spe­
cifically in transferable genetic elements such as transposons. The genetic environment harboring rmtA in P. aeruginosa was found to be flanked by two copies of a kappa-gam­ma element (predicted to be a relic of mobile genetic elements) that was previously found within the composite transposon Tn5041 that was previously associated with harboring mercury resistance determinant in Pseudomonas spp. (Yamane et al., 2004). Historically, the isolation of rmtA has been more infrequent than armA, with only a lim­ited number of P. aeruginosa isolates harboring rmtA from Japan and Korea (Yamane et 
al., 2004; Jin et al., 2009). 
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3.2.3.3 rmtB/B2 
rmtB was first reported on a plasmid downstream of a Tn3-like transposon flanked bytwo IS26 elements. The downstream region of rmtB has been shown to be quite varia­
ble, although typically associated with the fluoroquinolone efflux gene qepA1 or a varia­tion (Perichon et al., 2007; Yamane et al., 2007). More recently, rmtB has been identifiedwithin a multidrug resistant region on an IncI1 plasmid. In these plasmids, rmtB was
identified alongside blaTEM-1, , a class 1 integron cassette array (intI1-dfrA12-orfF-aadA2­
qacEΔ1-sul1) and the aminoglycoside N-acetyltransferase aacC2. 
Not unlike armA, the distribution of rmtB has been associated with the world-wideemergence of bla
NDM-1
 harboring Enterobacteriaceae with which both methyltransferasesare commonly associated (Carattoli et al., 2012). RmtB is also the first acquired meth­
yltransferase with an identified variant. Based on a single amino acid variation within
a conserved domain, RmtB 2 is classified as a distinct variant. Based on the similaritiesamong rmtB and rmtB 2, it is not surprising that their genetic environment has main­tained a high degree of conservation (Doi et al., 2016). 
3.2.3.4 rmtC When rmtC was initially discovered in a clinical strain of P. mirabilis, it was located on anon-conjugative plasmid adjacent to an ISEcp1-like element, which has been shown to alsoprovide the promoter region of the methyltransferase (Wachino et al., 2006). While this
ISEcp1 has been frequently associated with β-lactamases, it is expected that rmtC dissemi­nation will be greatly facilitated among the Enterbacteriaceae via the transposition activityof this genetic element (Toleman et al., 2011). Although currently rmtC is not as globallydisseminated as neither armA nor rmtB, its coproduction alongside blaNDM-1 is very worri­some, as it is believed that the global emergence of this resistance gene has facilitated thedissemination of the most prevalent 16S rRNA methyltransferases (Poirel et al., 2011). Inter­estingly, rmtC is one of the few acquired 16S methyltransferases that has been identified inthe chromosome of S. enterica clinical isolates in the United Kingdom (Hopkins et al., 2010) 
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3.2.3.5 rmtD/D2 
rmtD has, as of now, only been described in South America, and its general prevalence isconsidered to be quite low. In the Brazilian strain discovered, rmtD followed by an orf494(a putative transposase gene) and a 3’ conserved region harboring qacEΔ1 and sul1 ofthe class 1 integron In163 (Doi et al., 2008). In the area immediately upstream of rtmDan orfA (encoding a putative ribosyltransferase gene), ΔgroEL and a futher copy of orf494
were identified. Both orf494 copies were found to be truncated by an IS6. These flankingopen reading frames, have now been proposed as the putative transposase ISCR14 (Doi
et al., 2008). More recent variants of rmtD have been isolated in K. pneumoniae from Bra­zil alongside blaKPC-2 (Beuno et al., 2013). 
The genetic context of rmtD2 was highly similar to that of rmtD, however, a large por­tion of the 5’ extreme of the ΔgroEL gene was deleted as compared to rmtD (Tijet et al., 2011). Although rmtD and rmtD2 have been identified alongside β-lactamase resistance
determinants, as of now, they have never been identified on the same plasmid as the bla
gene. That being said, methyltransferases found alongside β-lactamase genes, such as
blaNDM-1 and blaCTX-M3, are among the most prevalent 16S methyltransferases in the world.Therefore the close proximity of rmtD and rmtD2 with, in this case blaKPC, could suggest awider future dissemination of these methyltransferases.
3.2.3.6 rmtE/E2 Both rmtE and rmtE2 are among the least described methyltransferases. Currently,there are only two reported cases of rmtE from a cow and a human isolate in the UnitedStates. In most cases rmtE was borne on a class 1 integron harbored by a self-conjugative199kb IncA/C plasmid designated pYDC637 (Lee et al., 2015). This plasmid has beenshown to be composed of a 144kb core region followed by a 55kb acquired region. Withinthis acquired region there are two class 1 integrons, one of which harbors rmtE bound by
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an ISCR20-like element and an IS1294-like insertion sequence that are commonly asso­ciated with resistance genes and 16S rRNA methyltransferases (e.g. rmtD/D2 and rmtF) (Lee et al., 2015). 
3.2.3.7 rmtF Of all the 16S rRNA methyltransferase, rmtF is perhaps the most closely associated withthe blaNDM-1 resistance gene. The first strain identified to express rmtF (a K. pneumoniaefrom the Reunion Islands) harbored the 16S methyltransferase downstream of blaNDM-1 on a class 1 integron (Galimand et al., 2012). In this case rmtF was harbored on a 40kbnon-self transferable plasmid pIP849 and it was cotranscribed with the aac(6’)-IB re­sistance gene (Galimand et al., 2012). Furthermore the rmtF gene was bracketed by a 3’portion of an ISCR5 element including oriIS and by a truncated insE gene for the ISCR5transposase together with oriIS (Galimand et al., 2012). Galimand et al., further stipulatethat the genetic environment of rmtF suggests that it was recruited either by ISCR trans­position or homolgous recombination similar to that proposed for rmtD1 and rmtD2 andthe associated ISCR14 (Toleman et al., 2006; Tijet et al., 2011). 
3.2.3.8 rmtG Like rmtD, rmtG has been almost exclusively described in South America. As of now,
rmtG has been identified in colistin resistant K. pneumoniae in the United States (Miami),Brazil and in Chile (Bueno et al., 2013; Poirel et al., 2014; Hu et al., 2014) alongside anumber of extended spectrum b-lactamase genes (e.g. blaCTX-M2, blaTEM-1, blaSHV-11) (Poirel
et al., 2014). While the epidemiological information pertaining to this methyltransferase
is limited, currently it has only been identified in K. pneumoniae. Carattoli et al. have con­
firmed via replicon typing that mtG was harbored on an 80-kb IncA/C plasmid (Carattoli
et al., 2005). 
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3.2.3.9 rmtH In 2006 a highly resistant K. pneumoniae strain was isolated from the wound of a sol­dier in Iraq. This strain, which presented very high levels of aminoglycoside resistancewas later shown to harbor the methyltransferase rsmH, which shares a 64% identitywith Arm family methyltransferases rmtB and rmtB 2 (O’Hara et al., 2013). This isolate
also presented resistance to cephalosporins, aztreonam and ciprofloxacin. Furthermore,as previously seen with the other 16S rRNA methyltransferases, rmtH was co-harboredalongside blaCTX-M-15 blaSHV-1 and blaOXA-1 (O’Hara et al., 2013). rmtH was bracketed by twocopies of ISCR2 which is an IS91-like transposable element that has been found to be as­sociated with a number of antibiotic resistance mechanisms (Toleman et al., 2006).
As demonstrated above the 16S rRNA methyltransferases are all harbored within mo­bile genetic elements readily capable of translocating the resistance gene, which have
been summarized in figure 11. 
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Figure 11. Diagram representing the genetic environment of the acquired 16S rRNA methyltransferases 
(Gutierrez et al., unpublished work)
 This versatility also results in the selection of a genetic environment that is most suitable for an expression of the methyltransferases that confers high-level resistance while mitigating the biological cost incurred on the host. However, possibly the most important factor underlying the rapid dissemination of the 16S rRNA methyltransfer­ases are the associated resistance determinants. A number of publications directly link the emergence of the acquired 16S methyltransferases with the global spread of ex­
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  tended spectrum β-lactamases including blaNDM-1 and blaCTX-M (Doi et al., 2016). Espe­cially when the resistance determinant is found alongside other resistance genes on the same plasmid, any antibiotic treatment will co-select for both resistance genes, which in turn maintains the genes within the population. 
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3.3 Regulation associated with antibiotic resistance Antibiotic resistance is, as repeatedly mentioned, a growing concern and, while there is a great emphasis on elucidating the mode of action of acquired resistance determi­
nants and the surveillance of their dissemination, another very important field per­
taining to antibiotic resistance is the study of their expressional regulation. This field is of great importance to elucidate the underlying factors of resistance gene dissemina­tion. Resistance genes, especially those like the 16S rRNA methyltransferase encoding genes, may interfere with the ‘natural order of things’ within their host. Such interfer­
ence generally incurs a fitness cost to the cell, which, in environments without selective pressure, can result in the out-competition of that strain and the subsequent loss of the resistance determinant (Wiesch et al., 2010). 
The complexity underlying regulation is immense and there are a plethora of strategies a
bacterium may apply in order to fine-tune the expression of required genes. In this chapter,I will outline the various strategies employed by antibiotic producers and their intrinsicresistance mechanisms, as well as the emerging regulatory mechanisms of acquired resist­ance genes. But before discussing regulation with regards antibiotic resistance, I will pres­ent various aspects of global gene regulation and transcriptional induction.
3.3.1 Global transcriptional regulation Depending on the environmental conditions and the current growth phase of the bac­terium, the transcription levels from one moment to the next, and between different 
genes, vary significantly. For most genes a key factor in their transcriptional induction is the recognition and interaction of the gene’s promoter region by the RNA polymerase (Browning et al., 2004). The RNA polymerase is a ~400 kDa molecule that consists of 5 subunits (Figure 12). 
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Figure 12. A representation of an RNA polymerase holoenzyme open complex. The core enzyme consists of a 
large β-subunit and a β’-subunit (blue and grey respectively), two α-subunits (orange and yellow), the small 
ω-subunit (not shown) and finally the sigma factor (turquoise) (Figure from Karpen et al., 2015). 
The large β-subunit and the β’-subunit are assembled by binding the N-terminal domains of the α-subunits whereby they form a cleft that constitutes the active site. 
The fifth RNA polymerase component, the ω-subunit, is mainly a chaperone for the β’­subunit (Murakami et al., 2003). However, this intact RNA polymerase alone is not able to recognize promoter regions without the presence of an additional protein known as a sigma factor, which is further explained in the next section (Figure 12). The in­teraction of the sigma factors with the core enzyme forms the complex known as the 
RNA polymerase holoenzyme, which is then able to interact with specific promoter re­gions (Gross et al., 1998). This interaction ultimately unwinds the DNA in the region of the transcriptional start site (+1), and can commence the transcriptional cycles of transcription. This complex mechanism can be regulated at various phases, either at the level of RNA polymerase holoenzyme formation, promoter recognition by the RNA 
polymerase (more specifically, the sigma factor bound by the RNA polymerase), or at the level of the RNA polymerase activity (Browning et al., 2016). 
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In recent years, the increasing importance of small regulatory RNAs has revealed an­other level of complexity within the regulatory network that underlies gene regulation. With regards to the objectives of this thesis, we will focus on the involvement of the 
sigma factors, as well as the specific promoter regions, in the induction of transcription.
3.3.1.1 Sigma factors 
The specific association of sigma factors with the RNA polymerase is required not only for the initiation of transcription, but also for the selection of the genes to be tran­scribed. RNA polymerases are capable of interacting with a variety of sigma factors that 
are each responsible for the induction of specific groups of genes (Figure 13). 
Figure 13. A representation of the complexes formed between RNA polymerases and the various sigma fac-
tors responsible for the variable transcription of genes (Figure from Tripathi et al., 2014) 
The conventional model for the promoter recognition mediated by σ70 involves main­ly the -35 box and -10 box (so called due to their respective distance from the tran­scriptional start site), as well as the discriminator sequence which are all recognized 
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by the sigma factor. In addition operator regions may also interact with the C-terminal domains of the α-subunits of the RNA polymerase holoenzyme (Browning et al., 2004). All bacteria have primary housekeeping sigma factors (such as σ70  in E. coli), which are responsible for recognizing most promoter regions (Gross et al., 1998). While the primary sigma factor recruits the RNA polymerase to most genes to be induced, most bacteria have a number of alternate sigma factors to dynamically modulate their tran­scriptome (Figure 13)(Gruber et al., 2003). 
Housekeeping σ70 factors are composed of four structural domains joined by flexible linkers that, when bound to the RNA polymerase, interact with the promoter elements (Murakami et al., 2003). These sigma factors, also known as RpoD, are especially ac­tive during phases of rapid growth and preferentially induce the transcription of genes involved in protein synthesis (Ozaki et al., 1991). These sigma factors are of vital im­portance, as there are a plethora of gene products associated with the assembly of the protein synthesis machinery that need to be induced dynamically to correspond to the growth conditions of the bacterium (Browning et al., 2016). Other sigma factors such as RpoH, FliA, PvdS and RpoN, to name a few, are involved in vital processes within 
the cell, such as heat-shock, adhesion and flagellin biosynthesis, iron metabolism and virulence, and nitrogen metabolism respectively (Benvenisti et al,. 1995; Starnbach et 
al., 1992; Cundliffe et al., 1995; Ishimoto et al., 1989). The fine-tuned orchestration of these factors governs the expression of a large number of genes within the cell respon­sible for vital processes (Browning et al., 2004). Many of the main sigma factor promot­ers also compete with anti-sigma factors that are able to reduce sigma factor activity when their respective gene products are no longer required (Hughes et al., 1998). 
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3.3.1.2 Sigma factor recognition of promoter regions initiates transcription The precise constitution of the promoter region has a great effect on the activity of these essential sigma factors and the subsequent transcriptional levels. The core of the sigma factors can be thought of as a harmonic oscillator that is capable of expanding and contracting to interact with the promoter elements (Aoyama et al., 1983). However, variations in the distance between the -35 box and the -10 box have a profound effect on the energy available for stabilization and the subsequent induction rate (Mandec­ki et al., 1982; Aoyama et al., 1983). The distance most commonly identified between sigma factor recognized promoter regions is 17 ± 1 bases, although initiation has been demonstrated with promoter regions separated by 15-20 bases (the spacings between the promoter elements are measured from the 3’ end of the -35 box to the 5’ end of the -10 box)(Figure 14)(Hawley et al., 1983; Dombroski et al., 1996). 
Figure 14. Representation of the promoter region conservation with regards to the spacing between the -35 
and -10 boxes. It represents the number of putative sigma factors identified in the upstream region of 599 
experimentally determined transcriptional start sites from the RegulonDb database (Salgado et al., 2001) 
(Figure adapted from Shultzaberger et al., 2007) 
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While the most common distance between two promoter regions appears to be 17 base pairs, it would not be accurate to describe this as the optimum distance for sigma 
factor recognition. In fact, this yet again, is a mechanism to fine tune the specific tran­scriptional levels required of each respective gene (Aoyama et al., 1988). Interestingly, 
as seen in figure 14 above, the precise promoter conservation alters depending on the distance between the -35 and -10 promoter regions, although the overall trend remains quite constant. That being said, although the promoter recognition by sigma factors is variable, reports demonstrate that the interaction of the sigma factor with certain -10 
boxes alone is sufficient to induce transcription (Kumar et al., 1993; Barne et al., 1997). 
Furthermore, there are a number of additional elements that may influence sigma factor interactions with the respective promoter regions, such as transcription fac­tors and repressors that are capable of binding to operators upstream of the promoter regions, where they either facilitate the recruitment of RNA polymerases or create a steric hindrance that inhibits the interaction with the RNA polymerase holoenzyme (Thieffry et al., 1998). Such factors may function as part of a two component regulatory pathway that reacts to environmental conditions or with biosynthetic intermediates that precisely orchestrate the sequential initiation of required gene products (Brown­ing et al., 2016). The transcriptional regulation of vancomycin resistance, for example, is regulated by such a two component system (Arias et al., 2000; Abadia et al,. 2002) 
As previously mentioned, the regulatory mechanisms here outlined regarding the global regulation of transcription are just a selection of the variables mediating the prokaryotic transcriptome. As such, here I have introduced a small selection of mecha­nisms to illustrate the immense complexity of this process. Additionally, although I will mention a number of post-transcriptional mechanisms of regulation in the sections to follow, the transcriptional induction is just a relatively small aspect when it comes to the arsenal of regulatory tools available to the prokaryotic cell. 
44 
     
 
3.3.2 Regulation of intrinsic antibiotic resistance mechanisms In order for the antibiotic producers to effectively protect themselves from the toxic activity of these potentially lethal secondary metabolites, it is fundamental that they express their intrinsic resistance genes in a timely fashion. Generally, there are two main strategies that can be employed to govern this timely expression. Firstly, in many antibiotic producers, the expression of the resistance gene is closely associated with the biosynthetic clusters that encode the antibiotic. The second expressional strategy is the induction by their cognate antibiotics or by intermediate molecules from their bio­synthetic pathways (Mak et al., 2014). There are some resistance genes, however, that are constitutively expressed, such as the ermE erythromycin resistance gene; although generally this is rare, and most of these genes are tightly regulated, most likely because the advantages of antibiotic resistance are typically only transient (Bibb et al,. 1985; Depardieu et al., 2007). 
With regards to the aminoglycosides, the Kgm and Kam family of intrinsic methyl­transferases confer resistance to aminoglycosides by methylating G1405 and A1408 respectively (Beauclerk et al., 1987). The genes of these intrinsic resistance determi­nants, such as grmA, kmr and kamA, are also commonly found within the biosynthetic clusters alongside the aminoglycosides gentamicin kanamycin and istamycin respec­tively (Magnet et al., 2005). 
3.3.2.1 Regulation of intrinsic resistance genes within the biosynthetic gene clusters ofthe antibioticIt is stipulated that the regulatory mechanisms coupling the resistance gene directlyto the production of the antibiotic are mechanistically diverse and have been associatedwith the origins of clinical antibiotic resistance and many of the resistance genes withinthese clusters have been shown to be expressed immediately before or alongside the anti­biotic itself (Mak et al., 2014). The regulatory mechanism underlying the induction of the
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factors leading to the synthesis of the antibiotic are also well described. These regulatorymechanisms commonly known as cluster-situated regulators (CSRs) monitor a numberof cellular aspects such as physiology, developmental states and environment (to name afew), to determine the appropriate quantity antibiotic to produce (Liu et al., 2013). One example of such a co-induction of resistance is the intrinsic streptomycin resist­ance gene aphD. This 6-phosphotransferase confers resistance to streptomycin in the producer S. griseus (Tohyama et al., 1984; Distler et al., 1987). The enzymatic modi­
fication produced by this enzyme renders the streptomycin inactive and permits the safe export of this potentially lethal secondary metabolite (Beyer et al., 1996). The so­called A-factor initially binds to the Arp protein, which is a repressor belonging to the TetR-family of repressors (Onaka et al., 1997; Cuthbertson et al., 2013). The interac­tion between the A-factor and the repressor ArpA subsequently causes it to liberate the promoter region of adpA, which is a global regulator of sporulation and secondary metabolites such as the str cluster, which encodes streptomycin (Ohnishi et al., 2005). 
The inducing activity of AdpA on the streptomycin pathway specific regulator strR also results in the expression of the downstream resistance gene product AphD (Figure 15) (Vujaklija et al., 1991). 
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Figure 15. Figure outlining the regulatory cascade governing the expression of the streptomycin biosyn-
thetic pathway (strR) alongside its respective resistance gene aphD (Mak et al., 2014) 
This elegant mechanism ensures the presence of the streptomycin modyfing enzyme AphD before the antibiotic can accumulate in the cytoplasm and, as such, protects its host from the deleterious activity of this secondary metabolite. Another advantage of this cascade is that the A-factor is a diffusible signal, which permits the activation of this cascade of adjacent cells within the culture (Horinouchi, 2002). 
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3.3.2.2 Regulation of intrinsic resistance genes modulated by intracellular concentrations of the antibiotic 
Depending on the specific antibiotic in question, the producing bacterium may draw an advantage from having a dynamically regulated resistance determinant that is not only expressed alongside the antibiotic, but also expressed proportionally according to the intracellular antibiotic concentrations. 
Such a regulation of intrinsic resistance gene regulation was identified, among oth­ers, in Streptomyces fradiae. This bacterium produces the macrolide antibiotic tylosin, which acts on the ribosomal 50S subunit (Zalacain et al., 1989). The biosynthetic gene cluster of this antibiotic harbors four tylosin resistance genes (tlrA-D) that protect the producer from the antibiotic (Liu et al., 2000). These resistance genes consist of 
three rRNA methyltransferases and one efflux pump (tlrC) (Rosteck et al., 1991). These four resistance genes constitute a type of fail-safe resistance mechanism for the host. TlrD, one of the rRNA methyltransferases, is constitutively expressed in small quanti­ties, which ensures a certain degree of protection to the host by methylating and pro­tecting the 23S rRNA whether the tylosin is being synthesized or not (Cundliffe et al., 1991). The expression of the other resistance genes, however, is more complicated. It has been proposed that the expression of the resistance methyltransferase tlrA is regulated via a ribosome mediated transcriptional attenuation (Keleman et al., 1994; Mak et al., 2014). This mechanism relies on the presence of a small upstream ORF that is constitutively transcribed and translated. In the absence of the antibiotic, the ribo­some rapidly translates a leader peptide sequence in the mRNA of tlrA, which results in a secondary structure in the mRNA that prevents the full length transcription of the 
trlA mRNA (Keleman et al., 1994). This group then demonstrated that in the presence 
of the ‘inducing’ antibiotic, however, the ribosome briefly stalls in the leader peptide of the tlrA mRNA, which resolves the secondary structure responsible for prematurely terminating the transcription of the resistance methyltransferase. This ‘stalling’ is a result of nascent peptide interactions with the exit tunnel of the ribosome (Sunohara et 
al., 2004). This in turn permits the complete transcription and subsequent translation 
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of the resistance determinant, but only in the presence of the antibiotic (i.e. only when actually needed). To further complicate this inducible intrinsic resistance conferred, the induction of tlrA requires the ribosome to have been previously methylated by the aforementioned tlrD (Liu et al., 2002). 
3.3.2.3 Regulation of intrinsic resistance genes in correspondence with the growth phase Another interesting mechanism of resistance gene induction is found within Strepto-
myces rimosus, which produces oxytetracycline. This antibiotic acts on the 30S rRNA and blocks the access to aminoacyl-tRNAs required for translation (Petković et al., 2006). Again, found within the biosynthetic cluster of this antibiotic, are the two intrinsic re­sistance genes otrA and otrB (also known as tetA and tetB) that provide self-defense 
via target protection and an efflux pump, respectively (Ohnuki et al., 1985).  Upstream 
of these resistance determinants, two promoter regions were identified, otrAp1 and 
oxySp1 (McDowall et al., 1999). Based on the constitution of these promoter regions, when the cells are growing exponentially, the otrA intrinsic resistance gene is tran­scribed as a monocistronic mRNA following the transcriptional induction of the otrAp1. However, when the cells enter the stationary phase, where the expression of second­ary metabolites increases, the activity of the otrAp1 ceases, and the second promoter region, oxySp1, mediates the expression of the otrA, but this time it is co-transcribed along with two genes involved in the maturation of the oxytetracycline (McDowall et 
al., 1999). Again, this mechanism ensures the expression of the resistance gene prior to the synthesis of the antibiotic, which will protect the cell from the deleterious effects of the antibiotic. Interestingly, the expression of the secondary metabolite and its various resistance genes has been linked to the activity of sigma factors, capable of modulating expression based on the growth phase of the cell (Mak et al., 2014). 
With the exception of a few more well characterized intrinsic resistance gene regula­tory mechanisms, the data available regarding the co-expression of intrinsic resistance 
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determinants with their respective antibiotics is limited. In summary, these genes are generally mechanistically coupled to the synthesis of the antibiotic agent, which allows the producer to minimize any biological burden incurred by the resistance gene. 
Due to the clinical relevance of the acquired resistance genes however, many moremechanisms have been described in detail, which I will outline in the following sections.
3.3.3 Regulation of acquired antibiotic resistance mechanisms The regulation of acquired resistance genes differs substantially from that of the in­trinsic resistance genes despite achieving the same goal (i.e. protection when required while mitigating the biological cost). One major difference, which I will describe to­wards the end of this section, is the fact that many (even most) of the acquired resist­ance genes are harbored within mobile genetic elements that are constantly evolving. Another major difference is that intrinsic resistance genes have co-evolved alongside 
the producer and optimized expressional profiles. Acquired resistance genes, however, 
tend to incur a more significant biological cost that is only mitigated after a period of compensation (Depardieu et al., 2007). As mentioned at the beginning of this section pertaining to resistance gene regulation, conferring resistance to a bacterial host is only transiently advantageous (i.e. in the presence of the antibiotic). As such, it appears that acquired resistance genes, more often than not, are found alongside domains capable of regulating their expression. 
As previously performed with the intrinsic resistance genes, I will focus on selected examples of both transcriptional and translational mechanisms of regulation common­
ly associated with clinically significant pathogens and antibiotics. 
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3.3.3.1 Transcriptional regulation of acquired antibiotic resistance genes (in class 1 integrons) Although there are many examples of post-transcriptional mechanisms of resistance gene regulation, transcriptional mechanisms have the added advantage that biological resources are not devoted to the partial transcription/translation of resistance genes that are repressed. In this section I will highlight a form of transcriptional regulation that is closely associated with the mobile genetic elements the acquired resistance 
genes are so often identified in. 
The transcription of cassette-associated resistance genes is often mediated by one or more ‘strong’ promoter regions and a number of ‘weak’ terminators (Collis et al., 2002). Collis et al, demonstrated that both the position of the gene within the cassette as well 
as the position of the overall cassette had significant effects on the levels of resistance observed. In such a scenario, the resistance genes are expressed in relationship to their distance from the promoter region. As the ‘weak’ terminators moderate the number of RNA polymerases that reach the downstream gene products, this method can differ­entially express a number of resistance genes simultaneously (Depardieu et al., 2007). Such an expression is often mediated by up to four integron-borne promoter regions of variable expressional capacities (Levesque et al., 1994). A number of studies have 
focused on these particular promoter elements and their inductional efficacy versus the resistance levels they confer (Levesque et al., 1994). These promoters have also frequently been associated with cassette-borne resistance genes that have lost their native promoter region. The expression of these genes is even more dependent on the order in which they appear within the cassette (Collis et al., 2002). 
Although there are a number of further transcriptional mechanisms associated with acquired resistance mechanisms, the above mentioned integron mediated regulation of resistance genes is a testament to the rapid evolutionary development facilitated by horizontal gene transfer. 
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3.3.3.2 Post-transcriptional regulation of resistance genes Acquired resistance genes have been described under the regulation of a variety of 
post-transcriptional mechanisms governing their expressional profiles (Breidt et al., 1990). As with the transcriptional feedback mechanisms (coupling the transcriptional levels of the resistance gene to the expression of the antibiotic or biosynthetic inter­mediates), acquired resistance genes have repeatedly demonstrated the capacity to be induced by their respective antibiotic (Bailey et al., 2008; He et al., 2013). This section will highlight a number of key post-transcriptional regulatory mechanisms associated with antibiotic resistance determinants. 
Riboswitch induction of resistance genes Since the molecular characterization of riboswitches, this molecular gene ‘switch’ has found wide ranging applications in both the industrial biotechnologies and the medical 
field (Ketzer et al., 2014). Riboswitches are small secondary mRNA structures found in the 5’ untranslated region (UTR) that selectively express their respective gene products based on the presence of an inducing agent (Vitreschak et al., 2004). 
In the most common configuration of a molecular riboswitch, which has recently 
been identified to modulate the expression of aminoglycoside resistance genes, this mRNA structure sequesters the ribosomal binding site preventing the translation of the regulated gene (Figure 16)(He et al., 2013; Jia et al., 2013). 
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Figure 16. Representation of a molecular riboswitch that has been shown to regulate the expression of 
aminoglycoside resistance conferring adenyl- and acetyl- transferases. The presence of the inducing antibi-
otic causes a conformational change of the secondary structure, which liberates the ribosomal binding site 
resulting in the translation of the resistance gene(Figure from He et al., 2013) 
This highly dynamic mechanism allows for the expressional levels of the resistance genes to be augmented by accumulating intracellular concentrations of the inducing 
antibiotic. By doing so, the host is sufficiently protected while minimizing the biological cost of producing the enzymes in the absence of antibiotic pressure (He et al., 2013). 
The riboswitch regulating the aminoglycoside modifying enzymes interacts directly with the inducing antibiotic. However, as the structurally diverse molecular ‘switches’ 
can potentially interact with a variety of molecules, it is possible factors specifically associated with the presence of the antibiotic can also interact with such riboswitches to induce the expression of the resistance gene (Vitreschak et al., 2004). 
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Ribosome stalling mediated expression of resistance genes Another regulatory mechanism that has been described for a number of resistance genes, especially ones acting on the ribosome, is ribosome stalling (Weisblum et al., 1995; Lovett et al., 1996; Bailey et al., 2008; Ramu et al., 2009). Such mechanisms rely on the programmed stalling of the ribosome as a result of amino acid interactions of the nascent peptide with ribosomal proteins of the exit tunnel. In the case of ermC, which is a macrolide resistance conferring 23S rRNA methyltransferase, in the absence of an inducing agent, hairpin loops that form the secondary structure within the 5’ mRNA sequester the ribosomal binding site and prevent the subsequent translation of the resistance gene (Figure 17, A)(Bailey et al., 2008). 
Figure 17. Representation of the secondary mRNA structures in the 5’ UTR of the ermC resistance gene. A. 
Demonstrates the structural conformation in the absence of the inducing antibiotic, and B. demonstrates 
the conformational changes of ribosomal protein L4 and L22 upon the interaction of the inducing anti-
biotic with its ribosomal target site. This alteration leads to a brief stalling of the ribosome (due to the 
interactions of the ribosomal proteins with the nascent peptide), which resolves the secondary structures 
and thereby liberates the ribosomal binding site of the downstream resistance gene. (Figure adapted from 
Ramu et al., 2009) 
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In the case of ermC, which is a macrolide resistance conferring 23S rRNA methyltrans­ferase, the presence of the antibiotic at its active site on the ribosome induces a confor­mational change, which in turn changes the position of ribosomal proteins L4 and L22 (Figure 17, B)(Bailey et al., 2008; Ramu et al., 2009). This conformational change alters 
the constitution of the ribosomal exit tunnel so that, specific amino acid sequences in the leader peptide (ermCL), which is constitutively transcribed and translated, briefly 
stall the ribosome at a very specific position (9th codon of ermCL)(Ramu et al., 2009). The brief stall at this location results in a conformation change of the secondary struc­tures, forming one large hairpin loop that ultimately liberates the ribosomal binding site of the downstream resistance gene, ermC, which in turn allows for the translation of the resistance gene in the presence of the inducing antibiotic (Bailey et al., 2008). 
Ramu et al., also suggested that this regulatory mechanism could be responsible for the induction of a variety of genes conferring resistance to protein synthesis inhibitors (Ramu et al., 2009). The chloramphenicol resistance genes (cml and cat), for example, are preceded by shorts ORFs that also appear to result in ribosome stalling in the pres­ence of the inducing agent (i.e. chloramphenicol)(Lovett et al., 1996). Furthermore, Ramu et al., identified a putative leader peptide in a number of tetracycline resistance genes (tetL, tetM and tetQ) and in the 5’ UTR of the aminoglycoside resistance confer­ring methyltransferase armA (Ramu et al., 2009). 
3.3.4 The impact of insertion sequences on the expression of resistance genes The following example of acquired resistance gene expression, like the previous ex­ample, depends on mobile genetic elements. Beyond the fact that elements such as insertion sequences and transposons greatly facilitate the dissemination of antibiotic resistance, sequence components they harbor may exert a delicate control over the ex­
pressional profile of adjacent resistance genes (Chandler et al., 2002). 
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Insertion sequence elements are transposable genetic elements generally between 0.8 and 2.5 kb that only harbor genes required for their translocation (Bennett et al., 
2004). Currently, over 1,000 IS elements have been identified in Gram-positive and Gram-negative bacteria (Siguier et al., 2014). Insertion sequences are another signifi­cant driving force of horizontal gene transfer and are typically located on the chromo­some or within plasmids, although for intercellular translocation they must be encoded on conjugative elements (Depardieu et al., 2007). 
Generally, there are two IS-mediated effects on antibiotic resistance gene expression. 
For genes encoding specific resistance mechanisms such as enzymes for target modi­
fication, antibiotic modification or efflux pumps, insertion sequences have been found to activate these genes via promoter region alteration (Depardieu et al., 2007). On the other hand, insertion sequences have been shown to affect resistance gene expression byinsertional inactivation of genes that have been associated with the modulation of resis­tance determinants such as repressors (e.g. ampD, mexR, acrR etc.)(Mahillon et al., 1998).
The activation of genes via promoter region alteration is an interesting concept that has been associated with a number of resistance genes (Toleman et al., 2006; Depar­dieu et al., 2007; Berçot et al., 2010). Essentially, insertion sequences harboring a -35 element or both the -35 and -10 promoter regions may insert upstream of genes that have a weak, incomplete or inactive promoter region, and thereby activate their expres­sion (Depardieu et al., 2007). Typically, promoter regions harbored on such insertion sequences correspond to the canonical consensus sequence TTGACA and TATAAT for the -35 box and the -10 box respectively, that are separated by 17 base pairs (Lisser 
et al., 1993). These insertion sequences may activate both intrinsic and acquired re­sistance determinants. In B. fragilis it was discovered that most antibiotic resistance genes are expressed by means of promoter elements that are entirely borne on inser­tion sequences (Podglajen et al., 1995). More recent studies have identified such in­sertion sequence borne promoters to regulate the expression of acquired resistance 
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genes such as the 16S rRNA methyltransferase rmtC as well as the extended spectrum b-lactamase gene blaTLA-1 (Karah et al., 2016; Berçot et al., 2010). 
As was the case with the integron mediated promoter elements, active promoter elements harbored on insertion sequences have the potential to rapidly evolve the 
expressional profile of resistance genes. Especially resistance genes that act in a concentration dependent manner such as modifying enzymes can, over time, develop increased expressional levels proportional to resistance levels (Depardieu et al., 2007). 
While such high-levels of expression may not always be beneficial to the host, when there is selective antibiotic pressure, the up regulation of certain resistance genes by integron- or insertion sequence- harbored promoters may confer a selective advantage to the cell. 
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4OBJECTIVES AND JUSTIFICATION Currently antimicrobial resistance remains one of the most serious threats to modernmedicine. As such, the selection and administration of antibiotics must be carefully con­sidered, especially since the discovery of novel antimicrobial agents has reduced substan­tially. Agents that have previously been dismissed for unfavorable secondary activity are
becoming increasingly valuable as the resistance prevalence towards the first choice anti­biotic increases drastically. The aminoglycosides are a family of antibiotics that belong tothis category. Shortly after their introduction to the market, problems with toxicity becameapparent and they were no longer considered a drug of choice for physicians. However,increasingly worrisome resistance trends have forced physicians to reevaluate the applica­tion of aminoglycosides for life-threatening infections caused by Gram-negative pathogens.
However, among other resistance mechanisms, the 16S rRNA methyltransferases haveemerged in Gram-negative pathogenic bacteria as an acquired resistance mechanism con­ferring high-level resistance to all clinically relevant aminoglycosides, even ones that havenot yet been released to the market. Since their discovery in 2003, a total of 13 acquired
methyltransferases have been identified including three variants. The rate at which these
resistance determinant are spreading, combined with the broad resistance profile they
confer to most clinically significant aminoglycosides, is jeopardizing the aminoglycosidesas a viable last resort antibiotic.
As such the objectives of this study are the following: 1.	 Conduct a comprehensive in silico and in vitro study of the acquired 16S rRNA meth­yltransferases in relation with both house-keeping and intrinsic resistance conferrigmethyltransferases to identify any regulatory mechanisms that may underlie the rap­id dissemination and prevalence of these resistance determinants.
2.	 Evaluate any proposed regulatory hypotheses by conducting an in depth study of themost prevalent acquired 16S rRNA methyltransferase, armA. 
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5MATERIALS AND METHODS 
5.1 In silico sequence management A variety of programs were utilized to analyze sequence elements. CLC Workbench® (Qiagen Bioinformatics, USA) was used to perform a number of sequence analyses in­cluding the alignment of all reference sequences, the evaluation of sequence elements such as upstream ORFs and secondary structures as well as dendrograms to investi­gate the degree of relatedness among acquired and intrinsic aminoglycoside resistance methyltransferases. Dendrograms were typically performed with at least 1,000 repli­cates for the boot-strap values, and up to 10,000. Serial Cloner® (Serial Basics, France) was used to perform sequence annotations and to verify sequences obtained via Sanger Sequencing, which were compiled using the 4Peaks® software suite (Nucelobytes, Neth­
erlands). Online sequence analysis tools such as β-prom (Softberry, USA) promoter prediction algorithms were used to identify upstream promoter elements. 
5.2 Strains utilized Unless otherwise stated, all the experiments in this project were carried out using the laboratory strain E. coli DH5α with the chromosomal genotype fhuA2, lac(Δ)U169, phoA, 
glnV44, Φ80’, lacZ(Δ)M15, gyrA96, recA1, relA1, endA1, thi-1 and hsdR17 (Life Technolo­
gies, USA). Besides usually exhibiting a high transformation efficiency, this E. coli strain 
also harbors the alpha acceptor allele Δ(lacZ)M15 which is required for the blue/white screening of many lacZ based vectors. Unless otherwise stated, this strain was trans­formed via electroporation under the conditions described for small plasmids: 2.5 kV/ cm, 25 μF and 200 Ω (San Millan et al., 2010). 
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5.3 Genetic constructions The armA used to make all of the following constructions was amplified via High-Fi­delity PCR from an E. coli strain bearing pMUR050 (Genbank accession number: AY522431.1). All constructions performed in this project were subcloned onto either the linearized pTOPO TA cloning vector with a pUC origin of replication derived from 
pBR322 (Thermo Fisher, USA) via amplification with Taq polymerase (Biotools, USA) using its un-templated adenine 3’ overhang or, if the constructions were intended to be co-transformed with ColE1-like plasmids, constructions were cloned directly onto the cloning vector pACYC-184, derived from the non-ColE1 miniplasmid origin of rep­
lication p15A1 (Mo Bi Tech, Germany) via PCR amplification using oligonucleotides (Sigma-Aldrich, Spain) bearing restriction sites. Primers designed to be used with the In-Fusion HD cloning kit (Clontech, USA) were designed according to the manufactur­
ers specifications. A full list of the oligonucleotides used to make the constructions used in this work can be found in table 2. 
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Table 2: Oligonucleotides used as part of this study, their sequence and reference 
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Table 3. Oligonucleotides designed as part of the -35 promoter region mutagenesis 
Table 4. Oligonucleotides designed as part of the -10 promoter region mutagenesis 
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All constructions were cloned onto the pACYC vector in the forward orientation (with regards to the origin of replication) in the RT-PCR (reverse transcriptase polymerase 
chain reaction) confirmed absence of an active upstream promoter. Prior to sequenc­
ing, all constructions were carefully examined via PCR to confirm insert orientation and size. Constructions made using the In-Fusion HD cloning kit (Clontech, USA) were 
confirmed via outward PCRs. All constructions were analyzed via Sanger Sequencing 
techniques using flanking primers in both orientations. 
Initial truncations were cloned onto the pTOPO-cloning vector using the Taq poly­merase as described above. Further truncations were later performed using the pA­
CYC-cloning vector. The various inserts were amplified using the high fidelity Phusion 
polymerase (Thermo Fisher, USA), and were then purified and digested using the EcoR1 
restriction enzyme (Thermo Fisher, USA) as indicated by the manufacturer. Purified pACYC was also digested using the EcoR1 enzyme and subsequently dephosphorylated using calf intestinal alkaline phosphatase (CiP) (New England Biolabs, USA) to avoid self-ligation in the following steps. The insert and vector DNA concentrations were then obtained via electrophoresis or Nano Drop (Thermo Fisher, USA). After further 
purifications, the ligation reactions were designed to achieve a 12:1 insert to vector ratio and incubated overnight at 16°C with the T4 DNA ligase (New England Biolabs, USA). Following ligation, all constructions were electroporated into E. coli DH5α as de­scribed above. 
5.3.1 lacZα reporter constructions 
lacZα reporter constructions were performed as described by Alexander Mankin’s group (Bailey et al., 2008) who provided the pERMCα vector used to investigate the induction of the 23S rRNA erythromycin resistance methyltransferase ermC. The initial full length armA 5’ UTR (400nt) including the first 4 codons of the armA gene were fused to codons 6-60 of the lacZα reporter gene using the NdeI (New England Bioloabs, 
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USA) and AflII (Takara, USA) restrictions sites of the reporter construct pERMCα. The construction was then subcloned onto the pTOPO-TA cloning vector prior to cloning onto the pACYC-184 vector via digestion enzymes. 
5.3.2 Western Blot constructions 
Constructions to be used for Western Blot protein quantification were performed us­ing the commercial 3xFlagTag-cloning vector (Sigma-Aldrich, USA) as described by the manufacturer. Using the BamH1 restriction enzyme (New England Biolabs, USA), armAwas cloned into the multiple cloning site, in frame with the 3xFlagTag, which consists 
of 3 tandem hydrophilic flag epitopes, 22 amino acids in length. The insert bearing the 3xFlagTag and the transcriptional terminator following the multiple cloning site 
was then amplified using oligonucleotides bearing the EcoR1 restriction site and later cloned onto the pACYC vector as all other constructions. 
5.3.3 Promoter region mutagenesis 
Finally, all site-specific mutations of the -35 and -10 promoter regions were performed using the In-Fusion HD cloning kit (Clontech, USA). Using the armA(wt):Ft construc­tions as a template, the plasmid was then linearized with an inverse PCR. As described by the manufacturer, primers were designed that include a 15bp overlap with each other at the 5’ end. The desired nucleotide substitutions were located within this 15bp overlapping region. After a 15-minute incubation at 50°C, the constructions were then electroporated into DH5α. After a 1-2 hour phenotypic expression shaking (100rpm) at 37°C, the transformants were selected using the plasmid mediated resistance to tet­
racycline. As always, the mutations were carefully confirmed via Sanger sequencing 
with both flanking primers. 
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5.4 Antimicrobial susceptibility testing the minimal inhibitory concentration (MIC) for each of the constructions bearing 
armA was determined in at least 3 independent replicates and according to both the CLSI and EUCAST guidelines (CLSI, 2017; EUCAST, 2017). Both broth micro-dilutions in 96-well plates and disk diffusion testing were performed in Mueller-Hinton media (Ox­
oid, UK) with all appropriate constructions. The final values obtained in mg/L are the compiled average of the independent replicates. Additionally, antibiograms and MICs performed in the presence of sub-inhibitory concentrations of aminoglycosides were performed using 50% of the MIC as previously described (Zhanel et al., 1992). 
5.5 Bacterial growth conditions All growth curves performed over the course of this project were performed in var­ious volumes of Lysogeny Broth (LB) media (Conda Laboratories, Spain) depending on the subsequent application of the sample. Before any growth curve, the stability of the cloning vector was assessed over a period of 48 hours. The most frequently used vector pACYC-184 was shown to be 100% stable in the absence of antibiotic pressure. Bacterial growth was always performed at 37°C while shaking at 100rpm and assessed via spectrophotometry at l600 using a Hitachi U-1900 spectrophotometer (Hitachi, Japan). Samples were diluted appropriately when the OD600 reached levels above 0.4­0.5. Measurements were taken, either every hour or in order to obtain the samples at a predetermined optical density (e.g. OD600 0.2 & 0.4). Furthermore, all inoculations were performed from an overnight culture at an inoculation ratio of 1:100. 
5.6 RNA extractions and reverse transcription a number of the techniques utilized in the process require cDNA generated from RNA extractions. Prior to any RNA extractions performed, multiple growth curves were con­ducted to determine the precise colony forming units (CFU) at each time point. This 
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was used to calculate and standardize the recommended number of cells for the RNA extractions (6x107) at each time point. Both the RNA extraction and the reverse tran­scription were performed exactly as outlined by the manufacturer. RNA extractions were performed using Qiagen’s RNeasy extraction kit (Qiagen, USA). As RNases are extremely abundant and stable in the environment, the working area, including pi­pettes, tip boxes and eppendorf racks were cleaned with RNase Zap (Thermo Fisher, USA) prior and during RNA extractions. Furthermore, this procedure was conducted with RNase free tips and eppendorfs to avoid RNase contamination. After every ex­traction performed, it is of upmost importance to perform a conventional PCR of the 
RNA to confirm the absence of any residual DNA. We performed this PCR using internal 
armA primers (Table 2). If this PCR indicated the presence of undigested DNA, the RNA was loaded back onto the micro-centrifuge column and treated with further courses of DNase treatments. 
 The RNA was then run on a standard electrophoresis gel to determine the quality of 
the RNA extraction based on ribosomal RNA degradation. After confirming the absence of residual DNA via PCR, the concentration of the RNA was determined using a Nano­drop. These concentrations were determined to generate cDNA from the same amount of RNA for each of the samples, especially if the samples were to be used for qPCR analysis. The reactions were then setup using the Superscript III reverse transcriptase (Invitrogen, USA) carefully following the instructions provided. 
5.7 Rapid amplification of cDNA ends (RACE) 
The rapid amplification of cDNA ends is an elegant approach to determine the full transcript lengths of any target gene. The SMARTer RACE kit (Clontech, USA) achieves this by extracting the total RNA from the samples followed by the joint action of the SMARTer II A universal oligonucleotide and the SMARTScribe reverse transcriptase. When the transcriptase acts on the 5’ end of the RNA, its terminal activity adds a few 
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additional nucleotides to the 3’ end of the first cDNA strand. The SMARTer II A Oligonu­
cleotide contains a terminal stretch of modified bases that anneal to the extended cDNA tail, allowing the oligo to serve as a template for reverse transcription. SMARTScribe reverse transcription switches templates from the mRNA molecule to the SMARTer oli­go, generating a complete cDNA copy of the original RNA with the additional SMARTer sequence at the end (Figure 18). 
Figure 18.  A representation of the SMARTer RACE activity with the SMARTer II A oligonucleotide tail (green) 
added to the total RNA prior to reverse transcription and the universal primer (yellow/blue) complementa-
ry to the previously added tail that can be used to amplify the 5’ UTR via conventional PCR using the gene 
specific primer (red) (Figure adapted from SMARTer RACE manual, Clontech, USA).
 Subsequently, the generated cDNA can be used directly in a standard PCR with 
gene-specific primers generating an amplicon from within the gene until the 5’ end of 
the transcript. This procedure was carried out exactly as specified by the manufactur­ers applying all available controls at all times. 
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5.8 lacZα Screening The lacZα blue/white screening was performed as outlined by Bailey et al (Bailey et 
al. 2008) utilizing either LB or MH plates as we found that BHI plates seem to complete­ly inhibit the alpha-complementation of lacZα. As our vector did not have an IPTG inducible promoter, our media did not require IPTG. Furthermore, rather than inocu­lating low percentage agar with the bacteria and applying this to media containing the x-gal (Sigma-Aldrich, USA) substrate, we chose to plate the bacteria directly on plates containing 40µg/ml of x-gal after performing a 0.5 McFarland from a fresh overnight inoculum. The effects of aminoglycosides on the expression of the lacZα reporter gene were assessed using a range of gentamicin concentrations applied either via disks or within the plate itself. After plating, the strains were incubated at 37°C between 18 and 20 hours, after which the plates were incubated at 4°C for approximately 4 hours be­fore taking the result of the screening. It is very important to standardize this screening method, based on the typical growth time of the bacteria, in our case E. coli. 
5.9 Western Blot Western Blots were carried out with an in-house protocol and self-made buffers com­
piled from literature (Biorad, USA). Please find the full protocol and buffer constitu­tions in the supplementary information. As previously described, all bacterial growth to be used for Western Blots was initiated with an inoculation ratio of 1:100 in LB from a fresh overnight culture. 1ml of the sample was then taken every hour or at the desired optical density, and pelleted by centrifugation at 13,400 rpm for 5 minutes. The pellet was then carefully air dried and suspended in 2-fold Laemli buffer containing fresh 
β-mercaptoethanol (Bio-Rad, USA) at a concentration of 1µl Laemli Buffer/0.01 Absor­bance Units to standardize the cell count at various optical densities. After re-suspend­ing, the samples were immediately frozen at -20°C for at least 24 hours. 
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Subsequently, the samples were de-thawed prior to denaturing the protein at 100°C for 5 minutes. Additionally, we prepared our own 50:50 mix of Magic Marker XP (Ther­mo Fisher, USA) and Benchmark (Thermo Fisher) Western Blot weight markers, as one 
can be seen on the membrane but not in the final image obtained, whereas the other 
reacts with the ECL reagents to be seen in the final image but not on the membrane. Un­
less otherwise specified, 2.5μl of the sample were then loaded onto a 4-20% Tris-Gly­cine gel (Invitrogen, USA) and run for 50-60 minutes at 200V. Once the electrophoresis was completed, we set up the Western Blot transfer to the nitrocellulose membrane (Bio-Rad, USA) overnight at 30V and 4°C. 
The following day, the membranes were blocked by submerging the membranes in TBS with 1% Tween 20 (Panreac, USA) and 10% milk (Nestle, Switzerland) for 2 hours at room temperature while shaking at 100 rpm. Following 3-5 washes in fresh TBS-T the membranes were then exposed to the primary antibodies for 2.5 hours (shaking at 100rpm and room temperature), in this case anti-FlagTag (Sigma-Aldrich, USA) and the control anti-DnaK (Enzo, Spain) at concentrations of 1:500 and 1:2000 respectively in 
TBS-T as specified by the manufacturers. 
The nitrocellulose membrane was simultaneously exposed to both primary antibodies in stomacher bags (Seward, UK) that were sealed around the membrane to achieve the highest possible exposure with relatively low volumes. Typically the antibodies were dissolved into 5-10mL of TBS-T/membrane, depending on the size of the membrane. 
After another 3-5 washes in TBS-T, the membranes were finally exposed to the second­ary goat anti-mouse IgG horseradish peroxidase (HRP) conjugate (Life Technologies, USA) at a concentration of 1:5000 in TBS-T, as recommended by the manufacturer, for 1.5 hours (also shaking at 100rpm and room temperature), similarly to the primary antibodies although typically in about 10ml/membrane. The membranes were then thoroughly washed in TBS-T before rinsing them in distilled water prior to ECL reagent (Thermo Fisher, USA) exposure for approximately 5 minutes. 
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Using the Image Lab (Bio-Rad, USA) Western Blot exposure and quantification soft­ware, the membranes were then exposed to UV light for a total of 5 minutes while tak­
ing pictures of the membranes every 10 seconds. Quantifications of the signal strength/ protein quantity were then performed using the same Image Lab software suite. Unless otherwise stated, Western Blot images used were after a 60 second UV exposure, after which the software was then used to automatically identify lanes and bands. Minor adjustments were performed to ensure that the lanes captured the full signal strength of each image. Finally, using the DnaK signal as a reference (e.g. 1) the relative signal 
strength of ArmA could then be quantified. Most Western Blots were conducted and 
quantified at least 5 times. The results of this technique are presented as the average of all replicates. 
5.10 RT-qPCR To investigate the growth phase dependent expression of armA, we performed RT-qP-CRs of samples taken every hour over a time span of 16 hours. As the RNA extractions should be performed with approximately 6x107 cells, prior to the actual growth curve a number of growth curves were conducted with the samples to determine the amount of colony forming units (CFU) at each time point and optical density. Using this we extracted the volume required to acquire 6x107 cells at each time point. Although the RT-PCRs were conducted with a monocopy reference gene (uidA), extracting the RNA from the same number of cells at each time makes the results much more reliable. In order to take the plasmid copy number into account, the curves were simultaneously performed in duplicate, extracting the RNA from one and the DNA from the other. Ad­ditionally, at each time point 1mL aliquots were taken for simultaneous Western Blot analysis. At each time point, the appropriate volume was pelleted down via centrifuga­tion for 5 minutes at 6,000 rpm and then stored at -80°C until the RNA and DNA extrac­tions were performed as outline above.  
77 
MATERIALS AND METHODS
 
The qPCRs were performed in quadruplicate with a My iQ Single Color Real-Time PCR Detection System (Bio-Rad laboratories), using the iQ SYBR Green Supermix (Bio-Rad Lab­oratories). qPCR conditions were calibrated to obtain the optimal amplification condi­tions for each gene (oligonucleotides utilized can be found in table 2). This includes determining the optimal primer concentrations, temperature and threshold for a high 
reaction efficiency (Table 5). 
Table 5. RT-qPCR conditions utilized (oligonucleotides presented in table 2) 
It is important to point out that qPCRs of plasmid borne genes have been shown to require prior restriction enzyme digestion (Providenti et al., 2006), which was per­formed using the PstL restriction enzyme (TaKaRa, USA) as directed by the manufac­
turer. As briefly mentioned above, the qPCR was conducted using the monocopy chro­mosomal control gene, uidA. All the primers designed generated an amplicon of 200nt. 
All conditions were carefully calibrated to achieve the optimal amplification of each of 
these genes prior to the first RT-qPCR. Additionally, we performed an efficiency control 
in each qPCR to be performed, using a five-fold dilution series of an independent PstI 
digested DNA extraction of the sample. Finally, RT-qPCRs with an efficiency lower than 97% (or over 105%) – as determined by the internal control dilutions - and an r2 lower than .99 were discarded and repeated. 
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6RESULTS 
6.1 In silico analysis of the 16S rRNA methyltransferases and their 5’ 
upstream regions 
6.1.1 Coding region conservation of the 16S rRNA methyltransferases 6.1.1.1 CDS conservation of the acquired aminoglycoside resistance conferring methyltransferases Our investigation of the regulatory mechanisms underlying the expression of the ac­quired resistance conferring 16S rRNA methyltransferases started with a comprehensive
in silico analysis. Initially, amino acid sequence alignments were performed to assess thedegree of relatedness among the acquired 16S rRNA methyltransferases (Figure 19).
Figure 19. Radial dendrogram of the acquired G1405 and A1408 methyltransferases. Bootstrap analysis 
conducted with 10,000 replicates. 
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Amino acid sequence based dendrograms demonstrate high degrees of conservation among methyltransferase variants such as RmtD:RmtD 2 and RmtE:RmtE 2, which is not surprising as, for the 16S rRNA methyltransferases, a single amino acid change is 
sufficient for the gene to be classified as a new methyltransferase variant. RmtA and RmtB exhibit the highest degree of relatedness among the other unique methyltrans­ferases (81% amino acid identity). RmtH and RmtB (and consequently RmtA) also 
share a significant amino acid identity (64% and 63% amino acid identity, respec­tively). Finally, RmtG and RmtD 2 share an amino acid identity of 59% and 57% with RmtD, respectively. While there appear to be three clusters of the acquired 16S rRNA methyltransferases (i. RmtA, RmtB, RmtB 2 RmtH; ii. RmtE, RmtE 2; iii. RmtD, RmtD 2, RmtG) the other acquired methyltransferases do not appear to exhibit a high degree of conservation. Generally, this suggests that the acquired 16S rRNA methyltransferases originated from distinct ancestral origins via convergent evolution. The only A1408 methyltransferase, NpmA, is made up of a unique amino acid sequence that is unlike any of the G1405 methyltransferases. 
6.1.1.2 Acquired vs. intrinsic aminoglycoside resistance conferring methyltransferases CDS conservation To further investigate any possible relationships between the acquired and intrinsic resistance conferring methyltransferases, which have been described as a putative ori­gin of several acquired methyltransferases (Liou et al., 2006), we constructed a further dendrogram including both groups of methyltransferases, some of which have been listed in table 1 of the introduction (Figure 20). 
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Figure 20. Radial dendrogram of the acquired resistance methyltransferases belonging to the acquired 
G1405 methylating Arm (red) and A1408 methylated Pam (yellow) family of methyltransferases contrasted 
with intrinsic resistance conferring methyltransferases belonging to the G1405 methylating Kgm (blue) and 
A1408 methylating Kam (green) family of methyltransferases. Bootstrap analysis conducted with 10,000 
replicates. 
Interestingly, the intrinsic methyltransferases do not exhibit a significant degree of relatedness to any of the acquired G1405 methylating enzymes. In fact, the methylases included within this dendrogram appear to segregate based on their origin (e.g. ac­quired vs. intrinsic) and function (e.g. G1405 or A1408 methylases). As such, NpmA 
and the methyltransferases belonging to Kam family differ significantly from the G1405 methylating enzymes. 
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6.1.1.3 The conservation between the resistance conferring and house-keeping 16S rRNA methyltransferases We then decided to increase the scope of this comparative study to include non-re­sistance-conferring, intrinsic methyltransferases (or house-keeping methyltransferas­es) to identify a possible origin of the acquired methyltransferases (Figure 21). 
Figure 21. Radial dendrogram presenting the acquired G1405 methylating Arm family (red), the acquired 
A1408 methylating Pam family (yellow) with the ribosomal small subunit methyltransferases of the Rsm 
family (pink). Bootstrap analysis conducted with 10,000 replicates. 
Based on the amino acid alignments performed, the acquired 16S rRNA methyl­transferases do not share a very high degree of conservation with 16S rRNA methyl­
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transferases from the Rsm family of methyltransferases. That being said, some house­keeping methyltransferases (e.g. RsmC) appear to be more closely related to acquired methyltransferases (such as ArmA) than to other members of the Rsm family. RsmC, which methylates position N2 of G1207, shares a 71.31% amino acid identity with the acquired methyltransferase ArmA. As previously observed, these methyltransferasesalso form clusters based on their target residue and origin as is to be expected. Interest­ingly NpmA appears to be more similar to members of the Rsm family of housekeeping methyltransferases than with the Arm family. 
Finally, we constructed a last dendrogram, presenting all the here analyzed methyl­transferases, again to ascertain any possible trends that could indicate a possible origin of the methyltransferases (Figure 22). 
Figure 22. Further dendrogram presenting all previously analyzed methyltransferase groups belonging to 
the acquired resistance methyltransferases (Arm and Pam), the intrinsic resistance conferring methyltrans-
ferases (Kgm and Kam) and finally the intrinsic 16S rRNA housekeeping methyltransferases (Rsm). Boot-
strap analysis conducted with 10,000 replicates. 
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While the above presented figure indicates that the Arm family of methyltransferases is more closely related to the Rsm family than to the Kgm family, the degrees of sim­ilarity are unfortunately too low to identify a conclusive origin. Generally amino acid conservations range between conserved areas and non-conserved areas. As such, the conclusion again, is that based on their amino acid sequences, the methyltransferases appear to have several ancestral distinct origins. 
6.1.2 The plasticity of the 16S rRNA methyltransferase 5’ upstream regions 
As literature has demonstrated the significance of the 5’ untranslated region in gene regulation (Breidt et al., 1990; Bailey et al., 2008; He et al., 2013), comprehensive eval­
uations of the 5’ upstream regions of the acquired and intrinsic resistance confirming methyltransferases in relation to their downstream coding regions were performed. 
6.1.2.1 Acquired 16S rRNA methyltransferase 5’ upstream region conservation Before presenting the results of the 5’ upstream region alignments, it should be point­
ed out that, for a number of genes, it was difficult or impossible to find sequences along­side an extended upstream region. rmtB 2, for example, only has two sequences upload­ed on Genbank, neither of which contains an untranslated region. As such, rmtB 2 has been excluded from the remainder of this study. For the acquired methyltransferases, full-length upstream region were generally available, however, the chromosomally en­coded intrinsic methyltransferases rarely contained sequences of the genetic environ­ment. We found that these methylases had far fewer annotated sequences uploaded to Genbank. Based on these limitations, all 5’ upstream region alignments were per­formed with a region of 400nt upstream from the coding region. Furthermore, as pre­viously shown, the genetic environment of the 16S rRNA methyltransferases is highly variable. As such, choosing to analyze 400 nt allows us to capture an upstream region 
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that is most conserved alongside the various genes. Sequences used were assessed to be the most representative upstream regions of the respective methyltransferases. 
In the previous section we aligned the amino acid sequences of the various 16S meth­yltransferases. We then analyzed the nucleic acid sequence conservation of the 5’ up­stream regions  (Table 6). 
Table 6. Nucleotide conservation of 400 nt upstream of the acquired methyltransferase coding regions. 
Conservations of more than 50% have been marked bold. 
Interestingly, this nucleotide sequence alignment demonstrated that 5’ upstream regions of armA and rmtE appear to share notable degree of conservation (73.25%). Further investigation revealed that armA and rmtE share a 243nt upstream element, which will be discussed in depth in the following sections. While rmtD and its variant 
rmtD 2 have maintained a highly similar 5’ upstream region (97%), it appears that rmtE 
2 has acquired a novel 5’ upstream region compared to rmtE. Further investigation re­vealed an ISCR20 insertion sequence upstream of the rmtE coding region. The original upstream region was still intact upstream of this insertion sequence. Additionally, the upstream regions of rmtG and rmtD (and consequently rmtD 2), show a surprisingly high conservation (63.75%). 
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The dendrogram generated based on these alignments further highlights the afore­mentioned associations (Figure 23). 
Figure 23. Dendrogram generated from alignments of the acquired methyltransferase upstream region 
(400 nt). Based on sequence availability, rmtB 2 was excluded from this analysis. Bootstrap analysis con-
ducted with 10,000 replicates. 
Figure 23 differs from previously presented trees of the coding regions, which has in­teresting implications regarding the conservation versus acquisition of novel upstream regions. To highlight this, Table 7 below is a table containing both the coding regions and the 5’ upstream regions of the acquired methyltransferases. 
89 
RESULTS
 Table 7. Nucleotide conservation levels of the 400 nt upstream region of the acquired methyltransferases 
(red) vs. nucleotide conservations of the methyltransferase coding regions (blue). 
In table 7, it is interesting that, although ArmA and RmtE have low levels of nucleotide conservation (30.9%), their 5’ upstream regions exhibit a high degree of relatedness. Similarly, RmtG and RmtD (and consequently RmtD 2) also harbor a low nucleotide se­quence conservation (28.55% and 30.82% respectively), while their upstream regions are quite conserved (63.75% and 64% respectively). Conversely, other methyltrans­ferases such as RmtA, RmtB and RmtH share high levels of amino acid conservation whereas their 5’ upstream regions have drastically changed over time. For clarity, fig­ure 24 below presents the aforementioned methyltransferases that exhibit 5’ upstream region conservation and/or coding region conservation. 
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Figure 24. Dendrogram of the acquired methyltransferases demonstrating the plasticity of the upstream re-
gion (400 nt) in contrast to the coding regions. High levels of conservation (>50%) have been marked with cor-
responding colors in both the table and the dendrogram Bootstrap analysis conducted with 10,000 replicates. 
The alignments presented demonstrate an interesting trend pertaining to the conservation of the 5’ upstream region among the acquired methylases. It appears that the 5’ region of the different methylases generally have low levels of conservation; nevertheless all the methyltransferases are capable of producing unusually high levels of aminoglycoside resistance under the regulation of each particular 5’ upstream region. 
The identified regions that maintain a high level of similarity within the 5’ upstream region may bear regulatory features that favor a stringent expressional pattern resulting in the high level resistance conferred. That being said, as the publications pertaining to these genes generally do not determine MIC over a concentration of 128 or 256 mg/L it is hard to ascertain whether or not the various methyltransferases and their 5’ upstream regionsconfer the maximum resistance possible. 
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6.1.2.2 Acquired vs. intrinsic resistance conferring methyltransferases 5’ upstream region conservation As previously conducted with the coding regions of the methyltransferases, our next step was to determine whether or not intrinsic resistance conferring methyltransferas­es shared a degree of conservation with elements found upstream of each other and/ or the acquired methyltransferases (Figure 25). As was the case with rmtB 2 in the previous section, there were no available sequences of the kamC 5’ upstream regions and, as such, it has been excluded from further analyses. Furthermore, unfortunately, based on sequence availability, we were unable to include the upstream regions of the housekeeping methyltransferases within the following assays. 
Figure 25. Dendrogram of the 400 nt upstream region of the acquired 16S rRNA methylases including the 
400 nt upstream region of the intrinsic resistance conferring methyltransferases. Bootstrap analysis con-
ducted with 10,000 replicates. 
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Figure 25 demonstrates substantial differences to amino acid alignments of acquired 
and intrinsic resistance methyltransferases (figure 20), generally there does not ap­
pear to be a significant degree of relatedness among the 5’ regions of the intrinsic and acquired methyltransferases. Unlike the amino acid alignments presented in section,the methyltransferases do not appear to form clusters based on origin or function with regards to their 5’ region identity. That being said, the rmtG upstream region shares 67% identity with the 5’ region of the intrinsic resistance methyltransferase fmrO.
6.1.3 Acquired 16S methyltransferases promoter predictions 6.1.3.1 Degree of -35 and -10 box conservation among the acquired 16S methyltransferases With the exception of certain cases, the in silico analysis of the methyltransferase cod­ing regions and 5’ upstream region demonstrated a high degree of plasticity in the up­stream region of the acquired methyltransferases. To further investigate any common features regarding the regulation of their expression, we then assessed whether or not upstream elements such as promoters harbor a higher degree of conservation.  
Utilizing the online promoter prediction algorithms, the 5’ upstream regions of the ac­quired 16S rRNA methyltransferases were processed for putative promoter elements. Figure 26 below portrays the position of the -35 and -10 promoter elements within the 400nt 5’ upstream region analyzed. 
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Figure 26. Alignments of the putative -35 and -10 promoter regions of the acquired 16S rRNA methyltrans-
ferases including a diagram of the promoter distance from the coding region of the methyltransferases 
(right). Promoter regions were analyzed within a region of 400nt upstream of the CDS. 
The nucleotide conservation of all promoters analyzed revealed a general conserva­tion of a -35 TTGACG motif and a -10 TTATACT motif. Interestingly, armA and rmtE (that harbored upstream regions that shared 73.25% nucleotide sequence conservation) both harbor this exact promoter sequence. This promoter sequence shares a high-level 
conservation with promoters that have been experimentally confirmed to interact with 
the σ70 factor, which will be further discussed in the following sections. The distance of the promoters from the start codons ranged between 67 and 330 nucleotides, measur­ing from 3’ of the -10 box, where the average distance of the promoter elements from the coding region was approximately 214 nucleotides. While the general conservation within the 5’ upstream region among the 16S rRNA methyltransferases was limited, 
it appears that the promoter motifs harbor a more significant degree of conservation. 
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6.2 The characterization of the armA 5’ UTR 
6.2.1 armA reference sequence conservation The remainder of this study will focus on the most disseminated 16S rRNA methyl­transferase, ArmA. In addition to being the most prevalent acquired methyltransferase, ArmA is also harbored by the broadest host-range compared to the other acquired methyltransferases. As such, it has been proposed to harbor a regulatory mechanism able to adapt to the large variations in ribosome count throughout the growth phases of the host bacteria (Ramu et al., 2009). 
To isolate the most representative 5’ upstream region of armA, all available reference sequences of armA were downloaded from Genbank and aligned to evaluate upstream conservation (Figure 27). 
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Figure 27. Alignments of all available reference sequences of armA from Genbank. Accession numbers and 
bacterial species are included on the left. The putative promoter regions identified are denoted by a green 
line within the highly conserved region. 
As armA has thus far almost exclusively been identified within the transposon Tn1548, it is not surprising that the upstream region is highly conserved. Generally, non-coding regions acquire more single nucleotide mutations than coding regions; however, we 
identified a 221 nt region immediately upstream of armA that was highly conserved in 100% of the available sequences of armA. This region contains the aforementioned 
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putative -35 and -10 element (between 186 nt and 156 nt from the start codon) that is 100% conserved throughout all sequences of armA (Figure 26). 4 of the 23 sequences analyzed (17.4%) harbored a 1,335 nt insertion sequence 221 nt upstream of the ATG start codon of armA. Using an online database (ISfinder), this insertion sequence was 
identified as the insertion sequence IS10a, which belongs to the IS4 family. Interesting­ly, this insertion sequence interrupts an open reading frame in the 5’ upstream region of armA that has previously been described as a putative leader peptide involved in the regulation of armA (Ramu et al., 2009). Based on the publications describing sequenc­es harboring this insertion sequence, resistance levels do not appear to be affected by the insertion sequence, suggesting that the translation of this leading peptide is not required for the functional expression of armA. 
6.2.2. In vitro identification of the armA 5’ Untranslated Region In order to accurately dissect the untranslated region of this 16S rRNA methyltrans­ferase it was necessary to identify the full-length of the 5’ UTR. This was conducted in 
the presence and absence of aminoglycoside pressure, via the rapid amplification of cDNA ends (RACE). After treating the synthesized cDNA with a 5’ terminal universal adaptor capable of interacting with the complementary SMARTer RACE oligonucleo­tide, it was possible to amplify the full 5’ UTR via PCR from within the gene using a gene 
specific primer. The resulting amplicon was then subcloned and sent to sequencing.Both in the presence and absence of antibiotic pressure the armA(wt) 5’ UTR was de­termined to be 139 nucleotides upstream of the armA start codon via Sanger Sequenc­ing (Figure 28). 
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Figure 28. Sequence map containing the armA coding region and orientation (blue arrow) as well as the 
RACE confirmed 5’ UTR of armA. The identified 5’ UTR of armA is precisely 139 nt from the armA coding 
sequence. 
The repeatedly obtained transcript length of 139 nt corresponds to the high-level 5’ UTR sequence conservation described in the previous section (Figure 27). In 100% of the armA sequences aligned the here-identified 5’ UTR is conserved. The results of the 
5’ UTR RACE were then confirmed by extracting RNA from E. coli DH5α bearing a WTplasmid that harbors armA. RT-PCR analysis then confirmed this transcript using vari­ous primers upstream and downstream from the predicted transcriptional start. 
The RT-PCR performed of RNA extractions after 2, 4, 6 and 8 hours of growth con­
firmed the absence of a transcript upstream of the here-predicted 139 nt 5’ UTR. While RT-PCRs conducted of a 139 nt or less of the 5’ UTR were positive, all RT-PCR using primers upstream of this region were negative at all time points analyzed (Figure 29). 
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Figure 29. Diagram of the RT-PCRs conducted using various primers from within the 5’ UTR (green) of armA 
(blue) to investigate the presence of any active promoter regions upstream of the RACE predicted 5’ UTR. 
Using primers from within the predicted 5’ UTR resulted in an amplicon suggesting the presence of this 5’ 
UTR within the mRNA, while RT-PCRS performed with any primers upstream (red) of the predicted 5’ UTR 
did not amplify the cDNA, suggesting no upstream promoter regions. 
These assays were conducted in various conditions to ensure a single transcriptional start site. Based on the plethora of possible regulatory mechanisms, it was important 
to confirm not only the length of the 5’ UTR but also to rule out multiple upstream transcriptional start sites. These results demonstrate that both in the presence and ab­
sence of aminoglycosides, throughout the growth phases of DH5α harboring pMUR050 bearing armA, the transcriptional start site of armA is always 139 nt upstream of the 
armA start codon. 
With regards to the armA 3’ UTR, we decided not to performed the 3’ UTR RACE iden­
tification because an in silico investigation revealed a very clear Rho-independent tran­scriptional terminator loop starting 20 nt from the 3’ extreme of armA. As such, we predict that the full transcript length of armA is 946 nt, which is made up of a 139 nt 5’ UTR and a 774 nt coding region followed by a 33 nt 3’ UTR. 
6.2.3 Phenotypic effects upon the truncation of the armA 5’ UTR To identify regulatory elements within this untranslated region, our next step was to perform various truncations of the 5’ UTR to determine the phenotypic impact on the 
armA resistance profile. These constructions were cloned onto the non-ColE1 cloning 
99 
RESULTS
   
 
 
vector pACYC-184. Subsequently RT-PCR analysis confirmed the absence of any active upstream promoter region. As described in materials and methods, these constructs 
were cloned via PCR amplification with a high fidelity polymerase, after which they 
were carefully confirmed via sequencing. As the resistance profile conferred by the various constructions is an informative method of assessing expressional levels, we 
performed MICs and antibiograms of five truncations to identify regions of the 5’ UTR required for the expression of this resistance determinant (Figure 30). 
Figure 30. The antibiotic resistance profile conferred by active ArmA with truncated 5’ upstream regions. 
MICs were determined with gentamicin according to the CLSI and EUCAST guidelines. Numbers reflect the 
measured halo size with the susceptible phenotype marked in bold. Antibiograms in the lower portion of 
the figure were conducted with selected 4,6 2-DOS aminoglycosides amikacin 30 μg (blue) kanamycin 30 μg
(red) and 10 μg gentamicin (green). All antibiograms were conducted according to the CLSI and EUCAST 
guidelines (CLSI, 2017; EUCAST, 2017). 
The results obtained from this truncational assay once again support the findings of the RACE predicted 5’ UTR. These results demonstrate that between -400 nt and -139 nt from the armA start codon there is a regulatory domain absolutely required for the expression of armA. Upon the truncation of this domain, the levels of resistance con­ferred drop to that of the susceptible DH5α control. As the construction bearing the 
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186 nt 5’ upstream region has a truncated putative leader peptide, it appears that the full length leading peptide is not required for the expression of armA. That being said, there is a one fold reduction in the MIC between the WT and the 186 nt construction, which will be further investigated in the following chapter. This seems to support the prediction of an in silico promoter region immediately upstream of the transcriptional start site. Both the minimum inhibitory concentrations and the antibiograms were per­formed in the presence and absence of subinhibitory levels of aminoglycosides. How­
ever, under no conditions did low levels of aminoglycosides affect the resistance profile exhibited by the constructions. 
To further investigate this expressional pattern, we then decided to directly quanti­fy the amount of ArmA translated via Western Blot. As outlined in the materials and methods, we initially tagged armA bearing the full 400 nt upstream region with a C-ter­minal domain Triple FlagTag. Truncations of this tagged construction then allowed us to directly assess translational levels of armA under the regulation of various lengths of the 5’ upstream region (Figure 31). 
Figure 31. Western blot analysis of armA variants with truncated 5’ upstream region. Western blots con-
ducted at an optical density (OD600) of 0.2. Expressional quantification was conducted using the DnaK West-
ern Blot reference protein. 
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Using Western Blots to directly quantify the translational levels of armA at various time points throughout the growth phases of E. coli bearing these constructions, once 
again confirmed the presence of a domain necessary for the accurate expression of 
armA encoded between -400 nt and -139 nt upstream of the armA coding region. Al­
though the Western Blot quantification indicates that the construction bearing the 186 nt upstream region has a lower level of expression, it still produces a substantial amount of ArmA, again suggesting that the leading peptide is not absolutely required for the expression of armA. 
6.2.4 Evaluation of the armA expressional profile 
To further elucidate the expressional profile of this resistance determinant, we de­signed a lacZα reporter construction using the pERMCα vector. By fusing 400 nucle­otides of the armA 5’ upstream region bearing the first 4 codons of armA to codons 6-60 of the lacZα reporter gene we were able to identify any environmental factors that 
influence the expression of this resistance methyltransferase (Figure 32). 
Figure 32. Genetic map of the armA upstream region of 400 nt harboring the putative leader peptide (dark 
yellow), the putative promoter region (green arrows) and the first four codons of armA (blue) fused to the 
lacZα reported gene (yellow). 
The first result of this expressional assay demonstrated that the expression of the 
armA resistance gene appears to be constitutive (Figure 33). 
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Figure 33. Plate of the armA:lacZα reporter construct on Mueller-Hinton agar with x-gal in the absence of 
antibiotics or any known inducing agents. Bacteria were plated after obtaining a 0.5 McFarland turbidity 
inoculum. 
Both in the presence and absence of aminoglycosides, there was a constitutive ex­pression of the lacZα gene product under the regulation of the full-length armA 5’ UTR. 
To further investigate the results of the truncational assay outlined in the previous section, we fused each truncation to the lacZα reporter gene (Figure 34). 
Figure 34. armA variants with truncated 5’ upstream regions plated on Mueller Hinton agar with x-gal. 
Both the WT and 186 nt UTR variant indicate the expression of the lacZα reporter gene under the regulation 
of the respective upstream regions (blue plates). 
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The results of the 5’ upstream region truncations fused to the lacZα reporter con­struct aligned perfectly with our previous results regarding essential domains of the 
5’ UTR. As previously identified, the region between -400 and -139 nt upstream of the 
armA coding region harbors domains absolutely required for the expression of the 16S rRNA methyltransferase armA. 
To investigate whether or not the presence of aminoglycosides is involved with the expressional levels of the armA:lacZα reporter construct, we then added gentamicin in the form of 10 μg disks to the screening (Figure 35). 
Figure 35. armA variants with truncated 5’ upstream regions plated on Mueller Hinton agar with x-gal in 
the presence of gentamicin. Bacteria plated after making a 0.5 McFarland turbidity inoculum. 
At first glance in Figure 35, in the WT as well as in the strain harboring a 186 nt UTR it does appear that there is a region of augmented lacZα expression in the presence of the aminoglycoside. We believe this is attributed to the colony size within the subinhib­itory range of the antibiotic disk. To ascertain whether or not this is case, we performed a number of Western Blots in the presence and absence of various concentrations of gentamicin (Figure 36). 
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Figure 36. Western Blot quantification of WT armA in the absence and presence of various concentrations 
of gentamicin. Quantification performed using DnaK as a reference (Y-axis). 
These Western Blots suggest that antibiotics do not augment the expression of active 
armA under the regulation of its full 5’ UTR. Although not shown, further Western Blots performed in the presence and absence of various 4,6 2-DOS aminoglycosides did not reveal any effect on the expressional levels of armA. 
Finally, to assess whether or not a feedback mechanism modulates the expressional levels of armA, we co-transformed E. coli DH5α with the armA:lacZα reporter con­struct alongside active armA and rmtC in trans (Figure 37). 
Figure 37. Cotransformations of the armA:lacZα reporter construct with active armA borne on the pTOPO 
cloning vector and rmtC on the pBAD cloning vector demonstrated no reduction in the expression of the 
reporter gene in the presence of the methyltransferase armA or the methyl group at postion G1405. 
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The co-transformations were maintained using selective antibiotic concentrations 
and the presence of both plasmids was confirmed via PCR. This assay was conducted in the presence and absence of two different acquired 16S rRNA methyltransferases. This was done to assess whether, either the presence of active methyltransferase or the presence of the methyl group on G1405 had an impact on the expressional levels of 
armA. However, neither the presence of armA on a high copy number plasmid, nor the presence of rmtC in trans appears to affect the expressional levels of armA. 
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6.3 Growth phase dependent expression of armA mediated by σ70 
transcription factor promoter region 
6.3.1 Evaluation of the predicted σ70 promoter region of armA Based on the data obtained to this point, the expression of armA does not appear to beaffected by post-transcriptional regulatory activities. Both the phenotypic and transla­
tional assays confirm the complete lack of ArmA upon truncation of the region containingthe promoter (Figures 30 and 31). Before experimentally investigating this promoter, wecarefully analyzed it in silico and compared it to previously identified promoters.
Online promoter prediction algorithms revealed that promoters of this sequence have known interactions with the s70 factor RpoD. The RpoD family of sigma factors preferentially induces the transcription of genes associated with fast growth, such as ribosomal operons and a number of other factors involved in protein synthesis. 
Figure 38. Conservation of the experimentally confirmed RpoD recognized promoter region (Figure adapt-
ed from Shultzaberger et al., 2007). 
Figure 38 contrasts the promoter region identified within the region required for the expression of armA with the most conserved nucleotides of promoters experimentally 
identified to interact with s70 factor RpoD. In addition to nucleotide conservation, a key modulator of activity for this type of transcription factor is the distance of the -35 and -10 box of the promoter region, where the most common distance between the 
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two elements identified was 17 nucleotides. This factor is capable of fine-tuning the transcriptional levels of the gene product, and as the distance between the -35 and -10 boxes of the armA promoter region is precisely this most common distance, it could support the unusually high MIC produced by this resistance determinant. Based on lit­erature dissecting promoter regions, the nucleotide conservation demonstrated above 
is sufficient to initiate transcription via this housekeeping sigma factor. Interesting­
ly, the RACE and RT-PCR confirmed transcriptional start site is 17 nucleotides from the 3’ end of the -10 box. Typically, the -10 box is between 8 and 14 nucleotides from the transcriptional start site, although larger spacings have previously been described (Shulzaberger et al., 2007). 
6.3.2 Single Nucleotide resolution of promoter elements required for 
the fine-tuned expression of armA 6.3.2.1 Initial mutagenesis of highly conserved nucleotides To assess whether or not this putative promoter is responsible for the expression of 
armA we performed mutations of conserved nucleotides within the promoter region. To achieve this we initially synthesized 3 mutants of the 400 nt armA variant bear­ing the 3xFlagTag to subsequently assess the translational levels alongside the resist­
ance profile. The first of them had the two most conserved nucleotides of the -35 box (TTèGG) substituted with a double guanine. The second mutant generated also had two base-pairs substituted with a double ‘GG’, but within the -10 we chose to mutate one highly conserved nucleotide and an adjacent less conserved nucleotide (TTèGG) to assess whether or not the expressional levels expected correspond with the s70 pro­moter region hypothesis. The third mutant generated as part of this initial mutagenesis contained ‘GG’ substitutions in both the -35 and the -10 box (Figure 39). Subsequently, we assessed the expression of armA via both the resistance profile generated and the translational levels. 
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Figure 39. Diagram of the initial promoter region substitutions performed in contrast to the RpoD recog-
nized promoter region conservation. ‘GG’ substitutions performed (framed red) of the -35 box, the -10 box 
and both the -35 and the -10 box (Figure adapted from Shultzaberger et al., 2007). 
These constructions, generated via an outward PCR and the In-Fusion HD cloning kit, were then carefully examined via Sanger sequencing, after which their resistance pro-
file and translational levels were examined (Figure 40). 
Figure 40. Antibiotic resistance profile conferred by armA(wt) and armA with initial GG substitutions of the 
-35 box, the -10 box and both elements (-35 & -10 boxes). MICs were determined with gentamicin according 
to the CLSI and EUCAST guidelines. Numbers reflect the measured halo size with the susceptible phenotype 
marked in bold. Antibiograms in the lower portion of the figure were conducted with selected 4,6 2-DOS 
aminoglycosides amikacin 30 μg (blue) kanamycin 30 μg (red) and 10 μg gentamicin (green). All antibio-
grams were conducted according to the CLSI and EUCAST guidelines (CLSI, 2017; EUCAST, 2017). 
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The results pertaining to the resistance profile of the initial -35 and/or -10 box mu­tants aligns precisely with the hypothesis of a promoter region recognized by a s70 factor. Interestingly, the -10 box, where the substituted nucleotides are one highly con­served and one less conserved, exhibits low levels of armA expression. This is to be expected as only one of the most conserved nucleotides was mutated, suggesting that 
the presence of the adjacent adenine is sufficient to induce very low levels of armAtranscription. To investigate the effects this has on the translational levels of armA wethen conducted Western Blot assays (Figure 41). 
Figure 41. Western Blot expressional analysis of the initial GG substitutions performed in the -35 and -10 
boxes of the predicted promoter region. Western Blot quantification carried out using DnaK as a reference 
as previously described. 
The Western Blot translational levels align very accurately with the results obtained 
regarding the resistance profile of each of these mutants. While there is a drastic re­duction in the translated ArmA in each of the mutants, the -10 box GG substitution (of one highly conserved and one less conserved nucleotide) displays levels of translation that are higher than in those constructions where the most conserved nucleotides are substituted. 
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6.3.2.2 Comprehensive -35 and -10 GG substitution assay The initial results obtained from the mutagenesis of the promoter region strongly suggest the presence and activity of a promoter known to interact with the s70 factor. To further investigate crucial elements within the promoter region we performed a number of further mutants of both the -35 and the -10 promoter regions (Figure 42). To obtain a complete understanding regarding the various promoter elements we de­cided to substitute nucleotides in pairs with both double guanine and double adenine mutations as previously described by Miura et al (Miura et al., 2015). 
Figure 42. Figure demonstrating the various substitutions performed to ascertain nucleotides required for 
the expression of armA at a single nucleotide resolution. 
This was necessary to not only identify the specific nucleotides most required for the appropriate transcriptional induction of armA, but also to identify the extremes of the promoter regions. To this point, every mutation of these regions has resulted 
in a significant reduction of MIC. Despite previous results indicating the appropriate 
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expression of armA even upon the truncation of the leading peptide, these mutants 
again confirm that the drastic reduction of aminoglycoside resistance is a result of the promoter region substitutions and not due to amino acid changes within the putative leader peptide. Again, after carefully examining the constructions via Sanger sequenc­
ing, we investigated the effects of the mutagenesis on the resistance profile and trans­lational levels. 
-35 box substitutions Figure 43 below presents the effects of the double base pair substitutions on both 
the resistance profile and the translational levels of each ‘GG’ substitution performed throughout the -35 box of the armA promoter. 
Figure 43. Resistance levels and Western Blot expressional analysis of GG substitutions throughout the -35 
box. Gentamicin MICs were determined according the CLSI and EUCAST guidelines (CLSI, 2017; EUCAST 
2017). Western Blots were performed in triplicate and quantified using DnaK levels as a reference. Western 
Blots presented are representative of the expressional trends observed and quantifications were performed 
using all replicates. 
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The GG substitutions performed at every position of the -35 promoter region clear­ly identify key nucleotides involved in the expression of armA. Modifying nucleotides at position 2 of the -35 box (TTèGG) had the most pronounced effect on both the resistance levels conferred and the Western Blot translational levels. Substitutions of 
positions 3 and 4 significantly reduced both this resistance levels as well as the trans­lational levels of armA. Based on the RpoD promoter region conservation, these results support the involvement of the RpoD housekeeping sigma factor in the translational induction of armA.
As mentioned above, substitutions were performed with both double guanine and double adenine nucleotide pairs. Figure 44 below presents the results obtained from the double adenine substitutions at every position of the -35 box. 
Figure 44. Resistance levels and Western Blot expressional analysis of ‘AA’ substitutions throughout the -35 
box. Gentamicin MICs were determined according the CLSI and EUCAST guidelines (CLSI, 2017; EUCAST 
2017). Western Blots were performed in triplicate and quantified using DnaK levels as a reference. Western 
Blots presented are representative of the expressional trends observed and quantifications were performed 
using all replicates. 
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The results obtained for the double adenine substitutions revealed further infor­mation required for the transcriptional induction of armA. Again, substitution of the two most conserved nucleotides results in a drastic reduction of MIC and Western Blot expressional levels. Interestingly, ‘AA’ substitutions at position 3 (GAèAA) reduces theexpressional levels of armA more than the previous substitution from (GAèGG). Thisindicates that in addition to the most conserved thymines at position 2, the guanine ofposition 3 is absolutely required for the transcriptional induction of the resistance gene.
Both ‘GG’ and ‘AA’ substitutions at position #1 and #5, outside of the conserved pro­
moter region, have little to no effect on both the resistance profile and translational levels of ArmA. This further supports that the phenotypic effects observed in the initial mutagenesis assay are a result of disturbing the promoter region rather than altering the putative peptide, which thus far has not demonstrated any involvement with the expression of armA. In fact, it appears that the entire promoter region, including gen­erally unconserved nucleotides of sigma factor recognized promoters, is required to generate WT levels of armA expression. 
-10 Box substitutions Following the same model as previously described for the -35 box, the -10 box was substituted at all positions with both ‘GG’ and ‘AA’ substitutions. Subsequently, the re­
sistance profile and translational assays were assessed via MIC and Western Blot re­spectively. Figure 45 below, presents the results obtained regarding the expressional levels of armA after substituting its -10 box with double guanine nucleotides. 
114 
 
 
Figure 45. Resistance levels and Western Blot expressional analysis of ‘GG’ substitutions throughout the -10 
box. We were unable to obtain the ‘GG’ substitutions of position 1 (N/A). Gentamicin MICs were determined 
according the CLSI and EUCAST guidelines (CLSI, 2017; EUCAST 2017). Western Blots were performed in 
triplicate and quantified using DnaK levels as a reference. Western Blots presented are representative of the 
expressional trends observed and quantifications were performed using all replicates. 
As observed with the substitutions of the -35 box, this study clearly reveals nucleo­tides required to produce WT levels of armA expression. While substitutions of the less conserved double thymine group of position 2 permit low levels of armA expression, substitution of the adenine in position 3 (the most conserved nucleotide of the RpoD recognized -10 box) results in a complete lack of MIC conferred. Futhermore ‘GG’ sub­stitution of position 4, which is generally unconserved in RpoD recognized promoters, also permits low levels of armA expression. While, substitutions of the first thymine of position 5 (the second most conserved nucleotide of the RpoD recognized -10 box) also results in a complete inhibition of armA expression. As previously observed, substitu­tions beyond the 5’ and 3’ extremes of the promoter regions do not affect the resistance level nor the expressional levels of armA. 
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Figure 46 below, presents the results of the -10 ‘AA’ substitutions as previously de­scribed. In this case, however, we have introduced one further position, to evaluate the involvement of an extended -10 region. 
Figure 46. Resistance levels and Western Blot expressional analysis of ‘AA’ substitutions throughout the -10 
box. The XX pertains to nucleotides that were not substituted as the original sequence harbors those nucle-
otides. Gentamicin MICs were determined according the CLSI and EUCAST guidelines (CLSI, 2017; EUCAST 
2017). Western Blots were performed in triplicate and quantified using DnaK levels as a reference. Western 
Blots presented are representative of the expressional trends observed and quantifications were performed 
using all replicates. 
The results obtained from the AA substitutions of Figure 46, confirmed the involve­ment of both the double thymine group at position 3 (previously position 2). Further­
more, it confirms the importance of the adenine group in position 4 (previously 3), because in this substitution series this nucleotide is not affected and the MIC and West­ern Blot levels are close to the WT phenotype. Positions 4 and 5 (previously 3 and 4 respectively) each already harbor an adenine, and as such, only the cytosine in mutated at each postion, which again permit armA expressional levels to reach almost that of the WT. Final, as also observed with the ‘GG’ substitutions (Figure 45), the substitution of the thymine at the 3’ extreme of the -10 box results in expressional levels close to the 
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susceptible DH5α control. Again mutagenesis of nucleotides adjacent to the promoter regions did not affect expressional levels of armA. 
Both -35 and -10 promoter regions harbor conserved elements that correspond with con­served promoter regions of the sigma factor RpoD. Mutagenesis of non-conserved nucleo­tides of this promoter region resulted in a drastic reduction of armA expressed althoughlow levels of expression were recorded. Substituting the most conserved nucleotides of thepromoter region completely inhibited armA expression resulting in the resistance pheno­type of the susceptible Dh5 α control. This study also demonstrated, that while some -10boxes alone are capable of inducing transcription, the expression of armA relies on bothpromoter regions being intact to reach WT expressional levels. Furthermore, substitutionsadjacent to the promoter regions had no affect on the expression of armA. As these sub­stitutions confer amino acid changes in every occasion the previously described putativeleader peptide does not appear to be involved for the expression of WT levels of armA. 
6.3.3 Growth phase dependent expression of armA All the previously obtained results demonstrate that the expression of armA is solely reg­
ulated by the above identified promoter region. As this promoter region was identified as aregion that has been shown to interact with the s70 factor RpoD, we decided to investigate
the expressional profile of armA throughout various growth curves. As previously men­tioned, the RpoD sigma factors are especially active in periods of rapid cellular growth andis strongly associated with the induction of genes involved in protein synthesis. Therefore,we decided to investigate both the transcriptional and translational levels of armA through­out growth. All growth curves were performed in the absence of antibiotics, as we havepreviously demonstrated that the presence of antibiotics has no effect on the expressionof armA. Prior to this study the stability of the armA bearing vector was shown to be 100%over a period of 48 hours.
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6.3.3.1 Translational levels of ArmA over a 12 hour growth period Primarily, we conducted a Western blot translational assay of both 3xFlagTagged con­structions bearing its promoter region within the pACYC-184 cloning vector. All growthcurves were conducted at least in triplicates and an average expressional value is presented
in the figures below (Figure 47). 
Figure 47. Western Blot expressional levels of armA over a 12 hour growth period. As with all previous Western
Blots the levels of armA were quantified using DnaK as a reference. All growth curves and Western Blots were
performed repeatedly and the average is presented. 
The translational assays conducted over a 12-hour growth curve presented above demon­
strate an interesting expressional profile of the 16S rRNA methyltransferase ArmA. armA
alongside its functional promoter exhibits significantly higher expression between 2-5hours after inoculation. This time period corresponds with the early exponential growthphase. As the exponential phase of bacterial growth is highly dependent on the upregulatedtranscription of genes involved in the protein synthesis machinery, it would appear that the
expressional profile of armA corresponds with that to be expected of a gene induced by thesigma factor RpoD. Such a mechanism would result in expressional levels of the resistancegene that accurately match the expressional levels of its target site within the host.
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To further investigate the association of this expressional peak with the identified promoter region, we performed growth curves using the initial ‘GG’ substitutions per­formed. The armA expressional profile of constructions harboring a ‘GG’ substitution of the most conserved nucleotides of the -35 box and/or ‘GG’ substitutions of one highly conserved nucleotide and one less conserved nucleotide of the -10 box were then also analyzed over a growth period of 12 hours (Figure 48). 
Figure 48. Western Blot expressional levels of armA(wt) (blue) and the initial ‘GG’ substitutions of the -35 
(purple), the -10 (green) and the -35 and -10 double mutant (red – levels too low to be visualized in the 
figure). As with all previous Western Blots the levels of armA were quantified using DnaK as a reference. 
While the very low levels of expression, of the armA construction harboring a ‘GG’ substitution within the -10 box, correspond to previous results, the expressional levels of all of the initial promoter region mutants are virtually 0. To further investigate the associated between the promoter region and the expressional peak observed, these constructions were cloned in the presence of an upstream promoter region. The results of this preliminary study will be discussed in the discussion. 
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6.3.3.2 Transcriptional levels of armA over a 12 hour growth period 
To ensure that our constructions are a reflection of the WT expressional pattern of
armA, we then performed RT-qPCRs of this resistance determinant in its WT environ­ment on the plasmid pMUR050. To quantify the levels of armA transcription we used the chromosomal reference gene uidA. The growth curves performed were conducted under exactly the same conditions as the growth curves used to investigate the transla­
tional profile in the previous section (Figure 49). 
Figure 49. Preliminary RT-qPCR analysis of the transcriptional levels of armA throughout the early expo-
nential phase of growth, using the chromosomal and constitutive uidA gene as a reference. Simultaneous 
DNA extractions were used to account for the plasmid copy number. Finally, the quantifications were per-
formed using the published formula (San Millan et al., 2014) 
The results obtained pertaining to the transcriptional levels of armA again demon­strate increased expressional levels between 2-5 hours after inoculation. The tran­scriptional levels of armA double in this period as compared to the uidA reference gene. This observed increase again corresponds to the early exponential phase of growth, thus supporting the hypothesis of the recognition of the rpoD transcription factor by 
the identified promoter region. That being said, surprisingly, the RT-qPCR expressional 
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analysis revealed lower transcriptional levels in the early growth phase than observed in the Western Blot analysis. We believe that this discrepancy is the result of perform­ing extractions in the very early phases of growth. Furthermore, these RT-qPCRs are a preliminary study of the transcriptional levels, further studies of the armA transcrip­
tional profile will be described in the discussion. 
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DISCUSSION 7 
7.1 The origin of the 16S rRNA methyltransferases and the evolution 
of their 5’ upstream regions 
7.1.1 The coding region conservation of the acquired 16S rRNA 
methyltransferases This study commenced with a comprehensive in silico investigation of the coding regions of the acquired 16S methyltransferases. The aim of this portion of the study was to identify conserved regions of this resistance determinant that could possibly provide indications of a putative ancestral methyltransferase capable of shedding light on the origins of the resistance determinant and any ‘original’ regulatory mechanism associated with its expression. 
Our results strongly suggest that the acquired 16S rRNA methyltransferases con­vergently evolved from several different ancestral enzymes (Figure 20). In terms of high-level conservation among the acquired methyltransferases, RmtB and its variant 
RmtB2, RmtD and its variant RmtD2, and finally RmtE and its variant RmtE2 display by far the highest level of identity, which is to be expected. For the aminoglycoside 
resistance conferring methyltransferases a single amino acid change is sufficient for the gene to be considered a variant. There are, however, limited examples of acquired methyltransferases that exhibit a degree of conservation, which may indicate a com­mon ancestor for those genes. For example, RmtA and RmtB exhibit the highest degree of amino acid conservation at approximately 81%. This suggests that these two meth­yltransferases, did at some point, share a common ancestor. To address this further it is interesting to look at the epidemiology of the two genes. Although RmtA was discov­ered prior to RmtB, RmtB is far more disseminated and described than RmtA. While it 
is possible that RmtA is a derivative of RmtB and, by chance, it was discovered first, it 
is also possible that the variations accumulated by RmtB have resulted in a significant 
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selective advantage of this novel resistance gene. To investigate such a relationship, more information and experimental evidence regarding factors such as biological bur­
den (e.g. fitness cost) of each gene, is required. Furthermore, the more recently identi­
fied methyltransferase RmtH shares a relatively high degree of conservation (64.47%) 
with RmtA (and consequently RmtB – 62.89% - and its variant RmtB 2). These findings would support a putative common ancestor for this cluster of acquired 16S rRNA meth­yltransferases (RmtA, RmtB ( and RmtB 2) and RmtH). However, some of these meth­yltransferases have not been described very often and further data regarding their re­
sistance profile and more importantly their biological cost would facilitate studies such as this one. 
When analyzing such trends within publications there is a slight problem with the acquired 16S rRNA methyltransferases, which is that, generally, studies investigating resistance levels in isolated bacteria do not typically determine the actual MIC con­
ferred by the methyltransferase (unless the publication specifically focuses on these resistance determinants). Generally, aminoglycoside MICs over 128-256 mg/L already strongly indicate the presence of a 16S rRNA methyltransferase, although such MICs can also be the result of numerous modifying enzymes. With regards to putative regu­latory domains underlying these resistance levels, it would be of interest to obtain the actual MICs of all acquired 16S rRNA methyltransferases as well as data pertaining to the biological burden they incur on the host. 
In summary, this portion of the study demonstrated a high degree of plasticity among the coding regions of the acquired resistance determinants suggesting that they con­vergently evolved from a number of ancestral genes. To gain further insights into the precise relationship of these genes, further in vitro studies with a broader selection of methyltransferases would be required. 
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7.1.2 Investigating the origin of the acquired methyltransferases We then decided to expand the analysis to include a number of key intrinsic, resist­ance conferring, 16S rRNA methyltransferases. As outlined in the introduction, for the producers of antibiotics that act on the prokaryotic ribosome, such as aminoglycosides, 
intrinsic resistance conferred via target modification is an advantageous strategy, due to the high-level resistance that is achieved. In these producers, such a resistance mech­anism has frequently been found within the cluster responsible for the biosynthesis of the antibiotics themselves (Cundliffe et al., 2010). The advantages of co-transcribing the resistance gene alongside the antibiotic are two fold. Primarily, the goal of the bac­terium is to produce the methyltransferase simultaneously or prior to the production of the antibiotic. By managing the expression of the resistance determinant in such a way, the bacterium can ensure resistance from the auto-toxic effects of the antibiotic. Secondly, depending on the growth phase of the bacterium, the secondary metabolite, that is, the antibiotic, is unlikely to be constitutively expressed and, as such, the con­stitutive expression of the protective resistance mechanism is not required. Although the transcription and translation of such methyltransferases have been shown to not 
incur a significant biological burden to the cell, modifications of a machinery as highly conserved as the prokaryotic ribosome has been shown to incur some reduction in host 
fitness (Lioy et al., 2014). 
The above-mentioned organization of intrinsic 16S rRNA methyltransferases is the underlying reason for our in silico investigation of the methyltransferase coding re­
gions. The identification of an intrinsic methyltransferase that bears high levels of conservation with any acquired methyltransferase would allow us to investigate the original environment and regulatory framework of the methyltransferases. That be­ing said, the dendrograms generated pertaining to these conservations revealed that, despite NpmA forming a segregated cluster with other N1-A1408 methyltransferases such as KamA-C as well as CmnU, it appears that amongst that cluster the amino acid conservation remains low and that these methyltransferases are also likely to have 
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evolved convergently.  FmrO also shares a degree of conservation with some of the N7­G1405 methyltransferases, although again, no clear ancestral linkage could be made. In fact, the dendrograms demonstrated clusters among the analyzed methyltransferases that clearly correspond with origin (e.g. intrinsic vs. acquired) and function (e.g. tar­get residue). Our results suggest that the ancestral origin of the acquired resistance methyltransferases is not one of the intrinsic resistance conferring methyltransferases described. That being said, based on the GC content of the intrinsic methyltransferases (64-72%) originating from their Gram positive aminoglycoside producers compared to the GC content of the acquired methyltransferases (30-59%), it is possible that the 
resistance genes have had to change significantly to compensate for their new genetic environment in Gram negative hosts (Liou et al., 2006). Liou et al went on to demon­strate that the acquired resistance methyltransferase armA is capable of functioning in the low GC content Gram positive bacterium B. subtilis. 
However, based on the results obtained until this point, it appears that, perhaps, these acquired resistance conferring methyltransferases may have originated from RNA methyltransferases other than those responsible for conferring aminoglycoside resistance to the producers. As such, we expanded our analysis yet again to include a select number of housekeeping 16S rRNA methyltransferases. While there are a vast amount of methyltransferases within the bacterial cell, based on the structure of their target molecule, we have limited this study to housekeeping methyltransferases that act on the 16S rRNA. The analyzed housekeeping methyltransferases belong to the ri­bosomal small subunit methyltransferase (Rsm) family and methylate a variety of res­idues within the 16S rRNA. The resulting CDS conservation corresponded with previ­ously observed trends of the methyltransferases. Again, clusters were formed based 
on the origin and function of the gene in question without any significant degrees of conservation among the various groups formed. The aminoacid sequence of ArmA did show a relatively high amino acid conservation with the housekeeping methyltrans­ferase RsmC (71.37%). However, a number of the highly conserved domains within the 
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methyltransferase regions were disrupted. As such it is insufficient to suggest it as a ancestral origin of ArmA. 
In conclusion, the coding regions of the various 16S rRNA methyltransferases did not indicate the direct linkage between the acquired, intrinsic and housekeeping meth­yltransferases analyzed. While there are clearly many more methyltransferases that could be included within this study, based on the scope of our study and the correctly annotated sequences available, we were unable to identify any strong correlations. 
7.1.3 The maintenance vs. evolution of the 5’ upstream  	regions of acquired 
methyltransferases Over the past decades, the literature pertaining to gene regulation has increasingly fo­cused on the involvement of the 5’ UTR in the accurate transcription and translation of gene products (Breidt et al., 1990; Bailey et al., 2008; Ramu et al., 2009; He et al., 2013). Furthermore, it has become clear that gene products associated with targets that dras­tically vary in quantity over growth phases, such as the protein synthesis machinery, oftentimes harbor a dynamic mechanism of regulation. While such mechanisms can be transcriptionally and/or translationally mediated, many domains responsible for such an auto-regulation rely on elements harbored within the 5’ upstream region of the gene in question. This information, along with the published in silico prediction of a regu­latory domain upstream of the armA methyltransferase, led us to focus on this region early on in the study (Ramu et al., 2009). 
The in silico dissection of this 5’ region was conducted identically to the analyses of the coding regions. Initially, our study focused on the acquired methyltransferases and then we broadened the analyses to include intrinsic methyltransferases with associat­ed non-coding regions on Genbank. Based on the aforementioned limitations regarding the availability of annotated sequences and their 5’ regions, we analyzed a region of 
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400nt upstream of the start codon. Although there are select examples of longer UTRs, the majority of 5’ UTR harbored regulatory domains are within 200-300 nucleotides of the coding region (Ramu et al., 2009). Furthermore, a number of both the intrinsic and acquired methyltransferases had a very small number of sequences uploaded. RmtB 2, for example, only had two sequences uploaded to Genbank, neither of which harbored a genetic environment. That being said, we proceeded to analyze the 5’ upstream re­gions of this group of methyltransferases with the data available to us. 
Initial alignments of this 400nt selection upstream of the CDS revealed a variety of interesting trends. Primarily, that the clusters generated among the methyltransferases 
have altered significantly. For example, NpmA, the only acquired N1-A1408 methyl­transferase, is no longer segregated from the rest of the methyltransferases as was ob­served within the coding region alignments. The second very interesting observation was the acquisition of novel 5’ regions among some methyltransferase variants (RmtE vs. RmtE 2) and the maintenance of others (RmtD and RmtD 2). Interestingly, although RmtE and its variant RmtE2 exhibit a 99.88% amino acid sequence conservation, the conservation of the 5’ upstream region is 32.19%, suggesting the acquisition of a novel upstream environment. Again, as the number of uploaded sequences and publications 
of RmtE and its variant are very limited, it is difficult to accurately interpret these re­sults. It is possible that RmtE has such a low prevalence because its current genetic en­vironment results in an over expression of the gene, which confers too high of a biolog­ical burden to the host (e.g. augmented levels of SAM sequestration). Over the course of our study, we did realize that bacteria carrying 16S rRNA methyltransferases on high copy number plasmids appear to grow at a slower rate, most likely due to such an in­
creased fitness burden. Conversely, it is very possible that, upon moving from one host species to another, rmtE acquired an insertion sequence to compensate its biological cost to the new host (Depardieu et al., 2007). However, as mentioned, without further 
sequences and experimental evidence pertaining to fitness cost and resistance profile, 
it is difficult to extrapolate more information from this phenomenon. 
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However, the aforementioned case of RmtE and its variant, is not the only observed case where the coding region displays high degrees of conservation whereas the 5’ upstream region appears to be entirely unique. RmtA and RmtB share a 76.32% nu­cleotide conservation within the coding region, however their 5’ regions share less than 23% identity. This phenomenon was also observed with RmtH and RmtA (and consequently RmtB), where in both cases the coding region conservation was elevated whereas the 5’ region conservation was <30%. One thing that is clearly demonstrated by this incongruence of 5’ region and the CDS is that the 5’ upstream regions of the ac­quired methyltransferases exhibit a high degree of plasticity. Such a genetic plasticity would be a very elegant mechanism for bacteria to develop regulatory domains capable of expressing appropriate quantities of the resistance determinant. 
However, despite not finding a universally conserved domain in the upstream region of these methyltransferases (which would not have been expected in genes derived from a variety of ancestors) there were a number of elements that appeared conserved among certain methyltransferases that do not share high levels of CDS conservation. One such example is the relatively high level conservation between the rmtG and rmtD5’ upstream region (and consequently rmtD2) – 63.75% (and 64%). Although these upstream regions harbor scattered fractions of conserved regions, closer analysis does not reveal any clear origin of this sequence. The high degree of conservation observed between the 5’ regions of armA and rmtE however lead to more interesting findings. These two sequences are the only two 5’ upstream regions that harbor a highly con­
served region upstream of the CDS. We identified a 243nt sequence that was 100% conserved between these two methyltransferases.
Initially, comparisons of this common sequence with online databases revealed only sequences upstream of either armA or rmtE based on the number of uploaded sequenc­es. However, further investigations using low similarity BLAST parameters revealed an ~80% conservation to a sequence previously identified upstream of a β-lactamase 
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 gene. In this publication this region was identified as a portion of an ISCR20 element (Berçot et al., 2010), but the experimental evidence was limited and degree of conser­vation, perhaps, too low to draw further conclusions. That being said, there are cases of 16S rRNA methyltransferases, such as RmtC, that are expressed by means of insertion 
sequence elements harboring promoter regions that have been identified to induce the expression of downstream gene products. As outlined in the introduction, insertion sequence borne promoters have been shown to modulate the expression of adjacent resistance genes (Depardieu et al., 2007). This evidence does suggest high levels of variability in the upstream region of the acquired 16S rRNA methyltransferases, as the 243nt most likely originate from an insertion sequence that has been interrupted by further insertion sequences. Or, perhaps, both methyltransferases were initially mobi­lized by the the same insertion sequence which was later deleted. 
7.1.4 The conservation of 5’ upstream regions with regards to select intrinsic 
resistance conferring methyltransferases The results obtained in this section are very interesting with regards to the prior results when comparing the CDS of the acquired methyltransferases to the intrinsic or housekeeping methyltransferases. When comparing dendrograms of the CDS, the various proteins analyzed clustered form based on their origin and function. If the 5’ el­ements of these proteins share a long evolutionary history with the coding region, then arguably they would be expected to also segregate into clusters based on the function and origin of their respective coding region. This was not the case for the analyzed 16S rRNA methyltransferases. The 5’ regions of the Kam and Pam family of methyltrans­ferases are no longer clearly distinguished from the N7-G1405 methyltransferases and, in general, the intrinsic Kgm methyltransferases appear to be far less segregated than previously observed with regards to their coding regions. 
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However, this analysis revealed a single case in which an intrinsic methyltransferase 
shared a significant identity with one of the acquired regions. The upstream region of the intrinsic resistance conferring methyltransferase fmrO shares a 67% nucleotide se­quence conservation with the upstream region of the acquired methyltransferase rmtG. And as was the case with the alignment between the rmtD and rmtG, the conservation of rmtG with fmrO consists of scattered portions of conserved nucleotides, however, the 
overall nucleotide identity is insufficient to reveal any ancestral origin of this region. 
Despite only finding a limited number of conserved regions or domains within the 5’ 
upstream region, whether novel or maintained, they mediate an expressional profile that leads to the high-level aminoglycoside resistance that is typical of the 16S rRNA methyltransferases. While the similarities between fmrO and certain acquired resist­ance methyltransferases could be an indication of a native 5’ upstream region, high degrees of sequence conservation would not really be expected based on their differ­ent genetic environment. While the intrinsic resistance methyltransferases are gener­ally harbored within chromosomal clusters alongside the antibiotic or intermediate components the acquired methyltransferases are on mobile genetic elements that have varied greatly over time. With regards to the GC content previously mentioned, the pos­sibility does remain that the acquired methyltransferases did originate from intrinsic resistance methyltransferases of Gram positive producers but they have had to evolve greatly to function within Gram positive bacteria, which could explain the diffuse pat­tern observed among the acquired resistance methyltransferase alignments.  
7.1.5 Coding region promoter elements identified 
To this point, no overwhelming conservations have been identified within the re­
gions upstream of the analyzed 16S rRNA methyltransferases. The final aspect of the upstream region analyzed as part of the in silico investigation were the putative pro­moter elements. As such, using the Softberry promoter prediction algorithms (Soft­
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berry, USA), we proceeded to predict any putative promoters in the regions upstream of the methyltransferase coding regions. These predictions revealed that all acquired 16S methyltransferases harbor a -35 and -10 box within the 400nt analyzed. These 
alignments were the first aspect of these resistance conferring methyltransferases that exhibited a high degree of conservation among all acquired methyltransferases. The promoter region of prokaryotes typically consists of a ‘TTGACA’ -35 box and a ‘TATAAT’ -10 element. The acquired methyltransferase promoter conservations differed by only one nucleotide from the most conserved -35 and -10 elements of prokaryotic promot­
ers. These predictions performed with β-prom did reveal further information though; in a number of the methylases, it predicted a promoter region known to interact with 
the σ70 factor RpoD, which will be further discussed in the following sections. 
Interestingly, the promoter prediction algorithms were unable to identify most pro­moter regions within the available 400nt upstream region of the intrinsic resistance conferring 16S rRNA methyltransferases. This is most likely due to the mechanism by which these intrinsic resistance conferring genes are regulated. As most commonly they are found within biosynthetic clusters alongside the antibiotic it is possible that their respective promoter region is harbored within the 5’ region of genes (related to the biosynthesis of the antibiotic or the antibiotic itself) that they are co-transcribed with. One intrinsic resistance conferring methyltransferase, fmrO, was predicted to harbor an RpoD recognized promoter region, however, it did not share sequence con­servation with the conserved promoter region of the acquired 16S methyltransferases. 
At an average distance of 221nt from the resistance gene coding region, the meth­yltransferase 5’ upstream regions correspond in length with untranslated regions demonstrated to harbor a number of regulatory mechanisms. Based on these lengths, we performed an extensive study of putative secondary structures within these regions; 
however, no secondary structure elements or patterns were identified that correspond with known post-transcriptional regulatory mechanisms. 
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7.2 The armA 5’ untranslated region Using the sequence alignments performed with all available sequences of armA, wewere able to demonstrate a very high level of conservation within at least 221nt from the armA coding region. The conservation observed within this region again suggested the presence of a putative regulatory domain harbored within the 5’ UTR. Interestingly, 17.4%  of the sequences analyzed harbored an IS10a insertion sequence immediately before this 221nt region (which contains the predicted promoter region). The publi­cations regarding those strains appeared to indicate WT levels of resistance conferred by ArmA. This is interesting because this insertion sequence truncates the 5’ portion 
of the leading peptide previously identified as a putative leader peptide involved in a regulatory mechanism mediated by ribosome stalling (Ramu et al., 2009). This infor­mation led us to question the involvement of this putative leader peptide. 
Furthermore, the high degree of conservation allowed us to pinpoint a region of in­terest for further experimental evaluations of the 5’ UTR. As armA has only ever been found within Tn1548 (until very recently), a certain degree of conservation is to be ex­pected. However, generally non-coding regions acquire point mutations at a higher rate 
than coding regions, and it was interesting to find such a high degree of conservation in all armA sequences available online. Such a high degree of conservation is typically indicative of a biological role played by that region. When comparing the level of con­servation within this highly conserved region to the upstream region, it was evident 
that there were significantly more point mutations and alterations. Now that we had 
identified a highly conserved region upstream of armA, we were able to design our ex­perimental approach to characterize the untranslated region governing the expression of armA. 
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7.2.1 Defining the extremes of the armA transcript 
The identification of the precise transcript of armA was a crucial first step for the experimental dissection of this promoter region. The 139nt 5’ UTR region demon­
strated via the RACE was, as mentioned, confirmed multiple times under conditions in the presence and absence of antibiotics. This analysis was performed with armA in its 
WT genetic environment harbored on pMUR050. As defining the 5’ UTR is of upmost 
importance to our study, we found it necessary to confirm these results via RT-PCR analysis. The RT-PCR conducted with RNA extractions at 2, 4, 6 and 8 hours were per­
formed to absolutely confirm the absence of any transcript longer than that identified via RACE. The 139nt 5’ UTR not only aligns with the highly conserved region identi­
fied when assessing the degree of conservation in the upstream region of armA, but it also corresponds with the predicted -35 and -10 promoter region. Additionally, this 
result provides further evidence as to the involvement of the previously identified pu­tative leader peptide. Under no conditions does this region appear to be co-transcribed alongside armA, which again suggests that this element is not required for the appro­priate expression of armA. In fact, this putative leader peptide is most likely a small portion of a transposase gene that has been truncated and altered over time. In the future, it would be of value to insert a frame shift mutation within this putative ORF to 
conclusively confirm whether or not it influences the expression of armA. 
7.2.2 Identification of regulatory domains within the 5’ UTR 
Now that we had identified the extremes of the armA transcript, we decided to in­vestigate the phenotypic effects observed upon the truncation of key elements with­in the 5’ UTR. As outlined in the materials and methods, the following constructions were all cloned onto the pAYCY-184 cloning vector. Prior to any further experiments, 
we performed RNA extractions to confirm the absence of any upstream, vector-borne, 
promoter regions that may influence the transcription rates of armA. This analysis con­clusively demonstrated the absence of a vector-borne upstream promoter region, and, 
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as such, we were able to proceed with the experiments regarding the 5’ UTR elements. 
The results obtained from this truncational assay were very informative regarding 
the significance of the identified upstream elements. Both the resistance profile and the Western blot analysis demonstrate a small reduction in the MIC and translational levels, respectively, between the construction bearing the WT 5’ upstream region. and the construction bearing the 186nt 5’ upstream region. While this could be indicative of a role played by the leading peptide, we believe this is based on the novel genet­ic environment immediately upstream of the promoter region after cloning onto the pACYC-184 vector. Based on environmental methyltransferases that confer high levels of resistance despite having this leader peptide truncated, in addition to later experi­ments where we induce amino acid changes within this ORF, it is unlikely that it plays a 
significant role in the expression of armA. 
Furthermore, this truncational study very clearly identified a region between -139 and -400 nucleotides that is absolutely required for the expression of armA. The trun­cation of the region bearing the putative promoter region leads to a complete reversion of aminoglycoside resistance to the levels of susceptible bacteria. The results obtained lead us to believe that the cause of this is the removal of the promoter region rather than the truncation of the putative leader peptide, as the construction bearing the pro­
moter region, yet missing a significant portion of the leading peptide, still produces 
high levels of aminoglycoside resistance. The resistance profiles of the constructions bearing a 5’ upstream region of 139nt or less demonstrated the absence of any further promoter regions within this area. 
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7.2.3 Environmental factors that influence armA expression The next step of our study was to gain insights regarding environmental factors that 
may influence the expression of armA. As literature demonstrates, there are a number of auto-regulatory feedback mechanisms that may affect the expression of a resistance determinant (Bailey et al., 2008; He et al., 2013). This was especially relevant to armAfor several reasons. Primarily, armA acts on the protein synthesis machinery, which drastically varies in quantity per cell based on the growth phase of the bacterium. As such, to adequately protect the cell, the expression of the methyltransferase should be proportional to the number of ribosomes present at any given moment. Secondly, 
such a regulatory mechanism is even more likely when considering the ramifications of modifying a macromolecule as highly conserved as the prokaryotic ribosome. Liter­ature has demonstrated that, while neither the transcription nor translation of armA
confer a significant biological burden to the cell, its action on the ribosome does reduce 
bacterial fitness (Lioy et al., 2014). This, again, constitutes a scenario in which it would 
be very beneficial to the host to only express the resistance determinant in conditions where it is absolutely required (i.e. in the presence of the antibiotic). Resistance con­ferring methyltransferases, such as ermC (a 23S rRNA methyltransferase that confers macrolide resistance) have been clearly demonstrated to regulate their expression based on the presence of an inducing antibiotic (Bailey et al., 2008). However, this type of regulatory activity is not the only post-transcriptionally mediated mechanism. For a 
number of aminoglycoside modifying enzymes, riboswitches have been identified that only permit the expression of the resistance gene in the presence of the inducing an­tibiotic (He et al., 2013). Furthermore, taking a step away from resistance conferring gene-products, ribosomal co-factors such as intrinsic methyltransferases and riboso­mal proteins have been shown to be, very frequently, regulated in a dynamic manner based on ribosome count (e.g. molecular mimicry)(Green et al., 1997). 
To determine the expressional profile of armA and to assess whether or not its ex­pression is affected by environmental factors such as the presence of an inducing anti­
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biotic, in this case aminoglycosides, or perhaps by the presence of excess methyltrans­ferase, we then constructed a lacZα reporter fusion. Initially, we fused the full (400nt)5’ upstream region of armA to lacZα, as previously described by Bailey et al (Bailey et 
al., 2008). All assays were again performed in the confirmed absence of any upstream 
promoter regions that may influence the transcriptional levels of armA. Initially, this reporter construct under the regulation of the full-length 5’ upstream region of armAwas then plated on x-gal to investigate the natural levels of expression in the absence of any known inducing agents. These early results demonstrated that the expression of 
lacZα under the regulation of the armA 5’ upstream region is constitutive in both the presence and absence of an inducing antibiotic, which in this case would be the amino­glycosides. X-gal plates containing various subinhibitory concentrations of aminoglyco­sides demonstrated no visual changes in the transcriptional levels of the reporter gene. Furthermore, the placement of a aminoglycoside bearing disk on an x-gal plate did not produce any increase in lacZα expression in the regions containing subinhibitory con­centrations of aminoglycosides, which would be the case if the transcriptional levels were affected by the presence of aminoglycosides. This is a very important result when investigating the expressional regulation of this resistance methyltransferase. 
This result, however, is not enough to suggest the absence of a post-transcriptional mechanism of regulation. Rather than requiring a transcriptional induction, the expres­sion of armA could very well be modulated by an inhibitory feedback mechanism. Such regulatory mechanisms are common to gene products involved with protein synthesis. Ribosomal proteins such as (but not limited to) S15, L20 and L35 have been shown to interact with their own 5’ UTR if their primary target site has already been acted on, as part of a regulatory mechanism known as molecular mimicry (Guiller et al., 2002; 
Ehresmann et al., 2004; Guiller et al., 2005). In such cases, the superfluous ribosomal proteins recognize portions of their own mRNA, which mimics their ribosomal target sites to prevent the translational of further, unnecessary, proteins. 
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 To determine whether or not this is the case, we then electroporated the various lacZαreporter constructs alongside active methyltransferases armA as well as rmtC (borne on cloning vectors pTOPO and pBAD respectively). We chose to perform this assay with two different methyltransferases to determine if the effects observed by the presence of active methyltransferases, were the result of the methyltransferases themselves or methylation of residue G1405 of the ribosome. An hypothesis at the time was that, ei­
ther, superfluous amounts of ArmA are inhibiting the expression of further methyl­transferases (by interacting with elements within the 5’ UTR) or perhaps, the methyla­tion itself is blocking the translation of further methyltransferase in a ribosome stalling type mechanism. Nevertheless, neither the presence of active ArmA nor the presence of active RmtC demonstrated any effects on the expression of our lacZα reporter con­struct. These results do indicate that, despite the highly conserved, relatively long 5’ UTR of armA, there do not appear to be any post-transcriptional regulatory effects on the expression of armA. Rather, they seem to indicate that constitutive expression of 
the resistance determinant mediate by the previously identified promoter region. 
Although, the RpoD sigma factor induces the transcription of a large number of genes, 
finding this highly conserved promoter region upstream of armA would permit expres­sional levels to match that of its target-site (i.e. the ribosome). While not being one of the post-transcriptional mechanisms previously described, this would be an elegant 
form of ensuring sufficient levels of the resistance gene in the cell. A high degree of ge­netic plasticity in the upstream region of armA would allow for a type of trial and error process in which the resistance genes gradually obtain an optimal promoter region. 
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7.3 Identification of -35 and -10 box nucleotides necessary for the 
transcriptional induction of armA 
7.3.1 Promoter region conservation with RpoD recognized promoters Despite suggestions from literature pertaining to the auto-regulatory capacity of the 
armA 5’ UTR, our studies to this point, have revealed an expression that appears consti­tutive both in the absence and presence of antibiotic pressure and excess gene product. As such, our attention shifted to dissect the promoter region elements required for the accurate expression of armA. As previously mentioned, the promoter region identified by the online prediction service was highly conserved with a region known to interact with the σ70   factor RpoD. This association is based on high sequence conservation and the precise distance between the -35 and the -10 elements. Literature review demon­strates that this common transcription factor is especially active in conditions of rapid growth (i.e. the exponential phase). This association is based on the fact that the RpoD family of sigma factors is responsible for the induction of a wide range of genes directly associated with ribosomal proteins and the protein synthesis machinery. It has been shown that in E. coli the ribosome count in the cell may vary from over 70,000 in fast growing cells to under 20,000 in slow growth conditions (Bremer et al., 2008). For protein synthesis to function correctly, this large variation must be complemented by a precise expression of all the cofactors required to accurately assemble a functioning 
ribosome. One such mechanism of the cell is to utilize specific groups of transcription factors that induce large clusters of genes associated with required functions. 
While some resistance genes might gain selective advantage by being under the strin­gent control of either an inducing or inhibiting agent, it appears that, based on the high sequence conservation with RpoD recognized promoter regions, armA may be co-in­duced alongside a wide variety of genes responsible for protein synthesis. Such a reg­ulatory mechanism would be an elegant form for an acquired resistance gene to miti­
gate the biological cost conferred to the cell while ensuring the expression of sufficient 
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methyltransferase in the cytoplasm to act on all ribosomes within the cell. While target 
modification is generally associated with very high levels of resistance, a co-induction of the resistance methyltransferase alongside components of its target site may also contribute to the high levels of resistance observed.   
7.3.2 Site-directed mutagenesis of most conserved -35 and -10 elements 
Initial site-directed mutagenesis was designed to experimentally confirm the involve­
ment of the identified promoter region in the expression of armA. Three separate mu­tants (‘GG’ substitutions) were initially created targeting the two most conserved nu­cleotides of the -35 box and two nucleotides of the -10 box (one highly conserved and 
another less conserved) as well as a final construction harboring both mutations. This 
was performed as such to not only confirm the involvement of the in silico predicted promoter region, but also to assess the degree to which the nucleotide conservation affects the expression of the resistance gene. The results obtained strongly indicate the involvement of this active promoter in the expression of armA. Furthermore, the 
effects of the mutagenesis were more significant when substituting two highly con­served nucleotides of the -35 than they were when mutating one highly conserved and one less conserved nucleotide of the -10 box. With this, we demonstrate that the highly 
conserved promoter elements of an RpoD recognized region are specifically involved with the expression of armA. 
Interestingly, the mutagenesis of the -35 region completely inhibited the expression of the downstream gene. Oftentimes, the -10 promoter region alone is capable of recruit­ing the RNA polymerase to commence transcription. In the case of the armA promoter, both elements appear to be required for the expression of the resistance determinant. This further supports the involvement of the RpoD sigma factor as the promoter sites on which they act maintain a high degree of conservation in both the -35 and -10 box of armA. 
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7.3.3 Dissection of the promoter elements required for the expression of armA 
The results obtained from the first mutants generated, conclusively demonstrate the activity of this promoter region in the expression of armA. Our next objective was to 
further analyze both the specific nucleotides involved in the induction of transcription as well as the 5’ and 3’ extremes of the -35 and -10 box. 
Interestingly, nucleotide substitutions performed adjacent to the conserved -35 and -10 box exhibited no reduction in the MIC and expression levels as assessed by Western Blot. This demonstrates two things: i. the armA promoter region conservation, again, aligns with that of the RpoD sigma factor recognized regions; and ii. the effects of the mutagenesis on the expression of armA are the result of altering nucleotides within the promoter region. This second point was important to address because this promot­er region is harbored within the putative leader peptide upstream of armA. While the 
substitutions alter the promoter region sequence, they also significantly alter the pu­tative amino acid sequence of the leader peptide. However, in total 6 regions adjacent to the promoter sites were substituted and none resulted in any reduction of neither 
the resistance profile nor the translational levels. Conversely, the substitution of any nucleotide that was highly conserved with the nucleotide sequence of an RpoD recog­nized region lead to the almost complete lack of expression. Interestingly, substitutions 
of much less conserved nucleotides also significantly reduced the expression of armA, 
although not completely. This may suggest that the specific promoter region responsi­ble for the expression of armA is closely associated with the high-level MIC achieved. Based on the low level of conservation of these nucleotides, we would have expected 
to witness less of an effect of the resistance profile and the translational levels. In all results of the promoter regions the MIC and Western Blot expressional levels appeared to be proportional. 
The extensive mutagenic dissection of this promoter region reveals that every nucle­otide of the promoter elements plays a role in the perfect expressional level of armA. 
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While some nucleotides are absolutely required to express armA, the substitution of others permits the expression of low levels of armA, although nowhere near the levels reached by the intact promoter region. 
7.3.4 Growth phase dependent expression of armA Expressional levels of armA were consistently shown to be up to 4 times higher throughout the early growth phases between 2-5 hours than during the stationary phase. These time points correspond to the exponential phase observed via spectro­photometry. After the exponential phase, while there is ArmA present, it is in a smaller but consistent quantity. Arguably, the levels of ArmA observed after the exponential phase could be the residual methyltransferase in the cytoplasm despite the lack of new­ly transcribed/translated protein. While this does correspond to patterns that would be expected of RpoD induction, these results do not conclusively determine whether the peak in protein levels in the cytoplasm is mediated transcriptionally or post-tran­scriptionally. 
Preliminary growth curves conducted of the initial constructions with ‘GG’ substi­tutions of the more or less conserved elements of the promoter region are an inter­esting way of implicating this particular promoter region with the expressional peak observed. Unfortunately, based on the extremely low levels of expression of the mu­
tants, it is difficult draw such conclusions. To address this, we have cloned the various constructions harboring mutated promoter regions in the opposite orientation on the pACYC vector. RT-qPCR analysis demonstrates, that in this orientation, there is a con­stitutive upstream promoter. These constructions permit baseline levels of expression that allow us to evaluate the expressional peak witness early in the exponential phase. Furthermore, these baseline expressions serve as a control for the expressional peak witnessed in armA harboring its native promoter. As the expressional pattern of armAwith an upstream promoter do not exhibit any form of expressional peak, this allows 
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us to conclude that the expressional peak in in fact a result of the promoter region and not plasmid copy number related. 
As such, the final experiments performed were to assess the transcriptional levels of armA throughout growth via RT-qPCR. This study revealed a similar pattern to the 
previously observed in the Western Blot quantified ArmA growth curves. There is a notably higher transcription of armA observed precisely between 2-5 hours, which again corresponds to the exponential growth phase observed via spectrophotometry. Furthermore this aligns with an expressional pattern to be expected from an RpoD in­duced gene. Additionally, this demonstrates that the levels of transcription and transla­tion of armA appear to be proportional, suggesting the absence of post-transcriptional 
regulatory events. It is, however, unfortunately not sufficient to conclusively demon­strate the association of the RpoD with the expression of armA. Additional controls at a 
known concentration would be necessary to confirm this expressional pattern. To our knowledge, uidA is constitutively expressed throughout growth; however, global tran­scriptional up regulation during the exponential phase may also lead to an expressional peak of uidA. Such a trend, would, in fact, strengthen our results as even with regards to the uidA expression during the exponential phase we observe a peak in the expression of armA. This qPCR was able to further demonstrate that the effects witnessed were a result of the transcriptional induction of armA rather than a phenomenon associated with the plasmid copy number. qPCRs performed of DNA exractions using uidA as a control demonstrated a relatively constant plasmid count over the growth period. To further elucidate such an association one would have to perform in vitro transcription 
assays in the presence and absence of this specific sigma factor. 
Nevertheless, the expression of armA does appear to be associated with conditions of rapid growth, which is, of course, mediated by the number of active ribosomes in the cell. This study was performed using the most prevalent 16S rRNA methyltransferase and, perhaps, this particular mechanism of induction underlies its epidemiological 
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success. The co-induction of armA with the protein synthesis machinery and all of its cofactors would be an elegant way to achieve maximum levels of resistance while mit­igating the biological cost. Furthermore, this promoter region is the representation of the most conserved promoter sequence among all 16S rRNA methyltransferases. That being said, not all of the promoter regions assessed were predicted to be RpoD family promoter sites. However, based on the levels of promoter region conservation, perhaps 
the 16S methyltransferases are slowly being selected alongside this specific promot­
er region. Our results show that any small modification of the promoter region has 
drastic effects on the resulting resistance profile, which has serious ramifications on the selective advantage conferred by the resistance gene. Whether by horizontal gene transfer (e.g. insertion sequences) or single point mutations, resistance genes may ob­tain, or develop, promoter regions capable of increased resistance levels with reduced 
biological cost. Several ISCR elements have been identified to be associated with the 16S rRNA methyltransferases and many other resistance genes (Reference). Of these, a number have been shown to harbor outward facing promoters to selectively regulate the expression of adjacent (resistance) genes (Toleman et al., 2006; Depardieu et al., 2007; Berçot et al., 2010). This variability within the promoter region greatly facilitates the acquisition and subsequent maintenance of a promoter region that, as previously mentioned, maximizes the resistance level conferred while minimizing the biological burden on the host. 
In environments with high levels of antibiotic use (e.g. hospitals, farms, etc.) resist­ance genes harboring a promoter that facilitates extremely high level resistance will 
confer a significant advantage to the host. Conversely, small modifications, in the case of armA, of nucleotides that are not highly conserved as part of the transcription factor binding region may render the bacterial host sensitive to antibiotics in the environ­ment. 
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7.4 Future work There are a number of studies that would permit this research line to reveal more de­tails about both the origin of the acquired 16S rRNA methyltransferases as well as their 
expressional profile. It would be extremely interesting to carry out in depth fitness as­says of all 16S rRNA methyltransferases including intrinsic ones. While Liou et al, have 
demonstrated that the fitness cost is a result of the methylation of residue G1405 itself rather than the transcription/translation of the resistance gene, it would be interesting to know if such a biological burden also occurs within the producers. Furthermore, a large scale in vitro study with a larger database of prokaryotic RNA methyltransferases would surely provide candidates for ancestral origins of the acquired 16S rRNA meth­yltransferases. Additionally, the availability of all extended 5’ upstream regions would permit further studies of elements within this region. 
With regards to the proposed growth dependent expression of armA, it would be very interesting to perform in vitro transcription assays to assess whether or not, the RpoD sigma factor alone is capable of inducing the transcription of armA, or if further factors are involved. 
Finally, our next steps are to investigate, the effects of both the aminoglycosides and 
the acquired 16S rRNA methyltransferases on the fidelity of the prokaryotic ribosome. 
Using a very novel technique known as ribosome profiling, we intend to elucidate the precise impact that both the antibiotic and this resistance determinant have to the 
translational rates and efficiency of the ribosome. 
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8CONCLUSIONS 
The conclusions of this doctoral thesis are as follows: 
•	 FIRST. The in silico analysis of the acquired, intrinsic and housekeeping 16S rRNA methyltransferases revealed that the acquired 16S rRNA methyltransferases con­vergently evolved from various ancestral origins. 
•	 PRIMERA. El análisis in silico de las metiltransferasas del ARNr 16S endógenas, intrínsecas y adquiridas indica que estas últimas, las metiltransferasas adquiri­das, evolucionaron de forma convergente a partir de varios orígenes ancestrales. 
•	 SECOND. Among all the acquired 16S rRNA methyltransferases, there is an overall conservation of the -35 (TTGACG) and -10 (TTACACT) promoter sequence. 
•	 SEGUNDA. Existe una conservación generalizada de las secuencias -35 (TTGACG) y -10 (TTACACT) del promotor de las metiltransferasas del ARNr 16S adquiridas. 
•	 THIRD. Using ArmA, the most prevalent 16S rRNA acquired methyltransferase, 
as a model system, we have identified a 5’ untranslated region of 139 nucleotides that is highly conserved among all available sequences. 
•	 TERCERA. Usando como modelo ArmA, la metiltransferasa del ARNr 16S adquiri­
da más prevalente, hemos identificado una región no codificante de 139 nucleóti­dos altamente conservada entre todas las secuencias disponibles. 
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•	 FOURTH. Despite having been previously identified as a region harboring post-transcriptional mechanisms of regulation, neither the presence of antibiot­ics nor active methyltransferase had any consequences on the intracellular levels of ArmA. 
•	 CUARTA. A pesar de haberse identificado previamente mecanismos de regulación post-transcripcionales en esa región, la presencia de antibióticos o de metiltrans­
ferasa activa no modifican los niveles intracelulares de ArmA. 
•	 FIFTH. We have demonstrated the involvement of a promoter region responsi­ble for the expression of armA, which shows a high degree of conservation with promoter regions known to interact with the sigma factor RpoD. 
•	 QUINTA. Hemos demostrado la existencia de una región promotora responsable de la expresión de armA, la cual presenta un alto grado de conservación con re­giones promotoras que interactúan con el factor sigma RpoD. 
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•	 SIXTH. A single nucleotide resolution of this promoter region demonstrates that substitution of its most conserved nucleotides completely inhibits the expression of armA. Even mutations of non-conserved nucleotides result in a drastic reduc­
tion of the high-level resistance conferred, suggesting that this specific promoter sequence is required to achieve the full resistance phenotype. 
•	 SEXTA. A través de una caracterización nucleótido a nucleótido de esta región promotora hemos comprobado que la sustitución de los nucleótidos más con­servados de dicha región inhibe completamente la expresión de armA. Yendo más allá, mutaciones de los nucleótidos no conservados suponen una drástica reduc­ción de los altos niveles de resistencia conferidos por ArmA, sugiriendo que la se­
cuencia específica de este promotor es necesaria para alcanzar el máximo fenoti­po de resistencia. 
•	 SEVENTH. The analysis of the armA expressional profile throughout bacterial growth demonstrates an increased activity of ArmA in the early exponential phase 
in-keeping with the transcriptional induction of the σ70 factor RpoD. 
•	 SÉPTIMA. El análisis del perfil de expresión de armA a lo largo del crecimiento bacteriano ha evidenciado una mayor actividad de ArmA en los comienzos de la fase exponencial, acorde con la inducción de la transcripción del factor σ70 RpoD. 
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